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ABSTRACT 
 
Opioids currently represent the best treatment option for severe and 
chronic pain conditions.  Opioids while effective at controlling pain states also 
come with a number of side effects such as respiratory depression, urinary 
retention, dependence, tolerance, and opioid-induced hypernociception (OIH).  
OIH is a phenomenon in which opioids induce pain and this pain is often 
experienced at a site separate from the site of injury.  Much research has been 
conducted investigating the mechanism of OIH, but the mechanism remains 
unsolved.  One potential mechanism that has yet to be adequately explored is 
chemokines.  Chemokines role in OIH is warranted given recent studies 
demonstrating the interaction between opioids and chemokines.  Chemokines 
were originally thought to solely function in the immune system, but have recently 
been found to play a major role in the nervous system, as well as being 
implicated in a number of different pain models.  Therefore, the purpose of these 
studies was to investigate a possible interaction between opioids and 
chemokines in the peripheral nervous system and the role this interaction plays 
in the development and maintenance of OIH.  To do this, I tested for changes in 
expression of SDF1 and CXCR4 signaling in the dorsal root ganglion following 
repeated morphine administration.  Secondly, I investigated if opioid or non-
opioid signaling was involved in the development of OIH and which of these
XVI 
 
receptor signaling cascades was responsible for changes in SDF1/CXCR4 
signaling in the dorsal root ganglion.  These studies employed the use of a 
number of different methods including animal behavior, in situ hybridization, 
immunocytochemistry, and calcium imaging.   
It was found that SDF1/CXCR4 signaling was indeed increased in OIH 
and that these changes in SDF1/CXCR4 signaling occur following activation of 
the mu opioid receptor.  Additionally, OIH appears to be induced by both opioid 
and non-opioid receptor signaling.  These results suggest that opioids are 
inducing a neuroinflammatory process that can be detrimental at anatomical sites 
separate from an injury.  Therefore, to improve the analgesic effectiveness of 
opioids these off target effects must be considered and new treatments that can 
bypass these effects should be explored. 
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CHAPTER ONE 
INTRODUCTION 
Pain 
The ability to experience pain has a beneficial role in humans and 
animals.  For example, the ability to withdraw your hand following touching a hot 
object protects against tissue damage.  Sherrington more than a century ago 
defined this type of stimulus as noxious, a stimulus with potential to damage 
tissue (Sherrington, 1906).  Therefore, it is beneficial to be able to distinguish 
between noxious and non-noxious stimuli.  Acute pain perception is essential for 
avoiding potential tissue damaging events which may hinder the healing process.  
In contrast, pain that persists beyond the wound healing period serves no 
beneficial role.  In fact, this type of chronic pain contributes to deterioration in the 
quality of life.   Chronic pain states are characterized using the following terms:  
hyperalgesia (increased sensitivity to painful stimuli), allodynia (non-noxious 
stimuli perceived as painful) and increased spontaneous pain.  It is important to 
note that pain involves the perception of pain and is a subjective experience.  
Therefore, animal models often employ the term nociception which involves 
observations of neural, physiological, and behavioral changes. 
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Nociceptive Pathway 
The nociceptive signal originates from stimuli activating nociceptors on 
primary afferent sensory neurons (Fig.1).  Primary afferent sensory neurons 
transduce stimuli to an electrical signal that is then transmitted up the sensory 
neuron axon to the dorsal horn of the spinal cord, the site of the first synapse of 
the signal.  Interneurons within the lamina I-II of the dorsal horn receive input 
from primary afferent neurons and are responsible for initiating the withdrawal 
reflex permitting fast reaction to potentially damaging stimuli.  Primary afferent 
sensory neurons also synapse with second order neurons of lamina I-II within the 
dorsal horn of the spinal cord which transmit the signal to higher centers in the 
central nervous system, thalamus and cortex; transmission of this signal is 
referred as the ascending pathway.  These supraspinal centers are responsible 
for the conscious and emotional experience of pain, are the site of conscious 
perception of pain in humans.  Descending pathways originate in the cortex and 
project to the periaqueductal grey (PAG).  Inhibitory neurons in PAG send axons 
to spinal cord dorsal horn and modulate incoming noxious signals from the 
periphery.  The descending pathway is often referred to as the modulatory 
pathway because it synapses with dorsal horn and primary sensory neurons and 
can regulate the level of excitation of the nociceptive signal.  Therefore, the 
nociceptive pathway has a built-in feedback system by which it can regulate the 
nociceptive experience. 
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Components of Dorsal Root Ganglia 
Sensory Neurons 
Primary afferent sensory neurons are psuedounipolar neurons.  Sensory 
neurons have a single axon composed of two branches that extend from the cell 
body located in the dorsal root ganglion (DRG).  One branch of the axon extends 
 
Figure 1.  Nociceptive Pathway.  
Brain clipart 
(http://www.artvex.com/content/Clip_Art/Anatomy/Brains/0015438.gif), 
Hand clipart (http://cliparts101.com/free_clipart/24783/hand.aspx) 
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to peripheral tissues such as skin, muscle, and viscera.  This branch of the 
sensory neuron is responsible for sensing changes in temperature, touch, 
proprioception, and pain in the environment.  The other branch of the sensory 
neuron extends into the dorsal horn of the spinal cord where it synapses and 
relays information from the periphery for further processing within the spinal and 
supraspinal level.  
Sensory neurons within the DRG vary in size, degree of myelination, and 
conduction velocity.  Large diameter, Aα, and medium diameter, Aβ, sensory 
neurons are both fast conducting, myelinated axons that are in charge of relaying 
information about touch and proprioception.  A subset of sensory neurons, 
nociceptive neurons, transmit sensory information about potentially damaging 
stimuli and thus are responsible for transmitting pain signals.  Nociceptive 
sensory neurons are polymodal responding to mechanical, thermal, and chemical 
stimuli and are further divided into two types, Aδ and C fibers.  Aδ are fast 
conducting, myelinated fibers and are often referred to as high-threshold 
mechanoreceptors (Burgess and Perl, 1967).  Aδ fibers are responsible for 
transmitting the initial stimuli of nociception.   C fibers are slow conducting, 
unmyelinated fibers and transmits a less robust signal.    
Sensory neurons have very unique and interesting characteristics.  DRG 
neurons express receptors for neurotransmitter such as, glutamate, serotonin, 
ATP, bradykinin, Substance P, and GABA (Sato et al., 1993; Huettner, 1990; 
Lovinger and Weight, 1988; Todorovic and Anderson, 1990; Bean et al., 1990; 
Bouvier et al., 1991; Thayer et al., 1988; Spigelman and Puil, 1991;  Aibara and 
5 
 
Akaike, 1991; Robertson, 1989).   Cell somas of the DRG are devoid of any 
dendrites and synapses, but are capable of releasing neurotransmitters and 
inflammatory mediators such as CGRP, Substance P, and glutamate in a 
calcium- dependent manner (Hingtgen and Vasko, 1994; Mason et al., 1984; 
Vedder and Otten, 1991; Holz et al., 1988; Jeftinija and Jeftinija, 1990; Huang 
and Neher, 1996).  DRG neurons are capable of sensing activity in neighboring 
neurons through transient depolarization (Liu et al., 1999; Utzschneider et al., 
1992; Amir and Devor, 1996), changing their excitable state following nerve injury 
(Wall and Devor, 1983) and increasing the expression of sodium channels 
following inflammatory pain models (Tanaka et al., 1998; Gould et al., 1998).  All 
of these changes would serve to change the excitability state of sensory neurons 
and thus change the state of the nociceptive pathway as a whole. 
Satellite Glial Cells 
The other important component of the DRG are satellite glial cells (SGCs) 
which surround each sensory neuron.  Glial cell involvement in the nervous 
system has only recently begun to be explored.  Glial cells were once thought to 
solely function as their name describes as the “glue” of the nervous system 
holding neurons in place.  However, research conducted in recent decades has 
begun to demonstrate the importance of these cells in the physiology of the 
nervous system.  Glial cells regulate the environment of the neurons they 
surround (Hansson and Ronnback, 2003; Reichenbach, 1991), as well as being 
important in the developing nervous system (Slezak and Pfrieger, 2003; 
Goldman, 2003).  There is very little known about SGCs but they do express 
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receptors, transporters, ion channels, and ligands demonstrating their ability to 
signal and regulate the environment in the DRG (reviewed in (Hanani, 2005)).  
SCCs are unique in that they form a protective envelope/sheath around the 
sensory neurons of the DRG.  Each sensory neuron is surrounded by several 
SGCs possibly serving to form a functional unit between each sensory neuron 
and its surrounding SGCs (Pannese, 1981; Hanani, 2005).  Although the SGCs 
form an envelope around each sensory neuron, ions, neurotransmitters, and 
macromolecules are able to penetrate through the sheath allowing for cross-
communication among sensory neurons in the DRG (Shinder and Devor, 1994).  
The SGC envelope can also serve to protect sensory neurons from toxic 
substances such as mercury and lead (Kumamoto et al., 1986; Schlaepfer, 
1969).  Therefore, it appears that the SGCs serve as the barrier for the sensory 
neuron’s cell bodies within the DRG.  Taken together these characteristics 
demonstrate the critical role SGCs have to regulate the environment of neurons.  
Satellite glial cells are capable of increases in intracellular calcium levels 
in response to stimuli (England et al., 2001).  Indeed, it appears that neuronal 
response to inflammatory mediators such as, bradykinin, is dependent on contact 
with SGCs (Heblich, 2001).  Additionally, SGCs properties such as increased 
glial cell coupling and more depolarized resting membrane potential can be 
altered following chronic compression of the DRG (Zhang et al., 2009).  Other 
interactions have been demonstrated between sensory neurons and SGCs 
through mechanisms involving the paracrine interaction of cytokine interleukin-1β 
(IL-1β) within the DRG.  IL-1β expression is increased in SGCs following 
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complete Freund’s adjuvant (CFA) injection (Takeda et al., 2007).  CFA 
treatment also induces increased firing frequency of sensory neurons (Takeda et 
al., 2007).  Interleukin-1 receptor antagonist treatment inhibits spontaneous and 
mechanical stimulation-induced increased neuronal firing frequency in CFA 
treated animals (Takeda et al., 2008), suggesting IL-1β is released from SGCs 
and acting on sensory neurons to induce the increased firing frequency.  To this 
end, it appears that the satellite glial cells may play a crucial role in the signaling 
and modulating interactions that occur within the DRG. 
Clinical Treatments for Acute and Chronic Pain 
There are a number of treatment options for acute pain states, such as 
local anesthetics which temporarily prevent neuronal activity.  Acute inflammatory 
pain states resulting from trauma or surgical procedures are often controlled with 
the use of non-steroidal anti-inflammatory drugs (NSAIDS).   Where there is a 
lack of effective treatment options are in chronic clinical pain states.  While a 
large percentage of the population suffer from chronic pain 40-50 percent of 
these individuals do not have adequate relief of their pain (Glajchen, 2001).  The 
class of therapeutics prescribed varies for depending on severity level and time 
course of the pain state.  Neuropathic pain states that result from injury to the 
nervous system, have limited treatment with only anti-convulsants and tri-cyclic 
anti-depressants being prescribed and have limited effectiveness.  These drugs 
are chosen for their potential to decrease cell excitability.  Chronic pain from 
inflammatory conditions is largely controlled by non-steroidal anti-inflammatory 
drugs (NSAIDS).  In the case of severe pain states opioid analgesics are often 
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prescribed in an attempt to control pain because of their substantial analgesic 
ability.  Opioids which target opioid receptors are often effective in controlling 
pain; however, they come with a number of side effects, such as respiratory 
depression, urinary retention, dependence, tolerance and finally opioid-induced 
hypernociception, which will be explained in more detail in later sections.  
G Protein Coupled Receptors 
 G-protein coupled receptors (GPCRs) are a large family of receptors that 
represent the target receptor for the majority of physiologically relevant ligands.  
GPCRs are seven transmembrane receptors that are coupled to heterotrimeric G 
proteins.  Ligand binding to the receptor initiates a conformational change 
allowing for the activation of the G protein.  The heterotrimeric G protein is 
composed of α, β, and γ subunits.  G proteins are classified by their α subunit 
and each α subunit initiates a different cascade of events.  Gs which activates 
adenylyl cylclase, Gi which inhibits adenylyl cylcase, and Go and Gq which 
activate phospholipase C which then activates IP3 and diacylglycerol production.   
 GPCR signaling can be regulated through the desensitization process.  
Following ligand binding to the GPCR, the GPCR is phosphorylated by G-protein-
linked receptor kinases (GRKs).  GRK phosphorylation of the receptor allows for 
arrestin binding to the receptor.  Arrestin binding to the receptor sterically hinders 
the G-protein from binding to the receptor, thereby uncoupling the G-protein from 
the receptor and preventing further receptor activation.   Arrestin binding to the 
receptor can also serve to initiate receptor internalization, further preventing 
ligand and receptor signaling events. 
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Opioid Receptors 
Opioid receptors are a family of seven transmembrane GPCRs that 
consist of three types, µ (MOR), δ (DOR), and κ (Kappa).  Opioid receptors are 
thought to be Gi coupled receptors.  Some studies have suggested that opioid 
receptors are also Gs coupled under both naïve and morphine treated conditions 
(Chakrabarti and Gintzler, 2007; Chakrabarti et al., 2005; Chakrabarti et al., 
1998).  All three opioid receptors were identified and cloned in the early 1990s 
(Evans et al., 1992; Chen et al., 1993; Meng et al., 1993).  MOR, DOR, and KOR 
have homologous sequences, with the highest conserved sequences in the 
transmembrane and intracellular regions (63-76%).  However, the extracellular 
regions, typically responsible for ligand binding are less conserved (34-30%) 
(Minami and Satoh, 1995). 
Opioid receptors are expressed throughout the nervous system both 
centrally and peripherally.  In particular opioid receptor expression correlates 
strongly with the regions important in the nociceptive pathway.  Opioid receptors 
are located in lamina I-III of the spinal cord and at the supraspinal level with the 
greatest expression in the striatum, amygdala, thalamus, and PAG of the central 
nervous system (Kuhar et al., 1973; Pert et al., 1976; Lamotte et al., 1976; Atweh 
and Kuhar, 1977; Fields et al., 1980; Ninkovic et al., 1982).  Peripheral 
distribution of the opioid receptors extends to cutaneous skin (Stein et al., 1990; 
Pare et al., 2001) and all opioid receptors are expressed on small, medium, and 
large diameter DRG neurons (Fields et al., 1980; Mansour et al., 1994; Minami et 
al., 1995; Buzas and Cox, 1997; Chen et al., 1997; Coggeshall et al., 1997; 
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Zhang et al., 1998; Wang and Wessendorf, 2001; Silbert et al., 2003; Rau et al., 
2005; Gendron et al., 2006). 
Opioid Agonists and Antagonists 
Each opioid receptor has both endogenous and exogenous ligands for 
which they have varying binding affinities, outlined in the table below.  
Exogenous natural and synthetic opioids are often employed for pain treatment.  
The analgesic mechanism of action of opioid agonists has long been believed to 
be through MOR.  This can be witnessed in the prototypical opioid analgesic, 
morphine, which has its greatest affinity for the MOR (14 nM) followed by lesser 
affinity for KOR (538 nM) and DOR (>1000 nM) (Raynor et al., 1994) (Table 1).   
Selective opioid agonists and antagonists exist for each of the opioid receptors 
and are often employed as pharmacological tools for identifying the role of each 
receptor in signaling events.  For example, DAMGO, a selective exogenous MOR 
agonist, has a 1000 fold greater affinity for the MOR over DOR and KOR (Schiller 
et al., 1989; Schiller et al., 1990; Raynor et al., 1994) (Table 1).  Non-selective 
opioid antagonists naloxone and naltrexone have similar affinities for the opioid 
receptors (Table 1), but differ by naltrexone having a longer half life than 
naloxone (Verebey et al., 1976).   
11 
 
 
 
Peripheral versus Central Opioid Analgesic Actions 
Opioid receptors are expressed throughout the central and peripheral 
nervous system as outlined previously; therefore the analgesic actions of opioid 
agonists could be acting through both.  Classically, opioid agonists have been 
thought to carry out their analgesic ability through actions in the spinal and 
supraspinal level, such as the PAG.  However, the ability of opioids to carry out 
their analgesic ability through acting on peripheral sites is possible because 
opioid receptors are located on sensory neurons (Fields et al., 1980; Mansour et 
al., 1994; Minami et al., 1995; Buzas and Cox, 1997; Chen et al., 1997; 
Coggeshall et al., 1997;Zhang et al., 1998; Wang and Wessendorf, 2001; Silbert 
et al., 2003; Rau et al., 2005; Gendron et al., 2006) and co-localize with known 
nociceptive substances, CGRP and Substance P (Dado et al., 1993; Wenk and 
Honda, 1999; Minami et al., 1995).  Additional evidence for opioids peripheral 
analgesic ability is provided by studies demonstrating  activation of mu opioid 
Receptor Type Agonists Antagonists 
µ (MOR) DAMGO 
Morphine 
CTAP 
Naloxone 
Naltrexone 
Κ (KOR) U-50,488 
Morphine 
Nor-BNI 
Naloxone 
Naltrexone 
δ (DOR) DPDPE 
Deltorphin 
Morphine 
Naltrindole 
Naloxone 
Naltrexone 
 
Table 1.  Opioid agonists and antagonists for each of the opioid receptors. 
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receptors on sensory neurons induces:  (1) a decrease in spontaneous activity 
(Russell et al., 1987), (2) decrease in calcium currents (Werz and Macdonald, 
1982; Borgland et al., 2001), (3) decrease in non-selective cation currents 
(Ingram and Williams, 1994), and (4) inhibits activation through prostaglandin 
(Gold et al., 1996), Transient Receptor Potential Vanillioid 1 (TRPV1) (Endres-
Becker et al., 2007), and purinergic receptors (Chizhmakov et al., 2005).  Several 
studies support peripheral action of opioid analgesics through the use of 
peripherally restricted opioid agonists and antagonists (Stein et al., 1991; Barber 
et al., 1994; Aley et al., 1995; Zhou et al., 1998; Likar et al., 1999; Machelska et 
al., 1999; Koppert et al., 1999; Pertovaara and Wei, 2001; Dionne et al., 2001; 
Reichert et al., 2001; Shannon and Lutz, 2002; Junger et al., 2002; Furst et al., 
2005; Labuz et al., 2007; Mousa et al., 2007).  In fact, it has been demonstrated 
that 50-80% of the analgesic ability of systemically administered opioids is 
carried out through their actions on peripheral targets (Reichert et al., 2001; 
Shannon and Lutz, 2002; Furst et al., 2005; Labuz et al., 2007).    
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Morphine Metabolism 
Morphine undergoes first pass metabolism and is mainly metabolized in 
the liver by the process of glucuronidation. Glucuronidation is a conjugation 
process carried out by the hepatic enzyme UDP-glucuronyl transferase, 
UGT2B7.   Glucuronide conjugation can occur at both the 3 and 6 position free 
hydroxyl sites on the morphine structure (Fig. 2) resulting in the formation of the 
two major metabolites of morphine, morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G) (reviewed in (Coller et al., 2009)).   M6G shares 
similar affinities at MOR, DOR, and KOR as its parent compound, morphine 
(Pasternak et al., 1987) and 9-10% of morphine is converted to M6G (Osborne et 
al., 1990; Hasselstrom and Sawe, 1993).  Because M6G has similar affinity for 
the MOR its analgesic ability is retained (Pasternak et al., 1987; Penson et al., 
2000).    M3G is the major metabolite of morphine with 44-55% of morphine 
being converted to M3G (Osborne et al., 1990; Hasselstrom and Sawe, 1993).  
 
Figure 2.  Morphine Structure.  Free hydroxyl groups at position 3 
and 6 are the sites of glucuronide conjugation. 
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Although M3G is a major metabolite of morphine it has very little affinity for the 
MOR, DOR, and KOR opioid receptors (Pasternak et al., 1987) with a greater 
than 100 fold less affinity for the MOR compared to morphine (Skarke et al., 
2005).  M3G’s loss of affinity for the opioid receptors is attributed to the lack of a 
free 3-hydroxyl group that is needed for strong affinity to opioid receptor binding 
(Pert and Snyder, 1973).  Thus, because M3G has limited affinity for the opioid 
receptors it does not possess analgesic abilities (Pasternak et al., 1987; Ekblom 
et al., 1993).  In fact, M3G has been proposed to be responsible for the negative 
side effects following morphine administration.  Increased plasma and cerebral 
spinal fluid levels of M3G correlate with decreases in analgesic activity of 
morphine (Baker and Ratka, 2002; Barjavel et al., 1995).  M3G has also been 
shown to antagonize the analgesic effects of morphine when co-administered 
(Smith et al., 1990) and can be neuroexcitatory and lead to nociceptive behavior 
(Bartlett et al., 1994; Labella et al., 1979; Yaksh et al., 1986; Woolf, 1981; Lewis 
et al., 2010).  Therefore, it is believed that the morphine metabolite, M3G, could 
be responsible for one of the negative side effects of morphine such as, opioid-
induced hypernociception. 
Opioid-Induced Hypernociception 
Opioids, such as morphine, currently represent the best option for the 
management of moderate to severe trauma-induced, perioperative and cancer 
pain.  Opioid compounds are also increasingly being used for chronic, non-
cancer chronic pathological pain.  However, prolonged administration of opiates 
is associated with significant problems including the development of 
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antinociceptive tolerance, wherein higher doses of the drug are required over 
time to elicit the same amount of analgesia.  These higher doses are also 
thought to increase pain sensitivity, a concept known as opioid-induced 
hypernociception (OIH).  This increased pain is usually experienced at a location 
separate from the original site of injury (Ossipov et al., 2004). 
OIH has been observed both clinically (Angst et al., 2003; Arner et al., 
1988; Singla et al., 2007) and experimentally (Laulin et al., 1999; Woolf, 1981).  
Many explanations for this phenomenon have been suggested. For example, 
OIH was once believed to occur as a result of ‘‘mini withdrawals’’, however OIH 
still occurs when opiates are constantly infused (Vanderah et al., 2000; Vanderah 
et al., 2001).  Some investigators will even go so far as to suggest that OIH is 
actually a form of antinociceptive tolerance, in which patients require a greater 
opiate dose in order to receive the same analgesic effect (Guignard et al., 2000; 
Luginbuhl et al., 2003).  Yet another explanation is that the hyperalgesic 
response to morphine is caused by a compensatory response to the inhibition 
produced by activation of the mu opioid receptor (MOR), causing a hyperactivity 
of the system (Gutstein, 1996).  In fact, higher doses are suggested to precipitate 
this effect largely because the hyperactive state becomes more dominant 
(Colpaert, 2002).  
Release of the neurotransmitter, glutamate, has also been implicated as an 
entity involved in OIH.  To this end, glutamate antagonism in the dorsal horn of 
the spinal cord has been somewhat effective in temporarily reversing OIH 
(Celerier et al., 2000; Laulin et al., 1998).  The involvement of glutamate 
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receptors is not surprising because the long lasting effects that are witnessed in 
OIH would require neural plasticity, changes that likely require glutamate 
receptors. However, the ability of glutamate blockade to effectively treat OIH is 
questioned. This is because the neural plastic changes that are occurring are 
present in two parts; i) the sensitivity of the glutamate receptor, and ii) the 
perceived decreased responsiveness of the MOR.  Blockade of the glutamate 
receptor would transiently reverse the nociceptive behavior, however it does not 
address the changes that have occurred in the MOR bearing cells (Mao et al., 
1995).  Despite a considerable amount of work on the topic little is known about 
the underlying mechanism. 
Much of the current studies on OIH have focused on the CNS, but the 
mechanism of OIH largely remains unsolved.  Given the peripheral actions of 
opioids outlined previously, peripheral opioid mechanisms role in the induction of 
OIH seems likely, but have largely been unexplored.   Another potential 
mechanism that has yet to be explored in OIH is the role of chemokines which in 
recent years has been connected to many pain models. 
Interaction between Opioids and Chemokines 
Chemokines and opioids are often co-expressed in various tissues and 
cells.  The first interaction noted was in the immune system.  Macrophages and 
T-lymphocytes express opioid receptors (Chuang et al., 1994; Chuang et al., 
1995; Wick et al., 1996; Wybran et al., 1979) and these cell types also express 
chemokine receptors.  Because opioid agonists are often employed to control 
inflammatory pain states, researchers sought to determine any effect that opioid 
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treatment would have on immune system function.  Chemotaxis achieved by the 
chemoattractant gradient of chemokines is utilized by immune cells in order to 
effectively move to their site of action.  Therefore chemotaxis is often employed 
as a functional test for cells of the immune system.  Pretreatment with opioid 
agonists reduces the chemotaxic response to chemokines (Chen et al., 2004; 
Grimm et al., 1998; Choi et al., 1999; Rogers et al., 2000; Miyagi et al., 2000).  
This reduction in chemotaxis is attributed to the heterologous cross-
desensitization between opioids and chemokines (Chen et al., 2004; Grimm et 
al., 1998; Szabo et al., 2002).  Desensitization is utilized by GPCRs to regulate 
the number of receptors that are available for ligand binding and receptor 
activation.  Desensitization occurs by phosphorylation of the GPCR following 
ligand binding and receptor activation, this phosphorylation sterically hinders the 
G-protein from binding to the receptor, thereby preventing downstream signaling 
events from occurring following ligand binding to the receptor.  All GPCRs share 
this mechanism therefore this process can occur through two means: 1) a 
receptor becoming phosphoralyted following its own activation, homologous 
desensitization and 2) one GPCR in a cell being activated and causing 
phosphorylation of other GPCRs within the same cell, heterologous 
desensitization.   
Another interaction between opioids and chemokines in the immune 
system was discovered when a correlation was found among opioid abusers and 
their susceptibility to HIV infection (Donahoe and Vlahov, 1998). This correlation 
was long attributed to lifestyle choices of addicts, unprotected sex and sharing 
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needles.  However other explanations began to be considered when studies 
demonstrated that morphine administration elevates HIV replication (Peterson et 
al., 1990; Peterson et al., 1994; Chuang et al., 1993).  Follow-up studies 
discovered that this correlation could be attributed to the ability of opioid agonists 
such as, morphine and DAMGO, to increase the expression of the chemokine 
HIV co-receptors, CXCR4 and CCR5, on monocytes and lymphoblasts (Steele et 
al., 2003; Miyagi et al., 2000).  Increased chemokine expression on immune cells 
essentially acts to increase the probability for viral entry/infection into cells.   
As chemokines role in systems other than the immune system became 
evident, possible interactions between opioids and chemokines in the nervous 
system began to be explored.   Several in vitro studies demonstrated that chronic 
morphine treatment led to an upregulation of CCL2 in human neurons (Rock et 
al., 2006), CCR2 and CCR5 in human astrocytes (Mahajan et al., 2005), and 
MCP1 in astrocytes (El-Hage et al., 2006).  These studies repeated what had 
already been demonstrated in the immune system that opioid treatment leads to 
changes in chemokine/receptor expression.  Functional interactions within the 
nervous system were also observed.  Similar to the effect on chemotaxis in the 
immune system, heterologous desensitization also occurs in the nervous system.  
The Rogers and Adler group demonstrated chemokine injections into the 
periaqueductal grey (PAG) leads to a decrease in the anti-nociceptive effects of 
opioids (Szabo et al., 2002; Chen et al., 2007a; b).  The chemokine induced 
decrease in opioid anti-nociception was short, lasting only 2 hours following 
chemokine administration (Szabo et al., 2002).  These short term, acute effects 
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were attributed to a heterologous desensitization mechanism, since changes in 
expression pattern are unlikely to occur in the utilized time frame.  Follow-up 
studies demonstrated intra-PAG administration of chemokines RANTES and 
SDF1 prior to systemic morphine injection is ineffective in decreasing the 
analgesic effect of morphine (Adler et al., 2005).  Chemokines ineffectiveness to 
completely block the analgesic effects of systemically administered morphine can 
be attributed to morphine acting on opioid receptors in both the central and 
peripheral nervous system to carry out its analgesic effect, as outlined previously.  
Heterologous desensitization between chemokines and opioids has also been 
demonstrated on in vitro culture conditions of the DRG, in which chemokine 
pretreatment led to a decrease in DAMGO induced calcium influx and decreased 
MOR present on the plasma membrane (Zhang et al., 2004a).  Current studies 
have provided evidence of an interaction between chemokines and opioids 
following acute administration and have attributed this acute interaction largely to 
heterologous desenstization.  However, the presence of chronic long lasting 
interactions among these two signaling systems has yet to be demonstrated. 
Chemokines/Receptors 
Chemokines (chemotaxic cytokines) are a family of small proteins (10-14 
kDa) traditionally thought to be involved in leukocyte trafficking under normal 
physiological and pathological conditions, as well as signaling in the developing 
and injured adult nervous system.  Chemokines are typically classified by the 
presence of a cysteine motif in the N-terminal region of the protein (Zlotnik and 
Yoshie, 2000).  Initial characterization of chemokines divided the family into α- 
20 
 
and β chemokines. In α chemokines, one amino acid separates the first two 
cysteine residues (cysteine-X amino acid-cysteine or CXC), whereas in β-
chemokines, the first two cysteine residues are adjacent to each other (cysteine–
cysteine, or CC).  Two additional classes were added for the chemokines, 
lymphotactin (single cysteine, XC) and fractalkine (first two cysteines are 
separated by three amino acids, CX3C).  The chemokine nomenclature herein 
utilizes both the original ligand name and the systematic name.  The systematic 
name uses XC, CC, CXC and CX3C, indicating the class to which the chemokine 
belongs, followed by the letter ‘‘L’’ (for ligand) and then a number.  The 
numbering system corresponds to that already in use to designate the genes 
encoding each chemokine.  All chemokines exert their biological effects through 
the activation of an extended family of seven transmembrane G-protein coupled 
receptors (GPCRs).  Nineteen chemokine receptors have been cloned including 
six CXC receptors (CXCR1-7), 10 CC receptors (from CCR1-10) and two single 
receptors each for lymphotactin (XCR1) and fractalkine (CXC3CR1).  Chemokine 
receptors are notoriously promiscuous, i.e. single chemokines can activate 
several different chemokine receptors.  There are, however, instances when a 
chemokine receptor is uniquely activated by a single chemokine.  
Stromal derived factor 1(SDF1) and CXCR4 
Stromal derived factor 1 (SDF1) was first identified in 1993 from murine 
bone marrow, hence the name (Li and Ransohoff, 2008; Tashiro et al., 1993). 
SDF1 was given the new name of CXCL12 in accordance with the new 
systematic naming system.  SDF1 is highly conserved between mice and 
21 
 
humans differing by only one amino acid, is widely expressed throughout the 
body, and exhibits a broad range of actions affecting stromal cell migration, 
leukocyte chemotaxis, vascularization of multiple organ systems, metastatic 
tumor formation, neural development and chronic pain (reviewed in (Miller et al., 
2008; White et al., 2007).  The molecular structure of SDF1 exhibits an amino 
acid sequence that contains four cysteine residues conserved by most CXC 
chemokines with the N-terminus of SDF1 particularly important for activity.  The 
monomer form of SDF1 is known to produce internalization of its receptor, 
CXCR4, and intracellular calcium mobilization.  Recent studies using nuclear 
magnetic resonance structure analysis of the SDF1:CXCR4-N-domain complex 
have also determined that the structural basis of the recognition of receptor 
residues by the chemokine is indicative of a constitutively active dimeric form of 
SDF1.  Importantly, this dimeric form serves only to activate intracellular calcium 
mobilization (Veldkamp et al., 2008). The differential effects on CXCR4-bearing 
cells by either the monomeric or dimeric forms reveal the latter to be a potent 
partial agonist (Veldkamp et al., 2008). 
The receptor for SDF1 was identified from the orphan GPCR, LESTR/fusin 
whose name was later changed to CXCR4 reflecting its ability to bind and 
respond to SDF1 (Bleul et al., 1996; Oberlin et al., 1996).  CXCR4 was also the 
first identified co-receptor for human immunodeficiency virus (HIV-1) (Feng et al., 
1996).   CXCR4 is a Gαi coupled GPCR capable of inducing calcium influxes 
(Boutet et al., 2001; Gillard et al., 2002).  The importance of SDF1/CXCR 
signaling in nervous system development is continuing to be explored.  
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SDF1/CXCR4 signaling importance in the development of the DRG  was 
demonstrated in CXCR4 -/- embryonic mice, which have small malformed DRGs 
(Belmadani et al., 2005).   
Until recently, CXCR4 was known to be the only receptor for SDF1. This 
idea was challenged when the chemokine receptor, CXCR7, was shown to bind 
SDF1 (Balabanian et al., 2005).  Initially described as a scavenger receptor 
(Boldajipour et al., 2008; Dambly-Chaudiere et al., 2007), more recent 
interactions describe CXCR7 as possibly moderating the response of CXCR4 to 
SDF1 by internalizing the ligand (Zabel et al., 2009). Although CXCR7 does not 
elicit activation of G-protein signaling pathways, it does activate MAP kinases 
through β-arrestin (Rajagopal et al., 2010).   
AMD3100, a CXCR4 antagonist 
AMD3100 is a bicyclam antagonist that was originally developed for the 
treatment of HIV infection.  It’s mechanism of action for HIV treatment being to 
block viral binding to the HIV co-receptor CXCR4 and therefore limiting viral entry 
(Schols et al., 1997; Donzella et al., 1998).  AMD3100 selectively blocks viral 
entry of R4 not R5 viral strains (Schols et al., 1997).  Additional functional studies 
of AMD3100 showed that AMD3100 blocked CXCR4 antibody labeling and 
inhibited SDF1-induced calcium responses (Schols et al., 1997; Donzella et al., 
1998).  AMD3100 has a 1000 fold greater affinity for CXCR4 over other 
chemokine receptors, CXCR1-3, CCR1-9 (Hatse et al., 2002).  An alternative 
chemokine receptor target for AMD3100 was demonstrated at CXCR7, where 
AMD3100 functions as an allosteric agonist (Kalatskaya et al., 2009).  However, 
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ongoing studies have demonstrated CXCR7 signals in a non-G-protein manner 
(Rajagopal et al., 2010).  Therefore AMD3100 agonist actions at CXCR7 should 
be re-examined taking into account non-G protein signaling.   
Chemokines and Pain 
Immune and non-immune cells associated with the injury response 
release pro-inflammatory mediators such as prostaglandins, histamine, 
serotonin, protons, bradykinin, nerve growth factor, and pro-inflammatory 
cytokines that can sensitize primary afferent neurons and contribute to pain 
hypersensitivity.  There is also adequate evidence demonstrating that like other 
inflammatory mediators, chemokines elicit hypernociception.  For example, Oh 
and colleagues (2001) demonstrated that a single injection into the un-inflamed 
adult rat hind paw of SDF1/CXCL12, Regulated upon Activation, Normal T-cell 
Expressed, and Secreted (RANTES/CCL5) or macrophage inflammatory protein 
1 (MIP1/CCL3) produces dose-dependent tactile allodynia.  These behavioral 
experiments in combination with accompanying RT-PCR, calcium imaging 
studies and immunohistochemistry confirmed the presence and functionality of 
the respective chemokine receptors, CXCR4, CCR5 and CCR4 in rodent dorsal 
root ganglion (DRG) sensory neurons (Oh et al., 2001).  Similar behavioral 
effects were observed following the introduction of interleukin-8 (IL-8 CXCL8) 
(Cunha et al., 1991) and intrathecal introduction of fractalkine (CX3CL1) (Milligan 
et al., 2005).  Studies conducted through intra- PAG injections of RANTES/CCL5 
demonstrated a similar dose dependent decrease in rat tail flick latency 
(Benamar et al., 2008a).   
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Perhaps, the chemokine/receptor pairing that has been studied the most 
extensively for its role in nociceptive behavior is MCP1/CCR2.  The importance 
of MCP1/CCR2 in neuropathic pain states was first demonstrated in CCR2 
knockout mice.  Testing of acute pain behavior in CCR2 knockout mice does not 
differ from wild type mice.  Following partial ligation of the sciatic nerve, a model 
known to induce hypernociception, CCR2 knockout mice failed to display 
mechanical hyperalgesia (Abbadie et al., 2003), while overexpression of glial 
MCP1 by transgenic mice produced enhanced nociceptive responses (Menetski 
et al., 2007).  Additional confirmation of a de novo role for MCP1/CCR2 signaling 
in injured neurons was observed following chronic compression of the dorsal root 
ganglia (a model of spinal stenosis). In this investigation, the injury produced 
neuronal upregulation of both MCP1 and CCR2 in the DRG while exogenous 
administration of MCP1/CCL2 produced a depolarized resting membrane 
potential and increased firing in the neuronal cell bodies (White et al., 2005). 
Subsequent studies demonstrated that sensory neurons following peripheral 
nerve injury exhibit chronic upregulation of functional MCP1/CCR2 signaling, an 
a CCR2 selective receptor antagonist could reverse hypernociceptive behavior in 
the injured animal (Bhangoo et al., 2007a).  Further investigations into the 
excitatory effects of MCP1/CCR2 signaling in sensory neurons have revealed 
that i) regulation of the CCR2 chemokine receptor expression in neurons is 
activity-dependent on the signal transcription factor, nuclear factor in activated T 
cells (NFAT) (Jung and Miller, 2008) and ii) MCP1 activates a non-cation 
selective voltage-independent, depolarizing current and inhibited a voltage 
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dependent outward current (Sun et al., 2006).  Moreover, MCP1 protein 
expression by DRG neurons following nerve injury is colocalized with calcitonin 
gene-related peptide in large dense core vesicles and release of MCP1 vesicles 
could be induced from the soma by depolarization in a Ca2+-dependent manner 
(Jung et al., 2008).  The role of MCP1/CCR2 signaling is not limited to the DRG 
soma.  Zhang and De Koninick (2006) recently demonstrated that MCP1/CCL2 is 
also present in central afferent fibers in the spinal cord. Electrical activity due to 
peripheral nerve injury may serve to stimulate central afferent release of 
MCP1/CCL2 into the spinal cord dorsal horn activating CCR2 bearing glial cells 
or neurons (Abbadie et al., 2003; Zhang et al., 2007; Zhang and De Koninck, 
2006).  
A less extensively studied chemokine and receptor pairing for the 
involvement in nociception is SDF1/CXCR4.  SDF1 application to sensory neuron 
cultures induces excitation and substance P release (Oh et al., 2001).  This same 
study demonstrated that hindpaw injection of SDF1 decreases paw withdrawal 
threshold (Oh et al., 2001).  Additionally, SDF1 injected into the PAG decreases 
the analgesic ability of opioid and cannabinoid agonists (Szabo et al., 2002; 
Benamar et al., 2008b).  SDF1/CXCR4 signaling has been shown to be central to 
chronic constriction injury (CCI) of the sciatic nerve (Dubovy et al., 2010) and  the 
nucleoside reverse transcriptase inhibitor, 2’,3’-dideoxycytidine (ddC)-induced 
tactile nociceptive behavior (Bhangoo et al., 2007b).  
Functional expression of chemokine/receptors in the damaged nervous 
system may both participate in the etiology and symptomology of diverse 
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pathological pain states.  To date, the evidence in animal models includes the 
upregulation of chemokine/receptors in partial ligation of the sciatic nerve 
(Abbadie et al., 2003; Tanaka et al., 2004; Lindia et al., 2005; Zhang et al., 
2007), chronic constriction injury of the sciatic nerve (Milligan et al., 2004; Zhang 
and De Koninck, 2006; Kleinschnitz et al., 2005; Dubovy et al., 2010), chronic 
compression of the L4, L5 DRG (CCD; a rodent model of spinal stenosis) (White 
et al., 2005; Sun et al., 2006), spinal cord contusion (Knerlich-Lukoschus et al., 
2008), chemically-induced focal nerve demyelination (Bhangoo et al., 2007a; 
Jung et al., 2007), bone cancer pain (Vit et al., 2006), zymosan or adjuvant-
induced inflammatory pain (Verge et al., 2004; Xie et al., 2006; Jeon et al., 2008; 
Sun et al., 2007) and the chemotoxic effects of some anti-HIV therapeutics 
(Bhangoo et al., 2007b).  Despite the potential importance of these factors for 
clinical pain syndromes, only a few studies have been designed to investigate the 
presence of altered levels of chemokines.  These include the measurement of 
chemokine levels in prostatic secretion from individuals diagnosed with chronic 
pelvic pain syndrome (Desireddi et al., 2008), herniated lumbar intravertebral 
disc specimens (Ahn, 2002) and the cerebral spinal fluid taken (CSF) from 
individuals diagnosed with chronic regional pain syndrome (CRPS) (Uceyler et 
al., 2007; Alexander et al., 2007; Alexander et al., 2005).  Although these studies 
did not reveal a specific molecule that could serve as a diagnostic marker of a 
chronic pain syndrome, it was notable that CSF from patients afflicted with CRPS 
did reveal a common pattern of elevated cytokines and chemokines in 11 of 22 
individuals tested (Alexander et al., 2007). 
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Goals 
In summary, the information outlined in the preceding sections has 
demonstrated the need for a greater understanding of the mechanisms of opioid 
induced hypernociception.  The mounting evidence of the interaction between 
opioids and chemokines in both the immune and nervous system, together with 
numerous studies showing the role that chemokines play in nociceptive models 
led me to pursue studies addressing the role that chemokines play in opioid 
induced hypernociception.  Furthermore, the peripheral nervous system, in 
particular the DRG, has been overlooked in studies examining OIH.  Providing 
evidence about the interaction of opioids and chemokines in sensory neurons will 
prove beneficial in developing new therapeutic options for opioid analgesics or 
treatment options targeted at chemokine signaling. 
In the first part, Chapter 2, of this project I set out to demonstrate an 
upregulation of SDF1/CXCR4 signaling in the dorsal root ganglion though the 
use of immunocytochemistry and in situ hybridization experiments in the DRG.  
Calcium imaging studies were employed to test the presence of functional 
chemokine receptors.  Finally, CXCR4 antagonism was used to demonstrate 
SDF1/CXCR4 signaling as a central component of OIH.  The second part of this 
project, Chapter 3, my focus was to determine whether opioid or non-opioid 
receptor signaling was responsible for changes in SDF1/CXCR4 signaling 
witnessed in morphine-induced hypernociception.  I utilized a number of 
pharmacological compounds to dissect the opioid and non-opioid receptor 
signaling components of OIH.  These studies also employed the use of 
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immunoctyochemisty techniques to examine changes in the expression of 
CXCR4 in the rodent DRG.  Calcium imaging studies were used to test for the 
presence of functional chemokine receptors.  CXCR4 antagonism was again 
utilized to determine the involvement of SDF1/CXCR4 signaling in any behavior 
induced by each of the pharmacological agents that were employed.  The results 
of these experiments provide evidence of SDF1/CXCR4 signaling in opioid 
induced hypernociception and provide further details about the mechanisms 
behind opioid induced hypernociception.  
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CHAPTER TWO 
THE ROLE OF SDF1/CXCR4 SIGNALING IN MORPHINE-INDUCED  
HYPERNOCICEPTION 
Overview 
Morphine and related compounds are the first line of therapy in the treatment of 
moderate to severe pain. Over time, individuals taking opioids can develop an 
increasing sensitivity to noxious stimuli, even evolving into a painful response to 
previously non-noxious stimuli (opioid-induced hypernociception; OIH). The 
mechanism underlying OIH is not well understood although complex intracellular 
neural mechanisms, including opioid receptor desensitization and down-
regulation, are believed to be major mechanisms underlying OIH. However, OIH 
may also be associated with changes in gene expression. A growing body of 
evidence suggests that cellular exposure to mu agonists upregulate 
chemokines/receptors and recent work from our lab implicates chemokine 
upregulation in a variety of neuropathic pain behaviors. Here we characterized 
the degree to which chemokines/receptors signaling is increased in primary 
afferent neurons of the dorsal root ganglion (DRG) following chronic morphine 
sulphate treatment and correlated these changes with tactile hypernociceptive 
behavior in rodents. We demonstrate that mRNA expression of the chemokine, 
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stromal-derived factor 1 (SDF1/CXCL12) is upregulated following morphine 
treatment in sensory neurons of the rat. The release of SDF1 was found to be 
constitutive when compared with the activity dependent release of the C-C 
chemokine, monocyte chemoattractant protein 1 (MCP1/CCL2) in a line of F-11 
neuroblastoma-sensory neuron hybrid cells.   We further determined that there is 
pronounced CXCR4 expression in satellite glial cells, and following morphine 
treatment, increased functional CXCR4 expression in sensory neurons of the 
DRG. Moreover, intraperitoneal administration of the selective CXCR4 
antagonist, AMD3100, completely reversed OIH in the rat. Taken together; the 
data suggest that opioid-induced SDF1/CXCR4 signaling is central to the 
development of long lasting OIH and that receptor antagonists represent a 
promising novel approach to the management of the side effects associated with 
the use of opioids for chronic pain management.  
Background 
Opioids such as morphine currently represent the best option for the 
management of moderate to severe trauma induced, perioperative and cancer 
pain. Opioid compounds are also increasingly being used for non cancer 
associated chronic pathological pain. However, prolonged administration of 
opioids is associated with significant problems including the development of anti-
nociceptive tolerance, wherein higher doses of the drug are required over time to 
elicit the same degree of analgesia. Repeated administration of higher doses of 
morphine or fentanyl also results in increasing pain sensitivity, a syndrome 
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clinically known as opioid-induced hypernociception (OIH) (Angst et al., 2003; 
Arner et al., 1988; Singla et al., 2007). This increased pain is usually experienced 
at different locations from the original site of injury (Ossipov et al., 2004).   
While it is thought that opioids modulate tactile hypernociception solely by 
acting at neuronal opioid receptors, administration of chronic morphine is also 
known to induce a rapid increase in the expression of proinflammatory cytokines 
such as TNFα, IL1β and IL-6 in a number of cell types within the nervous system 
(Johnston et al., 2004). These proinflammatory cytokines are powerful pain 
enhancing proteins that may, in turn, suppress acute opioid analgesia and 
contribute to the apparent loss of opioid analgesia upon repeated opioid 
administration (“tolerance”) (Hutchinson et al., 2008). The family of pro-
nociceptive cytokines includes chemotactic cytokines (chemokines). Proalgesic 
effects of chemokines have been implicated in both acute and chronic tactile 
hypernociceptive behavior (Abbadie et al., 2003; Bhangoo et al., 2007a; 
Bhangoo et al., 2007b; Johnston et al., 2004; Jung et al., 2009; Menetski et al., 
2007; Milligan et al., 2004; Oh et al., 2001; Wang et al., 2008; White et al., 2005; 
Xie et al., 2006).  However, the degree to which chronic morphine treatment 
alters gene expression of chemokines and their receptors, and whether this 
contributes to syndromes such as OIH is unknown. 
Effects of opioids on chemokine receptor expression are potentially important 
determinants of HIV-1 infection rates among intravenous drug users, as the 
chemokine receptors CCR5 and CXCR4 are co-receptors for the HIV-1 virus coat 
protein, gp120. To this end a number of studies using chronic morphine or the 
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selective µ opioid agonist, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) 
produce increased expression of monocyte chemoattractant protein-1 
(MCP1/CCL2), regulated upon activation normal T-cell expressed and secreted 
(RANTES/CCL5), and their respective receptors, CCR2 and CCR5, in astrocytes 
and neurons via largely unknown mechanisms (Avdoshina et al., 2010; Mahajan 
et al., 2005; Rock et al., 2006). A similar study demonstrated that DAMGO 
substantially increased the expression of both CCR5 and CXCR4 in leukocytes 
(Steele et al., 2003). Taken together, these observations raise the possibility that 
repeated exposure to opioids and subsequent increases in chemokine receptor 
signaling might also be central to OIH.  
We now demonstrate that many nociceptive neurons express functional 
receptors for a number of chemokines following systemic injection of morphine. 
Chemokine receptor signaling via the CXCR4 receptor may be central to OIH as 
the administration of the selective CXCR4 receptor antagonist, AMD3100, 
transiently reversed OIH in rats. Collectively, the data suggest that chemokine 
receptor antagonists represent a promising novel approach to the management 
of the side effects associated with long term opioids for chronic pain control. 
Methods 
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan 
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12-
hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard 
rodent chow and water available ad libitum.  Experiments were performed during 
the light cycle. These experiments were approved by the Institutional Animal 
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Care and Use Committee of Loyola University, Chicago and Indiana 
University/Purdue University in Indianapolis. All procedures were conducted in 
accordance with the Guide for Care and Use of Laboratory Animals published by 
the National Institutes of Health and the ethical guidelines of the International 
Association for the Study of Pain. All animals were randomly assigned to either 
treatment or control groups. 
Drugs and method of administration The drugs, morphine sulfate salt and the 
bicyclam, AMD3100, were employed in this study. Morphine sulfate salt and 
AMD3100 were purchased from NIDA Drug Supply Program (Rockville, MD) and 
Sigma-Aldrich (St. Louis, MO), respectively. All drugs were freshly prepared in 
saline on the day of the experiment. Morphine sulfate- and vehicle-treated groups 
were given intraperitoneal (i.p.) injections once daily for 5 days of 10 mg/kg or 
saline (vehicle). After tactile hypernociception was established, animals were 
given an i.p. injection of AMD3100 (10 mg/kg) (Fig. 3). Previous nociceptive 
behavioral studies from our lab using AMD3100 at doses of (1, 5, 10, and 25 
mg/kg) observed: no reversal of effect with 1 mg/kg, partial inconsistent effect 
with 5 mg/kg, reversal with 10 mg/kg, and reversal with side effects at 25 mg/kg 
(unpublished observations).  Therefore, 10 mg/kg AMD3100 was selected for 
these studies.  
Tactile Behavioral assessment Von Frey filaments were used to test 
mechanical sensitivity before, during and after cessation of morphine sulfate 
administration. Prior to initial von Frey tactile testing, all rodents were habituated 
to testing chambers for at least two days. Animals were tested for baseline 
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responses (BL) at least two times before undergoing the repeated morphine 
sulfate treatment (10 mg/kg, i.p. daily). Mechanical testing with von Frey 
filaments during the morphine sulfate dosing paradigm was limited to injection 
day (ID) 3. Behavioral assessment on ID3 occurred 18-20 hours after the ID2 
morphine administration and before ID3 morphine or vehicle treatment (Fig. 3). 
Additional behavioral assessment following drug or vehicle administration 
occurred on post-injection day (PID) 1, 2, 3, 7, 14, 21, and 28. All behavioral 
testing was performed by laboratory assistants who were blinded to the 
experimental conditions and unfamiliar with the experimental aims. 
The incidence of foot withdrawal in response to mechanical indentation of 
the plantar surface of each hindpaw was measured with a von Frey filament 
capable of exerting forces of 10, 20, 40, 60, 80 and 120 mN. These probes 
exhibit a uniform tip diameter (0.2 mm) and were applied to 6 designated loci 
distributed over the plantar surface of the foot (Ma et al., 2003). These 6 spots 
are representative of the distal nerve distributions of saphenous, tibial and sural 
nerves (medial to lateral) in the glabrous hindpaw.  During each test, the rodent 
was placed in a transparent plastic cage with a floor of wire with ~1×1 cm 
openings. The cage is elevated so that stimulation can be applied to each hind 
foot from beneath the rodent.  The filaments were applied in order of ascending 
force. Each filament was applied alternately to each foot and to each locus. The 
duration of each stimulus was approximately 1 s and the inter-stimulus interval 
was approximately 10–15 s. The incidence of foot withdrawal is expressed as a 
percentage of the 6 applications of each stimulus and the percentage of 
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withdrawals was then plotted as a function of force (Bhangoo et al., 2007a; Ma et 
al., 2003).  The von Frey withdrawal threshold was defined as the force that 
evoked a minimum detectable withdrawal observed on 50% of the tests given at 
the same force level. For cases in which none of the specific filaments used 
evoked withdrawals on exactly 50% of the tests, linear interpolation was used to 
define the threshold.   
Foot withdrawal to thermal stimulus To evaluate the paw withdrawal threshold 
(PWT) to thermal stimulation, the Hargreaves’ plantar test apparatus was used 
(Ugo Basile, Varese, Italy). Rats were placed on a 2-mm-thick glass floor; a 
mobile infrared heat generator with an aperture of 10 mm was aimed at the rat’s 
hind paw under the floor. Following activation of the heat source (IR setting = 70), 
the reaction time (the withdrawal latency of the hindpaw) of the rat was recorded 
automatically. A shortening of the withdrawal latency indicated thermal 
hypernociception. The temperature of the glass floor was kept at 22.5–23.5 °C. 
Measurements of the withdrawal latency of the paw began after the rats were 
habituated to the testing environment.  Animals were habituated to the testing 
apparatus each testing day for approximately 30 minutes.  Five trails of thermal 
measurements were taken, at 5 min intervals, on each hind paw, and the initial 
pair of trial measurements was not used. The averages of the three remaining 
pairs of measurements taken were employed as data.  Baseline recordings were 
taken 2-3 days prior to initiation of morphine dosing paradigm.  Thermal behavior 
was measured on during dosing paradigm (ID4) and following the cessation of 
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the dosing paradigm (PID 3-9).  The effect of the CXCR4 antagonist, AMD3100, 
on thermal behavior was determined PID7. 
Assessment of Withdrawal Behavior Withdrawal behaviors were monitored by 
a trained observer for each rat 1 min every 10 min over a 30-min period.  
Measurements recorded included locomotion:  jumping, wet dog shakes, tremor, 
ptosis, and piloerection.  The number of counts for each behavior over the 30 
minute period was recorded and the average count among the treated animals 
was used as the data for each time point.  Weight was also monitored during the 
testing period.  Baseline recordings (BL) were taken for 2 days prior to initiation 
of morphine dosing paradigm.  Withdrawal behavior was recorded following the 
cessation of morphine dosing paradigm (PID 1-8).  The effect of the CXCR4 
antagonist, AMD3100, on thermal behavior was determined PID7. 
Tissue processing and immunocytochemistry for neural tissue. Morphine or 
control treatments rats’ lumbar (L3-L6) DRG tissue was collected after animals 
were sacrificed and transcardially-perfused with saline followed by fixative.  Fixed 
tissue was then embedded for sectioning and processed using 
immunocytochemical methodologies commonly used in this lab (Bhangoo et al., 
2007a). Tissue sections from L4 and L5 were used in immunocytochemical 
experiments. Tissue sections were blocked with natural horse serum blocking 
buffer (SuperBlock® Blocking Buffer in PBS (Thermo Scientific, Rockford, IL, 
Natural Horse Serum (3% v/v), Triton X (0.4% v/v)).  Primary antisera used was 
the anti-CXCR4 rat monoclonal antibody, 2B11 (1:20,000 dilution; BD 
Biosciences, San Jose, CA) which binds to both human and mouse CXCR4 
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(Forster et al., 1998; Schabath et al., 1999). CXCR4 anti-body was dissolved in 
blocking buffer and incubated overnight.  After primary incubation, slides were 
incubated in secondary antibodies (1:1000 dilution; anti-rat made in donkey 
conjugated to CY3, Jackson ImmunoResearch, West Grove, PA). 
 Images were collected with a DeltaVision microscope (Applied Precision) 
equipped with a digital camera (CoolSNAP HQ; Photometrics), using a 1.4-
numerical aperture (NA) 20x objective lens, and were deconvolved with 
SoftWoRx deconvolution software (Applied Precision). 
Preparation of acutely dissociated dorsal root ganglion neurons. The L1-L6 
DRGs were acutely dissociated using methods described by Ma and LaMotte 
(Ma and LaMotte, 2005). Briefly, L1-L6 DRGs were removed from naive or 
morphine-treated animals four to six days following the last morphine injection. 
The DRGs were treated with collagenase A and collagenase D in HBSS for 20 
minutes (1 mg/ml; Roche Applied Science, Indianapolis, IN), followed by 
treatment with papain (30 units/ml, Worthington Biochemical, Lakewood, NJ) in 
HBSS containing .5 mM EDTA and cysteine at 35°C. The cells were then 
dissociated via mechanical trituration in culture media containing 1 mg/ml bovine 
serum albumin and trypsin inhibitor (1 mg/ml, Sigma, St. Louis MO). The culture 
media was Ham's F12 mixture, supplemented with 10% fetal bovine serum, 
penicillin and streptomycin (100 ug/ml and 100 U/ml) and N2 (Life Technologies). 
The cells were then plated on coverslips coated with poly-L lysine and laminin (1 
mg/ml) and incubated for 2-3 hours before more culture media was added to the 
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wells. The cells were then allowed to sit undisturbed for 12–15 hours to adhere at 
37°C (with 5% CO2). 
Intracellular Ca2+ imaging. The dissociated DRG cells were loaded with fura-2 
AM (3 uM, Molecular Probes/Invitrogen Corporation, Carlsbad CA) for 25 
minutes at room temperature in a balanced sterile salt solution (BSS) [NaCl (140 
mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (5 
mM)]. The cells were rinsed with the BSS and mounted onto a chamber that was 
placed onto the inverted microscope. Intracellular calcium was measured by 
digital video microfluorometry with an intensified CCD camera coupled to a 
microscope and MetaFluor software (Molecular Devices Corporation, 
Downington, PA). Cells were illuminated with a 150 W xenon arc lamp, and the 
excitation wavelengths of the fura-2 (340/380 nm) were selected by a filter 
changer. Sterile solution was applied to cells prior to chemokine application, any 
cells that responded to buffer alone were not used in chemokine responsive 
counts.  Chemokines were applied directly into the coverslip bathing solution. If 
no response was seen within 1 minute, the chemokine was washed out. For all 
experiments, MCP1, SDF1, regulated upon activation, normal T cell expressed 
and secreted (RANTES/CCL5), and interferon-gamma-induced protein 
(IP10/CXCL10) were added to the cells in random order, after which capsaicin 
(3nM), high K+ (50µM) and ATP (3nM) were added. The chemokines used were 
purchased from R & D Systems (Minneapolis, MN; <1.0 endotoxin per 1 μg of the 
protein by the LAL method), and all were used at a concentration of 100 nM to 
ensure maximal activation (Bhangoo et al 2007a; Bhangoo et al 2007b). 
39 
 
Chemokines were reconstituted in sterile 0.1%BSA/PBS, and aliquots were 
stored at -20°C.  Calcium imaging traces were analyzed by two independent 
analyzers and only responses that were in agreement between two individuals 
were used in the counts. 
In situ hybridization. In situ hybridization histochemistry for chemokine 
receptors was performed using digoxigenin-labeled riboprobes. Treated and non-
treated rodents were sacrificed using carbon monoxide. Lumbar DRGs from the 
injected and control animals were rapidly removed, embedded in OCT compound 
(Tissue Tek, Ted Pella, Inc., Redding, CA) and frozen. L4 and L5 DRG sections 
were cut serially at 12 m. The SDF1 probes were generated as described 
previously (Lu et al., 2002). Signals were visualized by using NBT/BCIP reagents 
(Roche Applied Science, Indianapolis, IN) in the dark for 2–20 h depending upon 
the abundance of the RNA. The in situ image was captured using a Retiga EX 
charge-coupled device camera (Q-imaging, Burnaby, BC). 
Plasmid construction. To make chemokine-fluorescent protein fusion 
constructs, MCP1 and SDF1-alpha protein coding sequence was cloned into 
pEGFP-N1 or pmCherry-N1 (Clontech).  
F11 Culture Conditions. F11 cells (a mouse N18TG2 neuroblastoma X rat DRG 
sensory neuron hybrid cell line) were grown as monolayers either in 100-mm 
plastic dishes under 5% CO2 in Ham’s F-12 medium supplemented with 20% 
fetal bovine serum (Hyclone), 100 pM hypoxanthine/ 1 pM aminopterin/ l2 pA4 
thymidine, and 50 IU/ml of penicillin/streptomycin. Cells were fed every other day 
for several days preceding an experiment with Ham’s F- I2 medium 
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supplemented with 1% fetal bovine serum, 50 ng/ml of NGF, 2 pM retinoic acid, 
0.5 mM dibutyryl cyclic AMP, 10 pM3-isobutyl-I-methylxanthine (IBMX), a 1:500 
dilution of 2.5 mg/ml of bovine insulin, a 1:100 dilution of 10 mg/ml of transferrin, 
and 50 IU/ml of penicillin/streptomycin.  
Enzyme-linked immunosorbant assay (ELISA). Constitutive and regulated 
release of MCP1-RFP (mCherry) and SDF1-RFP (mCherry) was measured by 
sandwich ELISA.  F11 DRG neuronal cells were transfected with MCP1-RFP or 
SDF1-RFP.  24 h after the transfection, cells were placed under differentiating 
conditions and allowed to differentiate for 48 h.  When cells were fully 
differentiated, culture medium was replaced with balanced salt solution (BSS) 
containing either 5 mM (normal) or 50 mM KCl (depolarizing).  Normal BSS (145 
mM NaCl, 5 mM KCl, 2 mM CaCl2,1 mM MgCl2) and depolarizing BSS (100 mM 
NaCl, 50 mM KCl, 2mM CaCl2, 1mM MgCl2) had the same osmolarity.  After 30 
min, released MCP1-RFP or SDF1-RFP was measured from supernatant by 
sandwich ELISA.  A polyclonal anti-RFP antibody (Abcam ab34771) was used as 
the capture antibody (1:50,000).  Chemokine-specific antibodies were used as 
the detecting antibodies: for SDF1, a mouse monoclonal anti-SDF1 antibody 
(Santa Cruz sc-74271); for MCP1, a goat polyclonal antibody (Santa Cruz sc-
1785). 
Statistics. Data for sandwich ELISA were presented as mean ± SEM and 
analyzed by one way ANOVA followed by Newman-Keuls multiple comparison 
tests. Prism 5 (GraphPad, LaJolla, CA) was used to determine the statistical 
significance of differences in the mean threshold forces for foot withdrawal to 
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punctate indentation as a function of time and between experimental groups by 
means of repeated measures analyses of variance (RMANOVA) followed by post 
hoc pairwise comparisons (Tukey method). Statistical significance was set at 
p < 0.05.  GraphPad Software (LaJolla, CA) was used to determine the statistical 
significance of differences in calcium response among naïve and treatment 
groups using Chi-square test with Yates correction with p<0.05 set as statistical 
significance.   
Results 
 
Repeated morphine treatment leads to tactile hypernociception  
     Initial experiments were conducted in order to determine the ability of our 
morphine dosing paradigm to induce nociceptive behavior as measured by tactile 
Figure 3.  Repeated morphine treatment paradigm.  Animals underwent 
baseline testing for 2-3 days prior to the start of injections.  Rats received 
once daily i.p. injections of morphine (10 mg/kg) for 5 days.  Behavioral 
testing that occurred during the 5 days of injections (ID) were carried out 24 
hours after the last morphine injection.  Following the injection period, 
behavior was conducted on animals for up to 28 days following the last 
morphine injection (PID).  Behavioral testing with the CXCR4 antagonist, 
AMD3100, occurred five days after the last morphine injection (PID5). 
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and thermal assessment.  Tactile hypernociception as measured by von Frey 
filaments is a characteristic behavioral response that develops in rodents 
following repeated administration of morphine (Celerier et al., 2000; Gardell et 
al., 2002). Our behavioral assessment of tactile hypernociception was performed 
prior to the start of the injection paradigm, during the 5 day dosing regimen, and 
for 28 days following the repeated morphine treatment paradigm (Fig.4).  In our 
experiments, the mean paw withdrawal threshold (PWT) of the tested hind paws 
exhibited a decrease after only two daily morphine injections relative to pre-
injection baseline PWT (ID3; 70.5±2.1 mN to 35.1±2.9 mN; n=12; p<0.0001). 
Statistically significant decreases in PWT were maintained until at least PID28 
(Fig. 2).  
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The changes in PWT observed at ID3 suggest that this nociceptive 
behavior is unaffiliated with morphine withdrawal signs such as jumping or wet 
dog shakes. Opioid withdrawal behaviors were observed between 24-48 hours 
following the last morphine injection and continued to be measured for 9 days 
following the cessation of the morphine dosing paradigm.   Alterations in the paw 
withdrawal latency evoked by thermal stimulation were not observed with this 
dosing paradigm (Fig. 5).   
These experiments demonstrated our repeated morphine dosing paradigm 
is able to induce tactile nociceptive behavior that persists for at least 28 days 
Figure 4.  Repeated morphine treatment (10 mg/kg for 5 days) results in the 
development of tactile hypernociception as measured by von Frey filaments.  
Tactile hypernociceptive behavior persists for at least 28 days following the last 
morphine injection.  ID, injection day, PID, post injection day (Repeated 
Measures  ANOVA; *p<0.05, significant difference from baseline). (n=6) 
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following the last morphine injection.  However, thermal nociceptive behavior was 
not observed.  
 
Repeated morphine treatment decreases CXCR4 immunoreactivity in the 
rat DRG.  
To assess the changes in CXCR4 expression in the rodent DRG following 
repeated morphine administration, immunocytochemistry experiments were 
conducted on DRG tissue sections using an antibody against the CXCR4 
receptor. 
 
Figure 5.  Thermal nociceptive behavior does not develop following 
repeated morphine treatment.  Thermal behavior, latency to withdrawal 
hindpaw, as measured by Hargreaves’ plantar test apparatus is 
unchanged over the entire testing period.  BL, Baseline, ID, injection day, 
PID, post injection day (n=8) 
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The CXCR4 antibody binds the N-glycosylation site g1 of human CXCR4. 
Although this site does not influence HIV-1 coreceptor function (Huskens et al., 
2007), this antibody is an effective neutralizing antibody in tumor formation and 
angiogenesis (Katoh and Katoh, 2010). In the adult rat dorsal root ganglia (DRG), 
CXCR4 expression is largely limited to presumptive nonmyelinating satellite glial 
cells (SGCs) of the DRG based on anatomical locale (Fig. 6A).  In addition to the 
SGCs, an occasional neuron was also observed to express the CXCR4. This 
expression pattern in the DRG coincides with CXCR4 mRNA expression pattern 
seen previously (Bhangoo et al 2007). By comparison, very few CXCR4-
immunoreactive, nonmyelinating SGCs were evident following repeated 
morphine treatment at PID5 (Fig. 6B). By PID21, CXCR4 immunoreactivity (-ir) in 
the nonmyelinating SGCs of the morphine treated rats was again evident (Fig. 
6C). Concurrent with return of CXCR4-ir, SGCs in the DRG at PID21 was the 
gradual return of PWT to pre-treatment BL thresholds (Fig. 4). 
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SDF1 mRNA is increased in sensory neurons following repeated morphine 
treatment and the protein is tonically released.   
     Given the apparent decline of CXCR4-ir in the DRG following the repeated 
morphine treatment paradigm, we determined whether SDF1 mRNA expression 
in the lumbar DRG was also altered by the dosing paradigm. We observed 
cellular expression patterns of SDF1 mRNA transcripts by in situ hybridization 
using digoxigenin-labeled riboprobes in relatively few cells of the saline-treated 
DRG (Fig. 7A). Following repeated morphine treatment both non-neuronal cells 
and numerous sensory neurons exhibited SDF1 mRNA transcripts (Fig.7B).  
 
Figure 6. Repeated morphine injections reduces CXCR4-immunoreactivity (-IR) in 
satellite glial cells of rat lumbar DRG sections.  Animals received repeated 
morphine injections (10 mg/kg for 5 days) and tissue was collected at 5 days 
(PID5) and 21 days (PID21) after the last morphine injection. A) CXCR4-IR (red) 
is largely restricted to satellite glial cells in the naïve rodent DRG. B) Following 
repeated morphine treatment, CXCR4-IR is reduced at PID5.  C) By PID21 
CXCR4-IR begins to return to naïve levels. Scale bar is 100 m (n = 7 for day 5 
and n = 7 for each day 21). 
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The observation that SDF1 is expressed in DRG neurons following 
repeated morphine treatment raises the possibility that the ligand may be 
tonically released from these cells. Hosung Jung from Dr. Richard Miller’s lab 
therefore examined the release of SDF1 using the F11 cell line. This cell line was 
derived from DRG neurons and maintains many of the differentiated properties of 
these cells (Platika et al., 1985). We compared the characteristics of SDF1 
release to those of MCP1/CCL2, another chemokine that has been shown to be 
expressed and released by DRG neurons (Jung et al., 2008). Following the 
expression of chemokine fluorescent fusion proteins (SDF1-RFP and MCP1-
Figure 7. SDF1 mRNA expression is increased in the lumbar DRG following 
repeated morphine exposure. In situ hybridization was used to assess the expression 
pattern of SDF1 mRNA. A) High power photomicrograph of basal expression of SDF1 
mRNA was observed in the lumbar DRG from saline injected rats in non-neuronal 
cells (black arrowhead indicates SDF1 mRNA transcripts in non-neuronal cell). Teal 
arrows indicate a lack of neuronal SDF1 mRNA transcripts. After a repeated 
morphine exposure, the level of SDF1 mRNA expression increased by post-injection 
day (PID) -5. SDF1 mRNA expression appears in both neuronal and non-neuronal 
cells. (Black arrows indicate neurons positive for SDF1 mRNA transcripts; 
arrowheads, presumptive glial cells positive for SDF1 mRNA transcripts). Scale bar A 
and B is 50 μm (n = 5 for each condition). 
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EGFP) we noted that the two chemokines localized to different sets of secretory 
vesicles (Fig. 8).   We measured constitutive and K+ depolarization induced 
release of each chemokine from F11 cells using a sandwich ELISA, and 
observed that the patterns of release for the two chemokines were also different. 
Release of MCP1-RFP from differentiated F11 cells was significantly increased 
by depolarizing medium containing high K+ (Fig 9A). However, the release of 
SDF1-RFP was quite apparent under non depolarizing conditions and was not 
increased further by K+ depolarization (Fig 9B), suggesting that most SDF1 
release was constitutive whereas a significant portion of MCP1 release was 
regulated by neuronal depolarization. This result implies that once the expression 
of SDF1 has been increased in DRG neurons (see Fig 7); it will be constitutively 
released from these cells. 
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Figure 8.  MCP1 and SDF1 are sorted into different pools of vesicles in F11 cells. (A) 
MCP1-RFP (left panel), SDF1-RFP (right panel), or RFP alone was transfected into 
F11 cells.  After 2 days, MCP1-RFP or SDF1-RFP was detected from the cell lysate by 
Western blot analyses using antibodies against MCP1, SDF1, and RFP.  The precursor 
form (**) as well as the mature form, (*) in which the signal peptide has been cleaved, 
could be detected both by the RFP antibody and the chemokine antibodies (MCP1 or 
SDF1), indicating that the fusion of RFP to the C-termini of MCP1 and SDF1 does not 
alter their processing into the secretory pathway. (B) MCP1-EGFP was cotransfected 
with RFP alone (top panels), MCP1-RFP (middle panels), or SDF1-RFP (bottom 
panels).  Unlike RFP alone which diffusively localized throughout the cell including the 
nucleus, MCP1-RFP and SDF1-RFP both exhibited perinuclear localization and 
punctate subcellular localization reminiscent of secretory vesicles.  MCP1-EGFP and 
SDF1-RFP did not colocalize (bottom panels) unlike MCP1-EGFP and MCP1-RFP 
(middle panels), indicating that MCP1 and SDF1 are packaged into different pools of 
secretory vesicles. 
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Repeated morphine treatment increases functional chemokine receptor 
expression by capsaicin sensitive DRG neurons.  
To further investigate the status of functional CXCR4 receptor expression in 
the DRG following repeated morphine treatment, we utilized Ca2+ imaging 
studies in acutely dissociated DRGs derived from animals subjected to repeated 
morphine conditions and naive controls.  The time points used corresponded to 
time points used for immunohistochemical and behavioral assessment (Fig 6).  
The acutely dissociated DRG preparations were categorized into three neuronal 
and non-neuronal cell types:  non-capsaicin sensitive neurons (high K and ATP 
responsive), capsaicin sensitive neurons (capsaicin, high K, and ATP 
responsive), and glia (ATP responsive only).  These cell response criteria were 
chosen strictly as an indicator of the types of cells that may be affected by the 
 
Figure 9.  Chemokine specific release from transfected F11 cells is by regulated 
(MCP1) or constitutive release mechanisms (SDF1). F11 DRG neurons were 
differentiated and then depolarized by high K stimulation (50 mM; 50K), either with 
or without extracellular Ca (2 mM or 0 mM; 2Ca or 0CA).  The amount of MCP1-
RFP released into the culture medium was measured by sandwich ELISA. The 
release of SDF1-mRFP1 was examined in the same manner as MCP1-mRFP1.  
Baseline levels of MCP1-RFP (A) or SDF1-RFP (B) in F11 cells prior to addition of 
50mM K were 6.3 ± 0.7 or 10 ± 1.1% of total media, respectively (A sandwich 
ELISA; *p<0.01 vs. any other group, Newman-Keuls Multiple Comparison Test). 
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repeated morphine treatment paradigm.  The tested chemokines were selected 
so as to activate a wide spectrum of chemokine receptors known to be 
expressed by neurons and non-neuronal cells (CXCR4-SDF1/CXCL12, CXCR3-
IP10/CXCL10, CCR2-MCP1/CCL2, CCR5-RANTES/CCL5). The chemokine 
concentration used for these experiments were based on their maximally 
effective concentrations using our previous observations on acutely dissociated 
DRGs (Bhangoo et al., 2007a; Bhangoo et al., 2007b). 
 
Application of all tested chemokines produced [Ca2+]i changes in small 
numbers of neuronal and non-neuronal populations of cells derived from control 
DRGs (Table 2). Following exposure to repeated morphine treatment, we 
observed a significant increase in the chemokine responsiveness of non-
Naïve Morphine-Treated 
Non-
capsaicin 
sensitive 
neurons 
Capsaicin
-sensitive 
neurons Glia 
Non-
capsaicin 
sensitive 
neurons 
Capsaicin-
sensitive 
neurons Glia 
SDF1 
7% 
(6/85) 
7% 
(5/72) 
21% 
(9/44) 
15% 
(17/112) 
34% 
(25/73)** 
27% 
(13/49) 
IP-10 
4% 
(3/85) 
0% 
(0/72) 
2% 
(1/44) 
13% 
(14/112)* 
25% 
(18/73)** 
8% 
(4/49) 
MCP1 
4% 
(3/85) 
6% 
(4/72) 
9% 
(4/44) 
16% 
(18/112)** 
29% 
(21/73)** 
25% 
(12/49) 
RANTES 
14% 
(12/85) 
4% 
(6/72) 
21% 
(9/44) 
17% 
(19/112) 
29% 
(21/73)** 
12% 
(6/49) 
 
Table 2.  Repeated morphine treatment increases nociceptive neurons 
chemokine calcium responsiveness.  Daily morphine injections (10 mg/kg for 5 
days) were administered to animals.  Lumbar DRGs were acutely dissociated 
from these animals 4-6 days following the last morphine injection.  The most 
significant increase in chemokine calcium responsiveness occurred in the 
nociceptive neurons (** p<0.01, * p<0.05, Chi-square with Yates correction). 
(naïve, n=8, morphine-treated n=6) 
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capsaicin sensitive and capsaicin sensitive neurons. This included a robust 
increase in SDF1 responsive capsaicin sensitive neurons (p<0.0001). Hence it 
appears that DRG nociceptive neurons express more functional chemokine 
receptors, including CXCR4 receptors, following the repeated morphine 
treatment paradigm (Table 2). 
Reduced CXCR4 expression following repeated morphine treatment is 
abolished by AMD3100 treatment   
     Given that tonic activation of CXCR4 by SDF1 leads to internalization of both 
chemokine and receptor (Burger and Kipps, 2006), it is entirely possible that the 
constitutive release of neuronal SDF1 and subsequent neuronal signaling via 
CXCR4 may result in diminished evidence of CXCR4-ir in the sensory ganglia of 
morphine treated rats (Fig 100C). This event would not be unlike previous 
reports in the dentate gyrus (Bhattacharyya et al., 2008; Kolodziej et al., 2008). 
Additional studies have shown that the binding capabilities of the CXCR4 
antibody utilized for these studies can compete with SDF1 binding sites 
(Dubeykovskaya et al., 2009). To test this possibility we intraperitoneally 
administered the CXCR4 antagonist, AMD3100, at doses of 1 and 10 mg/kg and 
sacrificed the animals one hour later.  Overall increases in CXCR4-ir binding 
were observed following AMD3100 administration in morphine treated animals at 
10 mg/kg (Fig. 10E), but not 1 mg/kg (Fig. 10D). As evidence of the de novo 
SDF1 signaling via CXCR4, CXCR4-ir was also observed in numerous neurons 
(Fig. 10E).  This data provides further support for the increased functional 
CXCR4 receptors observed in neurons (see Table 2).   Three hours after 
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AMD3100 administration, the CXCR4-ir was again qualitatively decreased in the 
DRG (Fig. 10F).  Following administration of AMD3100 in the naïve animal (Fig. 
10B), there was a noticeable decrease in CXCR4-ir when compared with the 
naïve animal (Fig. 10A). This is likely attributed to the competition that exists 
between AMD3100 and CXCR4 antibody for available receptor binding sites. 
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Decreased tactile hypernociception following intraperitoneal injection of 
CXCR4 antagonist, AMD3100.  
     To determine whether SDF1/CXCR4 signaling was involved in OIH, we 
administered a single systemic dose of either vehicle or 10 mg/kg AMD3100 i.p. 
 
Figure 10. The CXCR4 antagonist AMD3100 reverses loss of CXCR4 
immunoreactivity in DRG derived from repeated morphine treated rats. Untreated rats 
(A), naive animal administered AMD3100 1 hour before sacrifice (B), repeated 
morphine treatment alone (i.p., 10 mg/kg, once daily for 5 days) (C) repeated 
morphine treatment in combination with different doses of AMD3100 1 hour before 
sacrifice (D, E) and 3 hours before sacrifice (F). Treatment with AMD3100 reverses 
repeated morphine treatment-induced loss of CXCR4 immunoreactivity at PID5 (C) in 
a dose-dependent manner (D,E). CXCR4-immunoreactivity (red label) in rat DRG 
sections following 10 mg/kg (E), but not 1 mg/kg (D) dose of AMD3100 returns 
CXCR4 immunoreactivity to levels observed in untreated control rats (A). White 
arrows indicate the presence of CXCR4-immunopositive neurons following AMD3100 
treatment. Scale bar is 100 m. (n=4 each group)
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at PID5. Systemic injection of AMD3100 (10 mg/kg) in naïve rodents did not alter 
baseline PWT (70.5±2.1 mN; Fig 11). Vehicle injections in morphine treated rats 
did not alter PWT (data not shown).  However, 1 hour after AMD3100 was 
administered to morphine treated rats, PWT returned to baseline (69.25±2.75 
mN; p<0.01). The rapid onset of AMD3100 was short lived as PWTs returned to 
pre-dosing levels by three hours (35.25±4.59 mN) (Fig 11).  The return of 
morphine-induced behavior 3 hours post AMD3100 injection coincides with the 
returned loss of CXCR4-ir observed 3 hours post AMD3100 injection in rat DRG 
sections (Fig 10F).  
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Discussion 
The experiments reported here demonstrate that following repeated 
morphine exposure, rodents exhibited a prolonged tactile hypernociception. This 
change in paw withdrawal threshold was maintained at least until PID28. 
Importantly, morphine-induced tactile hypernociception could be transiently 
reversed by a chemokine receptor antagonist that is selective for CXCR4 
receptors. These results provide the first demonstration that morphine induced 
Figure 11.  Morphine-induced tactile hypernociception in rodents is transiently 
reversed with CXCR4 antagonist, AMD3100 treatment.  Five days following 
the last morphine injection (PID5) rats received an i.p. injection of AMD3100 
(10 mg/kg) and tactile behavior was measured by von Frey filaments 1 and 3 
hours post injection.  AMD3100 treatment completely reversed morphine-
induced tactile hypernociception by one hour post injection.  Tactile 
hypernociception returned 3 hours following injection of AMD3100.  
*Significant difference from baseline; one-way ANOVA; p<0.01).(n=6) 
57 
 
tactile hypernociception behavior in the rodent appears to be dependent on 
activation of CXCR4 receptors. Thus, morphine induced SDF1 signaling via 
CXCR4 receptors appears to change the balance between opioid analgesia and 
hypernociception. 
OIH has been observed both clinically (Angst et al., 2003; Arner et al., 
1988; Singla et al., 2007) and experimentally (Laulin et al., 1999; Woolf, 1981).  
Many explanations for this phenomenon have been suggested which have 
centered largely on changes within the central nervous system. These potential 
mechanisms include enhanced production/release of glutamate and 
neuropeptides in the spinal cord (Belanger et al., 2002; Ibuki et al., 2003; Mao et 
al., 2002), protein kinase C -induced signaling (Lim et al., 2005), spinal 
Ca2+/calmodulin-dependent protein kinase II alpha activity (Chen et al., 2010), 
enhanced descending facilitation of nociceptive pathways from the rostral 
ventromedial medulla (Vanderah et al., 2001) and activation of non-classical 
opioid receptors (Lewis et al., 2010). Alternative peripheral mechanisms also 
include sensitization of peripheral nociceptors (Aley and Levine, 1997; Liang et 
al., 2008).  
The mechanisms responsible for morphine induced SDF1/CXCR4 
signaling in primary sensory neurons of the DRG are largely unknown. Thus, the 
effects we have observed might be downstream of morphine’s interactions with 
µ-opioid receptors or possibly through interactions with TLR4 as has been 
recently suggested (Hutchinson et al., 2010). A number studies have been 
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conducted demonstrating the ability of chemokines and opioid agonists 
administration to induce heterologous desensitization to their respective systems 
(Szabo et al., 2002; Chen et al., 2007b).  These studies have clearly shown that 
there is a relationship between the chemokine and opioid signaling pathways 
during acute administration.  However, our results expand on these studies by 
suggesting that following the chronic administration of morphine produces an 
alteration in sensory neuron SDF1/CXCR4 signaling that lasts for at least 5 days 
after the last opioid injection.  
With respect to morphine induced changes in CXCR4 activation, there 
appear to be two important changes in the status of SDF1/CXCR4 signaling 
within the DRG. First, it appears that greater CXCR4 signaling occurs following 
the dosing regimen. This is indicated by the fact that during OIH there is an 
AMD3100 reversible decline in CXCR4-ir in the DRG, presumably resulting from 
SDF1 activation of CXCR4 receptors followed by their internalization and 
recycling mechanisms, as previously observed in the dentate gyrus 
(Bhattacharyya et al., 2008; Kolodziej et al., 2008). Secondly, the increased 
SDF1/CXCR4 activation could result from enhanced tonic release of neuronal 
SDF1 whose expression was upregulated under these conditions, or some 
postsynaptic effect of morphine which produces enhanced CXCR4 
desensitization in response to tonically released SDF1. In particular, the Ca2+ 
imaging experiments and the immunohistochemistry studies following AMD3100 
administration clearly demonstrate that morphine treatment results in 
considerable degree of upregulated expression of CXCR4 by DRG nociceptors. 
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Our results highlight the rapid timecourse of CXCR4 downregulation and 
recycling that occurs in the DRG and other cell types. Numerous studies have 
demonstrated that the time course and extent of CXCR4 recycling in different cell 
types is subject to a very large number of factors that can interact with the 
receptor and regulate the different stages of endocytosis, and recycling or 
degradation (Tarasova et al., 1998; Zhang et al., 2004b). Thus it is becoming 
clear that regulating the levels of CXCR4 cell surface expression is one important 
mechanism of adjusting the signaling possibilities through this pathway. As 
activation of chemokine receptors expressed by DRG neurons produces 
excitation (White et al., 2007), it is likely the activation of these receptors by 
SDF1 contributes to the ectopic excitability of these neurons and produces 
AMD3100 reversible tactile hypernociception. The transient effect of AMD3100 
may be explained by the short half life of 0.9 hours following a single 
administration (Hendrix et al., 2000).  To this end, our observations support the 
growing body of literature that chemokines can act as neurotransmitters under 
some circumstances (White et al., 2007). 
In the case of SDF1, its release mechanism may be unusual as it does not 
seem to require a depolarization induced increase in Ca2+, in contrast to the 
depolarization dependent release of MCP1. The different release mechanisms 
may be due to the observation that the two chemokines appear to be stored in 
separate subcellular compartments. Thus, it is possible that the SDF1 storage 
vesicles may be released by lower levels of Ca2+ or by low Ca2+ in cooperation 
with some other signaling mechanism. We demonstrated that morphine will 
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increase the expression of SDF1 within DRG neurons. According to our data 
increased concentrations of SDF1 within DRG neurons should result in increased 
tonic release of the chemokine. The fact that appreciable levels of SDF1 may be 
tonically released both in the DRG (data herein) and the dentate gyrus suggest 
that SDF1 may generally be secreted in this way when utilized in the nervous 
system (Bhattacharyya et al., 2008; Kolodziej et al., 2008). Until recently, CXCR4 
was known to be the only receptor for SDF1. This idea was challenged when the 
chemokine receptor, CXCR7, was shown to bind SDF1 (Balabanian et al., 2005).  
Initially described as a scavenger receptor, more recent interactions describe 
CXCR7 as possibly moderating the response of CXCR4 to SDF1 by internalizing 
the ligand (Zabel et al., 2009).  Whether SDF1/CXCR7 activation serves to 
modulate OIH is unknown. However, we have observed that CXCR7 is 
expressed in the DRG of adult mice (unpublished observations) and so this 
remains a possibility. 
In conclusion, ongoing SDF1/CXCR4 signaling within sensory neurons 
provides a mechanistic basis for understanding OIH modifications within the 
nervous system. Beyond its signaling relevance in the sensory neuron, the 
relationship between neuronal expression of SDF1/CXCR4 and tactile 
hypernociception in the rodent may imply that chemokine-sensitized sensory 
neurons may serve as an excitatory signal central to OIH. Thus, OIH represents 
another example of chronic pain behavior where chemokine signaling in DRG 
neurons has been observed to be upregulated (White et al., 2009), further 
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highlighting the potential role of chemokine signaling in the generation of chronic 
pain. 
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CHAPTER THREE 
THE ROLE OF OPIOID AND NON-OPIOID RECEPTOR SIGNALING IN 
SDF1/CXCR4 INDUCED CHANGES IN THE DORSAL ROOT GANGLION 
Overview 
Opioid analgesics such as morphine represent one of the most effective 
treatment options for moderate to severe pain.  Clinical usage of opioid 
analgesics while effective can also be accompanied by a number of side effects 
such as respiratory depression, urinary retention, or dependence.  Individuals 
taking opioids such as, morphine can also develop increased pain sensitivity 
referred to as opioid induced hypernociception (OIH).  The mechanism behind 
the development of OIH remains largely unknown.  However, recent work in our 
lab has implicated the upregulation of SDF1/CXCR4 signaling in OIH.  The 
purpose of the current study was to identify the receptor activation responsible 
for the upregulation of chemokines in the DRG of animals exhibiting OIH.   In 
order to dissect the receptor activation events responsible we used 
pharmacological tools with distinct receptor affinity patterns.  In order to test the 
role of non-opioid signaling we used the morphine metabolite, morphine 3-ß-D-
glucuronide (M3G), and morphine co-administered with the non-selective opioid 
antagonist naltrexone.  The selective mu opioid receptor (MOR) agonist, D-Ala2, 
N-MePhe4, Gly-ol-enkephalin (DAMGO), was employed to demonstrate the role 
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of MOR in changes in SDF1/CXCR4.  We demonstrate that OIH is induced 
through opioid and non-opioid signaling events as repeated administration of 
DAMGO, M3G, and morphine co-administered with naloxone all induced 
nociceptive behavior.  However, only repeated DAMGO administration is able to 
induce changes in SDF1/CXCR4 signaling in the rodent DRG.  Changes in 
SDF1/CXCR4 signaling within the DRG are indicated by a decrease in CXCR4-
immunoreactivity that is reversed by the CXCR4 antagonist, AMD3100.  
Additionally, DAMGO-induced nociceptive behavior is partially reversed with the 
administration of AMD3100.  The data presented implicate MOR activation as 
responsible for changes in SDF1/CXCR4 signaling previously witnessed with 
morphine.  Furthermore, the data demonstrate that the mechanism responsible 
for inducing OIH involves both opioid and non-opioid receptor signaling events.  
Therefore, future studies examining OIH should consider a multiple receptor 
approach is needed in order to prevent the development of OIH, which would 
lead to a better treatment options for pain management. 
Background 
Opioid analgesics typically have their greatest affinity for the mu opioid 
receptor (MOR).  Signaling through the MOR is also attributed to the analgesic 
mechanism of action. The opioid analgesic, morphine, shares this affinity profile 
having a greater affinity for MOR (14 nM) less affinity for the kappa opioid 
receptor (538 nM) and lowest affinity for the delta opioid receptor (>1000 nM) 
(Raynor et al., 1994).  Morphine like any drug has affinity for multiple receptors 
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and with an increased dose the probability of binding additional receptors 
increases.  Therefore, any effects adverse or therapeutic could be occurring 
through opioid or non opioid receptor binding. 
The receptor signaling events responsible for morphine-induced 
hypernociception is still unclear.  However, recent studies have shown that 
morphine-induced hypernociception occurs in triple opioid knockout mice 
demonstrating this behavioral state can induced through a non-opioid receptor 
(Juni et al., 2007).  The mechanism behind morphine’s non-opioid receptor 
signaling ability is undetermined.  However, one possible candidate is morphine 
3-ß-D-glucuronide (M3G), the major metabolite of morphine, which has limited 
affinity for all of the opioid receptors (Pasternak et al., 1987;Skarke et al., 2005) 
and lacks analgesic ability (Pasternak et al., 1987; Ekblom et al., 1993).  In fact, 
M3G has been shown to be neuroexcitatory and capable of inducing nociceptive 
behavior (Bartlett et al., 1994; Yaksh et al., 1986; Woolf and Fitzgerald, 1981; 
Lewis et al., 2010).  Therefore, M3G could be responsible for the non-opioid 
signaling taking place with morphine but the receptor that is responsible for 
binding M3G is unknown.  Watkins and colleagues have suggested that M3G is 
signaling through toll-like receptor 4 (TLR4) and that signaling through TLR4 
leads to M3G-induced hypernociception (Lewis et al., 2010; Hutchinson et al., 
2009; Hutchinson et al., 2010.  Further studies addressing this possibility are 
needed. 
Our previous studies with morphine demonstrated that morphine treatment 
induced a persistent hypernociceptive state which can be transiently reversed by 
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the CXCR4 antagonist, AMD3100 (Wilson et al., 2011).  An interaction between 
opioids and chemokines has previously been demonstrated by opioid agonists 
such as, morphine and DAMGO, increasing CXCR4 and CCR5 on monocytes 
and lymphoctyes (Steele et al., 2003).  Additionally, a number of studies from the 
Rogers and Adler group have demonstrated chemokine injections into the 
periaqueductal grey (PAG) leads to a decrease in the anti-nociceptive effects of 
opioids (Szabo et al., 2002; Chen et al., 2007a; b).  Therefore, opioid receptor 
signaling could be involved in morphine-induced changes in SDF1/CXCR4 and 
hypernociceptive behavior. 
The goal of our current study was to determine the receptor activation 
responsible for inducing changes in SDF1/CXCR4 signaling we previously 
witnessed following repeated morphine administration.  Various pharmacological 
tools were utilized to dissect the opioid and non-opioid receptor signaling 
components. To test the role of opioid receptor signaling the selective MOR 
agonist, DAMGO, was used.  Examination of non-opioid receptor signaling, M3G 
and morphine co-administered with the non-selective opioid antagonist, 
naltrexone, were assessed in their ability to induce hypernociceptive behavior 
and the changes in SDF1/CXCR4 signaling in the rodent DRG. 
Methods 
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan 
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12-
hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard 
rodent chow and water available ad libitum. Experiments were performed during 
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the light cycle. These experiments were approved by the Institutional Animal 
Care and Use Committee of Indiana University/Purdue University in Indianapolis. 
All procedures were conducted in accordance with the Guide for Care and Use of 
Laboratory Animals published by the National Institutes of Health and the ethical 
guidelines of the International Association for the Study of Pain. All animals were 
randomly assigned to either treatment or control groups. 
Drugs and method of administration. All drugs were freshly prepared in saline 
on the day of the experiment. Intraperitoneal (i.p.) injections were administered to 
animals following light anesthesia.  For all dosing paradigms, animals received 5 
once daily injections of the following drugs:  DAMGO, M3G, and morphine and 
naltrexone.  For D-Ala2, N-MePhe4, Gly-ol-enkephalin (DAMGO) experiments, 
DAMGO was administered at a dose of 10 mg/kg and purchased from Sigma-
Aldrich (St. Louis, MO).  Morphine 3-ß-D-glucuronide (M3G) was administered in 
doses of 1, 5, and 10 mg/kg, supplied by NIDA Drug Supply Program.   For 
morphine and naltrexone experiments, naltrexone (10 mg/kg) was administered 
30 minutes prior to morphine (10 mg/kg) injection.  Four hours following the first 
naltrexone injection an additional naltrexone (10mg/kg) was administered. 
Morphine sulfate and naltrexone were purchased from NIDA Drug Supply 
Program and Sigma-Aldrich (St. Louis, MO), respectively.  After tactile 
hypernociception was established, animals were given an i.p. injection of 
AMD3100 (10 mg/kg) five days after the last day of the dosing paradigm (PID5).  
AMD3100 dose was determined from previous experiments in our lab 
(unpublished observations, (Wilson et al., 2011).  
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Tactile Behavioral assessment von Frey filaments were used to test 
mechanical sensitivity before, during and after cessation of DAMGO, M3G, and 
morphine + naltrexone administration. Prior to initial von Frey tactile testing, all 
rodents were habituated to testing chambers for at least two days. Animals were 
tested for baseline responses (BL) at least two times before undergoing the 
injection paradigm (5 daily doses of M3G, DAMGO, or morphine + naltrexone). 
Mechanical testing with von Frey filaments during dosing paradigm was limited to 
injection day 3 (ID3) (data not shown). Behavioral assessment on ID3 occurred 
18-20 hours after the ID2 drug administration and before ID3 drug treatment. 
Additional behavioral assessment following drug or vehicle administration 
occurred on post-injection day (PID) 5, 7, and 14. All behavioral testing was 
performed by laboratory assistants who were blinded to the experimental 
conditions and unfamiliar with the experimental aims. 
The incidence of foot withdrawal in response to mechanical indentation of 
the plantar surface of each hindpaw was measured with a von Frey filament 
capable of exerting forces of 10, 20, 40, 60, 80 and 120 mN. These probes 
exhibit a uniform tip diameter (0.2 mm) and were applied to 6 designated loci 
distributed over the plantar surface of the foot (Ma et al., 2003). These 6 spots 
are representative of the distal nerve distributions of saphenous, tibial and sural 
nerves (medial to lateral) in the glabrous hindpaw.  During each test, the rodent 
was placed in a transparent plastic cage with a floor of wire with ~1×1 cm 
openings. The cage is elevated so that stimulation can be applied to each hind 
foot from beneath the rodent.  The filaments were applied in order of ascending 
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force. Each filament was applied alternately to each foot and to each locus. The 
duration of each stimulus was approximately 1 s and the inter-stimulus interval 
was approximately 10–15 s. The incidence of foot withdrawal is expressed as a 
percentage of the 6 applications of each stimulus and the percentage of 
withdrawals was then plotted as a function of force (Bhangoo et al., 2007a; Ma et 
al., 2003).  The von Frey withdrawal threshold was defined as the force that 
evoked a minimum detectable withdrawal observed on 50% of the tests given at 
the same force level. For cases in which none of the specific filaments used 
evoked withdrawals on exactly 50% of the tests, linear interpolation was used to 
define the threshold.   
Tissue processing and immunocytochemistry for neural tissue. Lumbar (L3-
L6) DRG tissue was collected from DAMGO, M3G, morphine co-administered 
with naltrexone, and naïve rodents after animals were sacrificed and 
transcardially-perfused with saline followed by fixative.  Fixed tissue was then 
embedded for sectioning and processed using immunocytochemical 
methodologies commonly used in this lab (Bhangoo et al., 2007a, Wilson et al., 
2011). Tissue sections from L4 and L5 were used in immunocytochemical 
experiments. Tissue sections were blocked with natural horse serum blocking 
buffer (SuperBlock® Blocking Buffer in PBS (Thermo Scientific, Rockford, IL, 
Natural Horse Serum (3% v/v), Triton X (0.4% v/v)).  Primary antisera used was 
the anti-CXCR4 rat monoclonal antibody, 2B11 (1:20,000 dilution; BD 
Biosciences, San Jose, CA) which binds to both human and mouse CXCR4 
(Forster et al., 1998; Schabath et al., 1999). CXCR4 anti-body was dissolved in 
69 
 
blocking buffer and incubated overnight.  After primary incubation, slides were 
incubated in secondary antibodies (1:1,000 dilution; anti-rat made in donkey 
conjugated to CY3, Jackson ImmunoResearch, West Grove, PA). 
Images were taken with an intensified CCD camera (Photometrics 
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) using Nikon 
Elements Software (Nikon Instruments Inc., Melville, NY). Tissue sections were 
illuminated with a Lamda DG-4 175 W xenon lamp with an exposure time of 300 
msec. 
Preparation of acutely dissociated dorsal root ganglion neurons. The L1-L6 
DRGs were acutely dissociated using methods described by Ma and LaMotte 
(Ma and LaMotte, 2005). Briefly, L1-L6 DRGs were removed from naïve and 
M3G treated animals four to six days following the last day of the dosing 
paradigm. The DRGs were treated with collagenase A and collagenase D in 
HBSS for 20 minutes (1 mg/ml; Roche Applied Science, Indianapolis, IN), 
followed by treatment with papain (30 units/ml, Worthington Biochemical, 
Lakewood, NJ) in HBSS containing .5 mM EDTA and cysteine at 35°C. The cells 
were then dissociated via mechanical trituration in culture media containing 1 
mg/ml bovine serum albumin and trypsin inhibitor (1 mg/ml, Sigma, St. Louis 
MO). The culture media was DMEM, Ham's F12 mixture, supplemented with 10% 
fetal bovine serum, penicillin and streptomycin (100 ug/ml and 100 U/ml) and N2 
supplement (Life Technologies). The cells were then plated on coverslips coated 
with poly-L lysine and laminin (1 mg/ml) and incubated for 2-3 hours before more 
70 
 
culture media was added to the wells. The cells were then allowed to sit 
undisturbed for 12–15 hours to adhere at 37°C (with 5% CO2). 
Intracellular Ca2+ imaging. The dissociated DRG cells were loaded with fura-2 
AM (3 uM, Molecular Probes/Invitrogen Corporation, Carlsbad CA) for 25 
minutes at room temperature in a balanced sterile salt solution (BSS) [NaCl (140 
mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (5 
mM)]. The cells were rinsed with the BSS and mounted onto a chamber that was 
placed onto the inverted microscope. Intracellular calcium was measured by 
digital video microfluorometry with an intensified CCD camera (Photometrics 
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) and Nikon 
Elements Software (Nikon Instruments Inc., Melville, NY). Cells were illuminated 
with a Lamda DG-4 175 W xenon lamp, and the excitation wavelengths of the 
fura-2 (340/380 nm) were selected by a filter changer. Sterile solution was 
applied to cells prior to chemokine application, any cells that responded to buffer 
alone were not used in chemokine responsive counts.  Chemokines were applied 
directly into the coverslip bathing solution. If no response was seen within 1 
minute, the chemokine was washed out. For all experiments, MCP1, SDF1, 
regulated upon activation, normal T cell expressed and secreted 
(RANTES/CCL5), and interferon-gamma-induced protein (IP10/CXCL10) were 
added to the cells in random order, after which capsaicin (3nM), high K+ (50µM) 
and ATP (3nM) were added. The chemokines used were purchased from R & D 
Systems (Minneapolis, MN; <1.0 endotoxin per 1 μg of the protein by the LAL 
method), and all were used at a concentration of 100 nM to ensure maximal 
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activation (Bhangoo et al 2007a; Bhangoo et al 2007b). Chemokines were 
reconstituted in sterile 0.1%BSA/PBS, and aliquots were stored at -20°C.  
Calcium imaging traces were analyzed by two independent analyzers and only 
responses that were in agreement between two individuals were used in the 
counts. 
Statistics. Prism 5 (GraphPad, LaJolla, CA) was used to determine the statistical 
significance of differences in the mean threshold forces for foot withdrawal to 
punctate indentation as a function of time and between experimental groups by 
means of one-way analyses of variance (One-way ANOVA) followed by post hoc 
pairwise comparisons (Tukey method). Statistical significance was set at 
p < 0.05.  GraphPad Software (LaJolla, CA) was used to determine the statistical 
significance of differences in calcium response among naïve and treatment 
groups using Chi-square test with Yates correction with p<0.05 set as statistical 
significance.   
Results 
Repeated morphine 3-β-D-glucuronide (M3G) treatment leads to tactile 
hypernociception which is not reversed CXCR4 antagonist, AMD3100 
administration 
 Repeated M3G administration (5 mg/kg, once a day for 5 days) was tested 
for its ability to induce tactile hypernociceptive as measured by von Frey 
filaments.  In our experiments tactile behavior was assessed prior to M3G 
administration (BL) and five days post M3G dosing paradigm (PID5).  The mean 
paw withdrawal threshold (PWT) was significantly decreased at PID5 when 
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compared to BL (72±1.4 mN to 31±3.0 mN; n=6) (Fig. 12).  A significant 
decrease in PWT was also witnessed with 1 and 10 mg/kg, however, no dose 
dependence was witnessed (Fig. 13).   
 
The ability of the CXCR4 antagonist, AMD3100, to reverse M3G-induced 
nociceptive behavior was assessed and no significant increase in PWT was 
observed (Fig. 10).  Suggesting that repeated M3G administration does not lead 
to changes in SDF1/CXCR4 signaling.  
 
 
Figure 12.  Repeated morphine 3-β-D-glucuronide (M3G) treatment (5 mg/kg 
for 5 days) results in the development of tactile hypernociception as measured 
by von Frey filaments.  ADM3100 (10 mg/kg) administration on PID5 does not 
result in any change in the PWT. BL, Baseline, PID, post injection day, AMD, 
AMD3100 (One-way ANOVA; ns, no significant difference between PID5 and 
PID5+AMD3100) (n = 6). 
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Figure 13.  Repeated M3G treatment (1 and 10 mg/kg, i.p. for 5 days) results 
in the development of tactile hypernociception as measured by von Frey 
filaments.  Repeated M3G administration at 1 mg/kg (A) and 10 mg/kg (B) 
resulted in a decrease in paw withdrawal threshold at PID5 compared to BL.  
ADM3100 (10 mg/kg, i.p.) administration on PID5 induces a statistical 
decrease in PWT. BL, Baseline, PID, post injection day, AMD, AMD3100 (One-
way ANOVA; * p<0.01 significant difference between PID5 and 
PID5+AMD3100) (n=6). 
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CXCR4-immunoreactivity (ir) in rat DRG is unchanged following repeated 
M3G treatment 
CXCR4-ir in the rat DRG is largely limited to the nonmyelinating satellite 
glial cells (SGCs) and a few neurons (Fig. 14A) in agreement with our previous 
findings (Wilson et al., 2011).  Our previous studies demonstrated following 
repeated morphine administration (10 mg/kg, once a day injections for 5 days) a 
decrease in the CXCR4-ir at PID5.  However, repeated intraperitoneal M3G 
injections (5 mg/kg) does not induce any change in CXCR4-ir in the rat DRG 
(Fig. 14B).  The lack of changes in CXCR4-ir supports the inability of the CXCR4 
antagonist, AMD3100, to reverse M3G-induced hypernociception. 
 
 
 
Figure 14. Repeated M3G injections does not change CXCR4-immunoreactivity 
(-IR) in satellite glial cells of rat lumbar DRG sections compared to naïve.  
Animals received repeated M3G injections (5mg/kg once daily for 5 days) and 
tissue was collected at 5 days after the last M3G injection (PID5). CXCR4-IR 
(red) is largely restricted to satellite glial cells is unchanged from naïve rodent 
DRG (A) and M3G PID5 (B) (n = 4 for each group). 
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Repeated morphine 3-β-D-glucuronide (M3G) does not increase functional 
CXCR4 receptors on DRG neurons.  
     To further investigate the expression of functional CXCR4 receptor, we 
utilized Fura-2 Ca2+ imaging studies in acutely dissociated lumbar DRGs derived 
from animals subjected to repeated M3G conditions and naive controls from 
previous studies.  The time points used corresponded to time points used for 
immunohistochemical and behavioral assessment (Figs. 12 and 14).  The 
acutely dissociated DRG preparations were categorized into three neuronal and 
non-neuronal cell types:  non-capsaicin sensitive neurons (high K and ATP 
responsive), capsaicin sensitive neurons (capsaicin, high K, and ATP 
responsive), and glia (ATP responsive only).  These cell response criteria were 
chosen strictly as an indicator of the types of cells that may be affected by the 
repeated M3G treatment paradigm.  The tested chemokines were selected so as 
to activate a wide spectrum of chemokine receptors known to be expressed by 
neurons and non-neuronal cells (CXCR4-SDF1/CXCL12, CXCR3-IP10/CXCL10, 
CCR2-MCP1/CCL2, CCR5-RANTES/CCL5). The chemokine concentration used 
for these experiments were based on their maximally effective concentrations 
used in our previous observations on acutely dissociated DRGs (Bhangoo et al., 
2007a; Bhangoo et al., 2007b).   
     Naïve acutely dissociated DRGs produced [Ca2+]i changes in a small 
percentage of neuronal and non-neuronal populations following application of all 
chemokines (Table 3), as shown in our previous studies (Wilson et al., 2011).  
Repeated M3G treatment induced a significant increase in the chemokine 
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(MCP1, IP-10, and RANTES) responsiveness of non-capsaicin sensitive and 
capsaicin sensitive neurons (Table 3).  Interestingly, no significant increase in 
SDF1 responsiveness occurred in any cell type following repeated M3G 
treatment (Table 3).  Therefore, it appears there is a lack of increased functional 
CXCR4 receptors on DRG neurons following repeated M3G treatment in 
agreement with the lack of changes in CXCR4-ir and inability of CXCR4 
antagonist, AMD3100 to reverse M3G-induced tactile behavior. 
 
 
 
Naïve Percent Positive Responding Cells 
SDF1 IP-10 MCP1 RANTES 
Non-capsaicin sensitive neuron 
(n=85) 7% (6/85) 4% (3/85) 4% (3/85) 14% (12/85) 
Capsaicin sensitive neuron 
(n=72) 7% (5/72) 0% (0/72) 6% (4/72) 4% (3/72) 
Glia (n=44) 21% (9/44) 2% (1/44) 9% (4/44) 21% (9/44) 
 
M3G Treated  
PID4-6  
SDF1 IP-10 MCP1 RANTES 
Non-capsaicin sensitive neuron  
(n=74)  18% (13/74) 55%**(41/74) 28%**(21/74) 31%* (23/74) 
Capsaicin sensitive neuron 
(n=117) 11% (13/117) 27%**(31/117) 21%**(24/117) 26%**(30/117)
Glia (n=25) 16% (4/25) 0% (0/25) 4% (1/25) 8% (2/25) 
Table 3.  Repeated M3G treatment does not induce any significant increase in the 
percentage of nociceptive neurons that respond to SDF1 administration as indicated 
by a change in intracellular calcium.  Daily M3G injections (5 mg/kg for 5 days) were 
administered to animals.  Lumbar DRG were acutely dissociated from these animals 
4-6 days following the last M3G injection.  Following repeated M3G administration 
there was a significant increase in calcium responsiveness with MCP1, IP-10, and 
Rantes application in capsaicin sensitive and non-capsaicin sensitive neurons. No 
significant increase was seen following SDF1 application in all cell types following 
M3G administration (** p<0.001, * p<0.05, Chi-square with Yates correction). 
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Repeated morphine and naltrexone treatment induces nociceptive behavior 
that is not reversed by CXCR4 antagonist, AMD3100, administration 
In order to ensure that M3G-induced signaling did not differ from non-
opioid receptor signaling induced by morphine administration we used the non-
selective opioid antagonist, naltrexone (10 mg/kg) co-administered with repeated 
morphine (10 mg/kg) treatment.  Naltrexone was selected over naloxone 
because of its longer half-life (Verebey et al., 1976).  Additionally, naltrexone was 
administered prior to morphine (10 mg/kg) injections in order to antagonize any 
opioid receptor activation with morphine administration and was administered 
four hours later to maintain naltrexone serum levels (Kim et al., 1988).  The 
naltrexone dose of 10 mg/kg was used because of its ability to have full 
occupancy of MOR (Brown and Panksepp, 2009).  The dosing paradigm of 
repeated morphine and naltrexone induced a reduction in PWT when compared 
to BL (72.2±1.3 mN to 32.8±2.2 mN; n=8) (Fig. 15).   
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The role of SDF1/CXCR4 signaling in this hypernociceptive behavior state 
was tested using the CXCR4 antagonist, AMD3100.  AMD3100 was unable to 
reverse the morphine and naltrexone induced tactile behavioral state (Fig. 13).  
Suggesting that SDF1/CXCR4 signaling is not involved in the hypernociceptive 
behavior induced by morphine and naltrexone injections. 
 
 
 
Figure 15. Repeated morphine and naltrexone treatment induces tactile 
hypernociception and which is not reversed with administration of the 
CXCR4 antagonist, AMD3100.  Morphine (10 mg/kg) and naltrexone (10 
mg/kg) 5 day dosing paradigm induced a decrease in PWT at PID5 
compared to BL.  AMD3100 (10 mg/kg) does not induce a significant 
change in PWT.  BL, Baseline, PID, post injection day, AMD, AMD3100 
(One-way ANOVA; ns, no significant difference between PID5 and 
PID5+AMD3100). (n = 8).
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CXCR4-ir is unchanged following repeated morphine and naltrexone 
treatment 
CXCR4-ir is localized in the SCCs in the naïve rat DRG (Fig. 16A) and is 
unchanged following repeated morphine and naltrexone treatment (Fig. 16B).  
The lack of changes in CXCR4-ir following repeated morphine and naltrexone 
treatment supports the inability of AMD3100 to reverse tactile behavior. 
 
Repeated DAMGO injections induce hypernociceptive behavior that is 
partially reversed by administration of the CXCR4 antagonist, AMD3100 
In order to determine the role of MOR activation in changes in 
SDF1/CXCR4 signaling witnessed following repeated morphine treatment we 
employed the selective MOR agonist, DAMGO.  DAMGO has similar half-life 
pharmokinetics to morphine, thus the same dosing paradigm was used (once a 
day injections for 5 days) (Szeto et al., 2001).  DAMGO is unable to cross the 
 
Figure 16. Repeated morphine and naltrexone dosing paradigm does not 
change CXCR4-immunoreactivity.  Rodents were administered the morphine (10 
mg/kg) and naltrexone (10 mg/kg) 5 day dosing paradigm and lumbar DRG were 
collected 5 days following the last day of injections (PID5).  CXCR4-ir (red) is 
unchanged between naïve (A) and morphine and naltrexone (B) administration 
lumbar DRG tissue sections. (n = 4 for each group). 
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blood-brain-barrier and therefore is rarely administered systemically, however, 
DAMGO (10 mg/kg, ip) injections have been shown to be anti-nociceptive to 
guarding behavior and was employed in our studies (Craft et al., 1995).  DAMGO 
injections (10 mg/kg, once a day for five days) induced a hypernociceptive state 
through a reduction in PWT at PID5 (27.2±1.7 mN; n=6) when compared to BL 
(76.5±1.3 mN) (Fig. 17).   
To test the role of changes in SDF1/CXCR4 signaling in DAMGO-induced 
hypernociception, AMD3100 was administered five days following the last 
DAMGO injection (PID5) and was able to significantly increase the PWT when 
compared to PID5 prior to AMD3100 administration (27.2±1.7 mN to 45.2±3.0 
mN; n=6) (Fig. 17).  
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Decrease in CXCR4-ir following repeated DAMGO administration is 
transiently reversed with administration of CXCR4 antagonist, AMD3100 
CXCR4-ir in the naïve rat lumbar DRG is localized primarily to the satellite 
glial cells (Fig. 18A) and decreases following repeated DAMGO administration 
(Fig. 18B).   Following intraperitoneal administration of the CXCR4 antagonist, 
AMD3100 (10 mg/kg) and sacrificing animals one hour post AMD3100 injection, 
CXCR4-ir returns to near naïve levels (Fig. 18C).  CXCR4-ir positive neurons 
 
Figure 17. DAMGO-induced tactile hypernociception is partially reversed 
with CXCR4 antagonist, AMD3100.  Repeated DAMGO (10 mg/kg once 
daily for 5 days) treatment decreases PWT measured 5 days following the 
last DAMGO injection (PID5) when compared to BL.  AMD3100 (10 
mg/kg) injection significantly increases PWT compared to PID5. BL, 
Baseline, PID, post injection day, AMD, AMD3100 (One-way ANOVA; 
p<0.01, *Significant difference between PID5 and PID5+AMD3100) (n = 
6).  
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(white arrows) are also evident in DAMGO treated lumbar DRG tissue sections 
following AMD3100 administration (Fig. 16C).  These findings mimic the changes 
in CXCR4-ir that we observed in our previous studies following repeated 
morphine administration (Wilson et al., 2011).  Additionally, the presence of 
CXCR4-immunopositive neurons supports the ability of AMD3100 to partially 
reverse DAMGO-induced tactile hypernociception. 
 
Discussion 
Our results demonstrate that repeated M3G, DAMGO, and morphine co-
administered with naltrexone are all capable of inducing nociceptive tactile 
behavior.  However, only repeated DAMGO administration induces changes in 
SDF1/CXCR4 signaling, similar to those reported in our previous findings with 
repeated morphine treatment (Wilson et al., 2011).  This change in SDF1/CXCR4 
Figure 18.  Repeated DAMGO administration induces a reduction in CXCR4-
immunoreactivity that is reversed by the CXCR4 antagonist, AMD3100.  Rodents 
received repeated DAMGO (10 mg/kg) dosing paradigm (once daily i.p. injections 
for 5 days) and lumbar DRG were collected 5 days following the last DAMGO 
injection (PID5).  CXCR4-ir (red) is decreased following DAMGO administration (B) 
compared to naïve lumbar DRG sections (A).  Treatment with AMD3100 (10 mg/kg, 
i.p.) 5 days following the last DAMGO injection (PID5 +AMD) reverses the decrease 
in CXCR4-ir (C).  White arrows indicate the presence of CXCR4-immunopositive 
neurons following AMD3100 treatment (n = 4 for each group). 
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signaling is evident by the decrease in CXCR4-ir following repeated DAMGO 
administration that is reversible by the administration of AMD3100, CXCR4 
antagonist.   Additionally, AMD3100 is able to partially reverse DAMGO-induced 
tactile nociceptive behavior.   
The results of our current study suggest that morphine-induced 
nociceptive behavior is induced by two mechanisms, opioid and non-opioid 
receptor signaling.  MOR signaling through repeated DAMGO administration is 
capable of inducing a decrease in paw withdrawal threshold.  Similarly, 
compounds that prevent or have limited opioid receptor signaling capability, M3G 
and morphine co-administered with naltrexone, are also capable of inducing 
nociceptive behavior.  To our knowledge, we are the first to demonstrate the 
ability of systemic M3G administration to induce nociceptive behavior.  
Interestingly, although DAMGO, M3G, and morphine + naltrexone all induced 
nociceptive behavior the behavior is not as long lasting (data not shown) as 
previously seen with repeated morphine administration which persisted for at 
least 28 days (Wilson et al., 2011).  Therefore, the mechanism needed to 
maintain the nociceptive behavior over time must require the signaling events 
from both opioid and non-opioid receptors that would be occurring from morphine 
treatment.   
Our findings indicate that the changes in SDF1/CXCR4 signaling are 
induced by MOR activation through DAMGO administration.  These findings are 
in agreement with previous studies conducted in immune cells (Happel et al., 
2008).  These studies demonstrated that increased CXCR4 expression on 
84 
 
leukocytes is induced with DAMGO administration and is naloxone reversible 
(Happel et al., 2008).  Therefore, while nociceptive behavior is capable of being 
produced though opioid and non-opioid receptor signaling, the SDF1/CXCR4 
signaling component of this behavior is dependent on MOR activation.   
Treatment with the CXCR4 antagonist, AMD3100, only partially reversed 
the nociceptive behavior following repeated DAMGO administration.  However, 
following repeated morphine administration AMD3100 was capable of fully 
reversing the nociceptive behavior (Wilson et al., 2011).  One possible 
explanation behind these results is that DAMGO is unable to cross the blood 
brain barrier and therefore any signaling it induces would be occurring in the 
peripheral nervous system.  While CXCR4 expression is limited in the spinal 
cord, central canal and neuroepithelium, (personal observation), there is a great 
deal of opioid receptor expression in the spinal cord (Kuhar et al., 1973; Pert et 
al., 1976; Lamotte et al., 1976; Atweh and Kuhar, 1977; Fields et al., 1980; 
Ninkovic et al., 1982).  Therefore, perhaps opioid signaling in the CNS is needed 
to perpetuate the changes in SDF1/CXCR4 signaling previously seen with 
morphine administration.   
An alternative explanation is that other opioid receptor signaling, DOR and 
KOR, is needed to potentiate changes in SDF1/CXCR4 signaling.  As noted 
previously morphine has affinity for all three opioid receptors and therefore could 
be signaling through KOR or DOR in order to induce changes.  DOR signaling 
could be involved in our previous findings with morphine, Gendron and 
colleagues demonstrated that similar repeated morphine treatment induces 
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increased DOR expression on the DRG cell membrane (Gendron et al., 2006).  
DOR in the naive rat DRG is located in vesicles at the cell membrane and 
following repeated morphine administration DOR are inserted into the cell 
membrane (Gendron et al., 2006).  DOR would be available for signaling and 
have potential in potentiating changes in SDF1/CXCR4 signaling.  Although, 
studies conducted with a selective delta agonist such as, [D-Pen2,5] Enkephalin , 
[D-Pen2,D-Pen5] Enkephalin (DPDPE), could give a false negative result because 
although DORs are not responsible for the initial signaling events with morphine, 
DOR signaling events could occur with later morphine administration or signaling 
events following the cessation of morphine administration.  Morphine signaling 
through the KOR should also be explored.  KOR’s role in the changes in 
SDF1/CXCR4 signaling is questionable.  The selective KOR agonist, U-50488, 
inhibits LPS and HIV-tat-induced increases in cytokine levels in a number of cell 
types (Zhang and Rogers, 2000; Belkowski et al., 1995; Alicea et al., 1996; 
Neudeck et al., 2003; Sheng et al., 2003).  However, one study conducted by the 
Rogers lab demonstrated that KOR activation is capable of increasing the 
expression of CCR2 mRNA in thymocytes treated with LPS (Zhang and Rogers, 
2000).  Most studies point to an opposing effect between MOR and KOR in 
cytokine expression and it would be interesting to see if this holds true in the 
DRG.  Furthermore, most of these studies were conducted in activated cells; the 
ability of KOR agonist to induce changes in cells at a resting state should also be 
explored.    
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In conclusion, opioid and non-opioid receptor activation is responsible for 
the induction of OIH.  However, changes in SDF1/CXCR4 signaling found in our 
previous studies with repeated morphine treatment (Wilson et al., 2011) are 
dependent on mu opioid receptor activation.  These findings are interesting 
because the analgesic ability of opioids is also thought to result from mu opioid 
receptor activation.  Thus, new analgesic treatment options should take into 
account both the beneficial and detrimental effects of opioid receptor activation 
and attempt to develop treatments to address these issues. 
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CHAPTER FOUR 
DISCUSSION 
 
Chronic pain affects many individuals decreasing their quality of life.  The 
treatment options for controlling these individuals pain is limited and often times 
ineffective.  The mechanism of action behind most current therapies is unknown.  
Much of this stems from a lack of understanding of the diverse causes of chronic 
pain and all possible targets for drug treatments.  A better mechanistic 
understanding of current treatment options, such as opioid analgesics, would 
allow for the development of new, more effective pain therapeutics and was 
therefore the goal of this project.  By providing a better understanding of opioid 
agonist effects and receptor targets will allow for the development of more 
effective opioid analgesics or alternative therapeutics. 
Overview of Results 
The purpose of this project was to examine the role of SDF1/CXCR4 
signaling in opioid induced hypernociception and to identify receptor signaling 
events responsible for these changes.  The first part of the project was to first 
establish a morphine dosing paradigm that would induce long lasting changes in 
nociceptive behavior.  The repeated morphine paradigm (once daily 10 mg/kg i.p. 
injections for 5 days) induced tactile nociceptive behavior that persisted for at
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least 28 days following the cessation of morphine administration.  No change in 
thermal behavior was witnessed, which is in contrast to other dosing protocols of 
opioids of twice daily injections or intrathecal administration (Mao et al., 1994; 
Raghavendra et al., 2004).  The systemic morphine dosing paradigm was 
selected because it better mimics the route of administration in the clinical 
setting.   
Following the establishment of long lasting nociceptive behavior we found 
this morphine dosing paradigm induces changes in SDF1/CXCR4 signaling in the 
DRG.  The decrease and return of CXCR4-ir in rodent DRG tissue sections 
witnessed coincides with the development and recovery of OIH.  Furthermore, 
administration of the CXCR4 antagonist, AMD3100, following the cessation of 
morphine administration transiently reversed the established tactile nociceptive 
behavior.  Indicating the central role that SDF1/CXCR4 signaling is playing in 
OIH.  Administration of AMD3100 revealed the tonic activation process taking 
place between SDF1 and CXCR4 in the rodent DRG through the ability of 
AMD3100 to reverse the decrease in CXCR4-immunoreactivity.  Release studies 
in F11 cells provided evidence of SDF1’s constitutive release characteristics 
further validating the tonic activation between SDF1 and CXCR4 in the rodent 
DRG following morphine administration. 
The second part of this project focused on investigating the receptor 
signaling events responsible for the observed morphine-induced tactile behavior 
and changes in SDF1/CXCR4 signaling.  Tactile nociception was found to be 
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induced by both non-opioid receptor signaling compounds, M3G and morphine 
co-administered with the non selective opioid antagonist, naltrexone, and the 
selective MOR agonist, DAMGO.  These results suggest that OIH witnessed with 
repeated morphine administration is induced by opioid and non-opioid receptor 
signaling events.  However, changes in SDF1/CXCR4 signaling in the rodent 
DRG were found to be dependent on MOR activation, as shown by repeated 
DAMGO administration. 
 
Figure 19.  Proposed Mechanism.  Morphine action through the MOR 
induces changes in SDF1/CXCR4 signaling.  These changes in 
SDF1/CXCR4 signaling were found to be contributing to the hyperexcitable 
state of the nociceptive pathway as the CXCR4 antagonist, AMD3100, is 
capable of transiently reversing nociceptive behavior. 
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Another notable finding from this project was revealed in the calcium 
imaging studies.  All chemokines examined (SDF1, RANTES, MCP, IP-10) had a 
significant increase in responsive neurons following morphine administration.  
Following M3G administration all chemokines except for SDF1 had a significant 
increase in the percentage of responsive neurons.  These results indicate that 
signaling from other chemokine and receptor pairings are upregulated in both 
morphine and M3G tactile nociceptive behavior states.  Further investigation into 
the role of other chemokines in each of those tactile behavior states is warranted.   
A preliminary study evaluating MCP1/CCR2’s role in OIH presented in Appendix 
B.  CCR2 antagonism was incapable of reversing morphine induced tactile 
behavior (Fig. 18).  These results were surprising following calcium imaging 
studies revealing an increase in MCP1 responsive neurons, indicative of 
increased functional CCR2.  The calcium imaging and behavioral studies were 
conducted at the same time point following repeated morphine treatment.  
However, an increase in CCR2 positive neurons is not indicative of increased 
signaling.  The absence of a CCR2 ligand in the DRG would prevent increased 
CCR2 signaling, thereby preventing the ability of CCR2 antagonism to be 
successful at reversing any established nociceptive behavior.  Therefore, these 
results indicate the importance of multiple techniques in demonstrating changes 
in chemokine signaling.  Changes in receptor or ligand expression are not 
sufficient in demonstrating a central component of any physiological state.  
Additionally, changes in MCP1/CCR2 or the other chemokines could require a 
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longer time to develop.  Further studies investigating the time course of the 
development of chemokine changes and the role of the other chemokines in OIH 
is warranted. 
Possible non-opioid receptor targets 
 Our results using non-opioid signaling compounds to induce tactile 
nociceptive behavior were not surprising.  Previous studies in triple opioid knock-
out mice revealed morphine’s retained ability to induce nociceptive behavior (Juni 
et al., 2007).  Additionally, intrathecal administration of M3G induces nociceptive 
behavior (Lewis et al., 2010).  However, studies investigating the receptor or 
receptors responsible for these non-opioid signaling compounds effect are 
largely limited.  Watkins and colleagues propose that TLR4 is the receptor 
responsible for these changes (Lewis et al., 2010; Hutchinson et al., 2009; 
Hutchinson et al., 2010.  My data presented in Appendix A demonstrate a 
significant increase in the number of TLR4 responsive neurons following 
morphine and M3G administration (Table 3).  Additionally, immunocytochemistry 
studies reveal the presence of TLR4-ir positive neurons in the lumbar DRGs of 
naïve, morphine, and M3G treated animals (Fig 17A).  Repeated morphine (10 
mg/kg) and M3G (10 mg/kg) both induced a significant increase in TLR4-positive 
neurons (Fig 17B).  The presence of TLR4-positive neurons show the possibility 
of TLR4 signaling to be occurring in the rodent DRG.  However, the binding 
ability of morphine and M3G to TLR4 and the ligand responsible for increased 
TLR4 signaling within the DRG needs to be further examined.   
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An alternative explanation for the increased LPS responsiveness following 
morphine and M3G could be linked to increased neuronal CXCR4 expression.  
CXCR4 has been proposed to be part of the LPS “sensing apparatus” 
(Triantafilou et al., 2008).  These studies conducted in CXCR4 transfected HEK 
cells demonstrate that both SDF1 and LPS are capable of inducing changes in 
IL-6 levels, p-MAPK, and inducing chemotaxis (Triantafilou et al., 2008).  Indeed 
LPS competitively inhibit the binding of SDF1 in CXCR4 transfected HEK cells.  
Therefore, the increases in LPS calcium responsiveness could be occurring from 
the increased CXCR4 neuronal expression.  However, the presence of increased 
LPS responsiveness following M3G administration, conditions where SDF1 
responsive cells are not significantly increased suggests that a separate LPS 
signaling receptor is required.  The specific receptor responsible for non-opioid 
signaling has yet to be determined and future studies investigating this topic 
would serve to provide better more selective opioid analgesics. 
CXCR7 
With the discovery of SDF1’s capability of binding to not only CXCR4 but 
also CXCR7 raises the question of CXCR7’s role in SDF1 signaling (Balabanian 
et al., 2005).  CXCR7 was initially described as a scavenger receptor 
(Boldajipour et al., 2008; Dambly-Chaudiere et al., 2007); more recent 
interactions describe CXCR7 as possibly moderating the response of CXCR4 to 
SDF1 by internalizing the ligand (Zabel et al., 2009). Although CXCR7 does not 
elicit activation of G-protein signaling pathways, it does activate MAP kinases 
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through β-arrestin (Rajagopal et al., 2010) and is therefore capable of altering the 
excitation state of cells.  Additionally, like SDF1, AMD3100 was previously known 
to selectively block CXCR4 signaling.  Recent studies have demonstrated that 
SDF1 and AMD3100 both stimulate arrestin recruitment to CXCR7, and 
AMD3100 may act as an allosteric agonist of CXCR7 (Kalatskaya et al., 2009). If 
so, changes in CXCR7 neuronal expression in the DRG following M3G 
administration (1 and 10 mg/kg, i.p.) could explain the significant decrease in 
paw withdrawal threshold following AMD3100 administration in these animals 
(Fig. 11).  However, the presence of CXCR7 in the rodent DRG is unknown and 
future studies would need to be conducted to investigate this possible signaling 
event.  These results would challenge the effectiveness of AMD3100 in states 
where both CXCR4 and CXCR7 are both present. 
Given the possibility that CXCR7 signaling via β-arrestin may contribute to 
SDF1-mediated cellular functions following repeated morphine treatment, it is 
important to know the neuronal distribution of CXCR7 in the rodent. The lack of 
reliable CXCR7 antibodies thus far has prevented the ability of anatomical 
localization of this receptor in the rat DRG. However, CXCR7-GFP mice 
developed in Dr. Richard Miller’s lab increase the expression CXCR7 in both 
sensory neurons and SGCs following LPS treatment (unpublished observations). 
Merely the observation of neuronal CXCR7, regardless of the conditions, 
provides us with a basis to speculate about possible SDF-1 influences on 
CXCR7 in the DRG, including neuronal excitability. One possibility that has been 
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described in T cell lymphocytes is that CXCR7 forms heterodimers with CXCR4 
which may alter CXCR4 Gαi-protein activation and subsequent calcium fluxes 
(Levoye et al., 2009). Additionally, CXCR7 could be working in our model of 
repeated morphine treatment to further regulate the levels of SDF1 in the DRG.  
Clearly, the role of CXCR7 in neurobiology still needs to be determined and its 
role in nociceptive states is an area requiring further investigation.  
SDF1/CXCR4 Changes in Satellite Glial Cells 
Changes in SDF1/CXCR4 signaling in sensory neurons directly affect the 
nociceptive behavior witnessed in OIH.  However, the reduction in CXCR4-
immunoreactivity in the satellite glial cells (SGC) following repeated morphine 
and DAMGO administration demonstrate increased SDF1/CXCR4 signaling in 
SGCs as well.  While SDF1/CXCR4 signaling in SGCs would be indirect the 
signaling event could still be contributing to OIH.  A potential mechanism of 
SDF1/CXCR4 signaling in SGCs could be occurring through the release of pro-
inflammatory mediators into the milieu of the DRG thereby, indirectly affecting the 
excitatory state of sensory neurons.  Recent evidence has emerged that 
implicates SDF1 induction of the pro-inflammatory cytokine, IL-6 (Tang et al., 
2008) and may also control expression of other chemokines such as neuronal 
fractalkine (Cook et al., 2010).  SDF1’s ability to induce IL-1β would further 
contribute through the paracrine interactions within the rat DRG.  IL-1β can be 
released from satellite glial cells whereupon it acts on nearby small-diameter 
sensory neurons bearing interleukin type I receptor (IL-1RI) (Takeda et al., 2008). 
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In turn, IL-1β signaling significantly increases the spontaneous neuronal activity 
in Aδ mechanosensitive neurons and may be important in hypernociception 
(Takeda et al., 2008).  Furthermore, it is commonplace that cytokines induce 
chemokine promoter activation and increase secretion of chemokines during 
inflammation, which could be responsible for the maintenance of the observed 
OIH behavior. 
The satellite glial cells in the rodent DRG could have an alternative role.  
In the naïve rodent DRG the majority of CXCR4 expression is located on SGCs.  
However, the role that CXCR4 expression on SGCs is playing in OIH was not 
addressed in these studies.  One possibility is that CXCR4 on SGCs is acting as 
a “sink” for released SDF1, serving to buffer any SDF1 that is released within the 
DRG or SDF1 from the systemic circulation.  In support of this theory, calcium 
imaging studies conducted on acutely dissociated DRGs, only 20 percent of glial 
cells have a calcium response to SDF1 in both naïve and morphine treated 
conditions (Wilson et al., 2011).  This suggests SDF1/CXCR4 signaling in SCCs 
occurs through a different mechanism.  SDF1 is unable to bind the non-signaling 
chemokine receptors, D6 and DARC, and was shown to be alternatively 
internalized by CXCR4 to maintain the homeostatic levels of SDF1 (Dar et al. 
2005).  This theory would coincide with other studies that have shown the ability 
of SGCs to take up molecules from the milieu of the DRG (Kumamoto et al., 
1986; Schlaepfer, 1969).  This mechanism supports the need for CXCR4 on 
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SGCs to act as a buffering system for circulating SDF, preventing any 
unnecessary CXCR4 activation by circulating levels of SDF1.   
Opioid-induced changes in PNS chemokine/ receptor expression 
The mechanisms underlying the effects of chronic opioid treatment on 
chemokine/receptor expression are not fully understood, but is based on 
evidence that opioids stimulate the production and release of cytokines in many 
cell types including leukocytes, keratinocytes, and glial cells (Volk et al., 2004; 
Messmer et al., 2006; Wang et al., 2007; Liang et al., 2008; Johnston et al., 
2004; Tai et al., 2006). It is well known that cellular activation by these cytokines 
initiate signaling cascades that eventually lead to the expression of 
chemokines/receptor.  For example, upregulation of CXCR4 following DAMGO 
administration is thought to be dependent on the naloxone-reversible increases 
in TGF-β production (Chao et al., 1992; Steele et al., 2003; Happel et al., 2008). 
Chronic morphine treatment also increases the expression of the chemokine 
receptors, CCR2 and CCR5, in human astrocytes and CCL2 in human neurons 
via largely unknown mechanisms (Mahajan et al., 2005; Rock et al., 2006). 
Taken together, this evidence suggests that chronic opioid treatment directly or 
indirectly can lead to upregulation of chemokine signaling in leukocytes, neurons 
and glial cells.    
Despite evidence of direct or indirect, opioid-induced transcription factor 
regulation in variety of cells types, little work has been conducted to investigate 
transcriptional control of chemokine/receptor expression in either glial cells or 
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neurons.  The promoter regions of a number of chemokine/receptors were 
analyzed by Hosung Jung in the Miller lab and candidate transcription factors 
were identified which include NFAT, NF-KB, CREB, and C/EB.  The Miller lab 
further investigated the transcriptional control of chemokines in F11 cells and 
acutely dissociated sensory neurons subjected to pathological circumstances of 
chronic excitability (Jung and Miller, 2008).  Jung and Miller (2008) demonstrated 
that DRG-like F11 cells expression of the chemokine receptors, CCR2 and CCR5 
is depended on nuclear factor of activated T cells (NFAT) activation, whereas 
chemokine receptor, CXCR4, was not.  With this outlined information known 
about the transcriptional control of chemokines and their receptors which of these 
transcription factors is induced by opioid treatment needs to be examined. 
  Opioid receptor control of transcription factors has been explored in a 
number of different cell types.  Neurons, macrophages, and immune cells treated 
with MOR agonists induce the activation and increased DNA binding of the 
transcription factors NF-KB, CREB, and AP-1 (Hou et al., 1996; Roy et al., 1998; 
Bilecki et al., 2004; Happel et al., 2010).  Furthermore, DAMGO treatment 
increases CCL2 expression in polymorphonuclear cells which is dependent on 
NF-KB activity (Happel et al., 2010).  Selectively targeting the downstream 
transcriptional regulation of chemokines and receptors following opioid 
administration could serve to prevent some of the detrimental effects of opioid 
analgesic and improve their therapeutic effects. 
 
98 
 
 
 
Chemokines Role in Inflamed vs. Un-inflamed Tissue 
Cells of the immune system utilize the chemoattractant gradient of 
chemokines in order to localize to sites of injury.  Stein and colleges were able to 
demonstrate a secondary role in which the chemokine CXCL2/3 is able to 
stimulate the release of opioids from opioid-containing immune cells such as 
leukocytes (Rittner et al., 2006).  This chemokine-induced release of endogenous 
opioids is beneficial and analgesic when chemokines are injected into the 
hindpaw in a model of inflammatory pain (Rittner et al., 2006).  This is in direct 
contrast to the nociceptive effects of chemokines injected into an un-inflamed 
hind paw (Oh et al., 2001).    In the un-inflamed hindpaw the chemokines have 
no opioid containing immune cells to act on and are in this instance detrimental 
because chemokines are capable of activating sensory neurons (White et al., 
2005).   
 SDF1 was also tested in these studies and was unable to induce 
the release of endogenous opioids from leukoctyes expressing CXCR4 (Rittner 
et al., 2006).  However, SDF1 application did not lead to as substantial of a 
calcium response at the concentration used and the concentration of SDF1 
needed to induce a significant chemotactic response was 100 fold greater  than 
that required for CXCL2/3 (Rittner et al., 2006).  Additionally, while SDF1 was not 
found to be analgesic in these studies SDF1 did not  induce to a nociceptive 
response (Rittner et al., 2006), which differs from the findings of SDF1 in an un-
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inflammed paw (Oh et al., 2001).  Suggesting a greater concentration of SDF1 
might be needed for the same response seen with CXCL2/3.  
Findings from our lab and others demonstrate that opioid administration 
from both in vitro and in vivo studies act to increase the expression of both 
chemokines and their receptors on cells of the immune and nervous system 
(Steele et al., 2003; Miyagi et al., 2000; Rock et al., 2006; Mahajan et al., 2005; 
El-Hage et al., 2006; Wilson et al., 2011).  It can be theorized that opioid-induced 
increases in chemokine/receptors expression would beneficial in inflammatory 
pain states of which opioids are often employed.  In these conditions opioids 
would act to increase the expression of chemokines/receptors and would thereby 
increase the infiltration of immune cells and increase the release of endogenous 
opioids at the site of injury.  Opioid usage in non-inflammatory pain states would 
increase the expression of chemokines/receptors however; the absence of 
opioid-containing immune cells for the chemokines to act upon would be 
disadvantageous.  Without the presence of opioid containing immune cells, the 
chemokines would act directly on the sensory neurons, inducing a hyperexcitable 
state.  This explanation could explain why OIH in the clinical setting is reported at 
a site separate from the injury.  At the injury site the opioid-induced increase in 
chemokine/receptor expression would be analgesic inducing an increase in the 
release of endogenous opioids.  However, following the systemic administration 
of opioids locations away from the site of injury would also have increased 
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expression of chemokine/receptor, but the lack of infiltrated immune cells at 
these sites would lead to a hypernociceptive state. 
If this theory holds true future use of opioids in pain treatment should 
consider the use of locally applied opioids.  This approach would allow for the 
beneficial effectiveness of opioids, acting directly on sensory neurons and 
inducing increased expression of chemokines/receptors locally, thereby 
increasing the release of endogenous opioids and recruitment of other immune 
cells needed for healing.  Furthermore, local opioid treatment would prevent the 
increase in chemokine signaling at sites separate from the injury site and avoid 
the hypernociceptive state that can be induced from systemic opioid 
administration.  The analgesic ability of locally applied morphine has been 
demonstrated in clinical studies following knee surgery and chronically inflamed 
tooth pain (Dionne et al., 2001; Likar et al., 1999; Stein et al., 1991).  In two of 
the studies locally applied morphine had a higher analgesic effect than systemic 
morphine (Dionne et al., 2001; Stein et al., 1991).  An additional benefit of local 
application of opioids is the avoidance of a number of problematic side effects of 
opioids such as, respiratory depression and urinary retention.
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APPENDIX A: 
TLR4 DISTRUBUTION IN DORSAL ROOT GANGLION AND LPS 
RESPONSIVE CELL IN ACUTELY DISSOCIATED DORSAL ROOT 
GANGLION 
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Methods 
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan 
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12-
hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard 
rodent chow and water available ad libitum. Experiments were performed during 
the light cycle. These experiments were approved by the Institutional Animal 
Care and Use Committee of Indiana University/Purdue University in Indianapolis. 
All procedures were conducted in accordance with the Guide for Care and Use of 
Laboratory Animals published by the National Institutes of Health and the ethical 
guidelines of the International Association for the Study of Pain. All animals were 
randomly assigned to either treatment or control groups. 
Drugs and method of administration. All drugs were freshly prepared in saline 
on the day of the experiment. Intraperitoneal (i.p.) injections were administered to 
animals following light anesthesia.  For all dosing paradigms, animals received 5 
once daily injections of the following drugs:  M3G (1, 5, and 10 mg/kg) and 
morphine sulphate (10 mg/kg).  Morphine 3-ß-D-glucuronide (M3G) and 
morphine sulfate were supplied by NIDA Drug Supply Program.  
Tissue processing and immunocytochemistry for neural tissue. Morphine, 
M3G or naïve control treatments rats’ lumbar (L3-L6) DRG tissue was collected 
after animals were sacrificed and transcardially-perfused with saline followed by 
fixative.  Fixed tissue was then embedded for sectioning and processed using 
immunocytochemical methodologies commonly used in this lab (Bhangoo et al., 
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2007a). Tissue sections from L4 and L5 were used in immunocytochemical 
experiments. Primary antisera used was the anti-TLR4 goat M16 extracellular 
monoclonal antibody, (1:200 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA).  After primary incubation, slides were incubated in secondary antibodies 
(anti-goat made in horse conjugated to CY3, Jackson ImmunoResearch,West 
Grove, PA).  Positive control immunocytochemistry staining was conducted in rat 
spleen sections.  Specific labeling of white pulp was observed. 
Cell Counts.  Images were taken with an intensified CCD camera (Photometrics 
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) using Nikon 
Elements Software (Nikon Instruments Inc., Melville, NY). Tissue sections were 
illuminated with a Lamda DG-4 175 W xenon lamp.  Within elements software 
each images maximum threshold was set between 8000 and 8500.  Total cell 
counts for each section were taken using the grid function to aide in total cell 
count.  TLR4 positive cell counts were conducted using Image Pro Software 
(Media Cybernetics, Bethesda, MD).  The following parameters were used for 
cell counts:  Intensity range (40-255), smoothness (20), measurement window 
size (10µM-∞).  Images fluorescent artifacts such as axons and cell debris were 
unselected so that these were not used in cell counts.  TLR4 cell counts were 
taken from each tissue section image and combined for each treatment group. 
Preparation of acutely dissociated dorsal root ganglion neurons. The L1-L6 
DRGs were acutely dissociated using methods described by Ma and LaMotte 
(Ma and LaMotte, 2005). Briefly, L1-L6 DRGs were removed from naïve, M3G, 
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and morphine-treated animals four to six days following the last day of the dosing 
paradigm. The DRGs were treated with collagenase A and collagenase D in 
HBSS for 20 minutes (1 mg/ml; Roche Applied Science, Indianapolis, IN), 
followed by treatment with papain (30 units/ml, Worthington Biochemical, 
Lakewood, NJ) in HBSS containing .5 mM EDTA and cysteine at 35°C. The cells 
were then dissociated via mechanical trituration in culture media containing 1 
mg/ml bovine serum albumin and trypsin inhibitor (1 mg/ml, Sigma, St. Louis 
MO). The culture media was DMEM, Ham's F12 mixture, supplemented with 10% 
fetal bovine serum, penicillin and streptomycin (100 ug/ml and 100 U/ml) and N2 
(Life Technologies). The cells were then plated on coverslips coated with poly-L 
lysine and laminin (1 mg/ml) and incubated for 2-3 hours before more culture 
media was added to the wells. The cells were then allowed to sit undisturbed for 
12–15 hours to adhere at 37°C (with 5% CO2). 
Intracellular Ca2+ imaging. The dissociated DRG cells were loaded with fura-2 
AM (3 uM, Molecular Probes/Invitrogen Corporation, Carlsbad CA) for 25 
minutes at room temperature in a balanced sterile salt solution (BSS) [NaCl (140 
mM), Hepes (10 mM), CaCl2 (2 mM), MgCl2 (1 mM), Glucose (10 mM), KCl (5 
mM)]. The cells were rinsed with the BSS and mounted onto a chamber that was 
placed onto the inverted microscope. Intracellular calcium was measured by 
digital video microfluorometry with an intensified CCD camera (Photometrics 
CoolSnap HQ2) coupled to a Nikon microscope (Nikon Eclipse Ti) and Nikon 
Elements Software (Nikon Instruments Inc., Melville, NY). Cells were illuminated 
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with a Lamda DG-4 175 W xenon lamp, and the excitation wavelengths of the 
fura-2 (340/380 nm) were selected by a filter changer. Sterile solution was 
applied to cells prior to chemokine application, any cells that responded to buffer 
alone were not used in chemokine responsive counts.  Chemokines were applied 
directly into the coverslip bathing solution. If no response was seen within 1 
minute, the chemokine was washed out. For all experiments, MCP1, SDF1, 
regulated upon activation, normal T cell expressed and secreted 
(RANTES/CCL5), and interferon-gamma-induced protein (IP10/CXCL10) were 
added to the cells in random order.  Following chemokine application LPS 
(1µg/mL) was applied to coverslip, after which capsaicin (3nM), high K+ (50µM) 
and ATP (3nM) were added. The chemokines used were purchased from R & D 
Systems (Minneapolis, MN; <1.0 endotoxin per 1 μg of the protein by the LAL 
method), and all were used at a concentration of 100 nM to ensure maximal 
activation (Bhangoo et al 2007a; Bhangoo et al 2007b). Chemokines and LPS 
were reconstituted in sterile 0.1%BSA/PBS, and aliquots were stored at -20°C.  
Calcium imaging traces were analyzed by two independent analyzers and only 
responses that were in agreement between two individuals were used in the 
counts. 
Statistics. GraphPad Software (LaJolla, CA) was used to determine the 
statistical significance of differences in calcium response and TLR4-positive 
neurons among naïve and treatment groups using Chi-square test with Yates 
correction with p<0.05 set as statistical significance.   
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Results 
Repeated morphine and M3G administration induces a significant increase 
in TLR4-positive neurons. 
Animals were subjected to repeated administration of morphine (10 mg/kg, once 
daily for 5 days) and M3G (1, 5, and 10 mg/kg, once daily for 5 days) and lumbar 
DRG were collected from animals 5 days following the last injection.  TLR4-
positive neurons (red) were present under all conditions (Fig. 20A).  A significant 
increase in TLR4-immunopositive neurons was present following repeated 
morphine (10 mg/kg) and M3G (10 mg/kg) administration as compared to naïve 
DRG tissue (Fig. 20B).  Each treatment condition had similar numbers of total 
numbers that were analyzed (Fig. 20C).   
LPS responsive neurons are significantly increased following repeated 
morphine and M3G administration. 
     Lipopolysaccharide (LPS) is a major part of the outer component of gram 
negative bacteria that is crucial for the virulence of the bacteria (Cryz et al., 
1984).  LPS-induced effects have been demonstrated to dependent on binding to 
CD14 and TLR4 receptors (Pugin et al., 1993; Hoshino et al., 1999).  
Furthermore, LPS induced calcium response can be blocked by both CD14 and 
TLR4 antibodies (Song et al., 2001).  Therefore, to investigate the presence of 
functional TLR4 receptors within the rodent DRG we applied LPS to acutely 
dissociated DRGs.  The acutely dissociated DRG preparations were categorized 
into three neuronal and non-neuronal cell types:  non-capsaicin sensitive neurons 
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(high K and ATP responsive), capsaicin sensitive neurons (capsaicin, high K, and 
ATP responsive), and glia (ATP responsive only).  These cell response criteria 
were chosen strictly as an indicator of the types of cells that may be affected by 
the repeated morphine and M3G treatment paradigm.  Naïve acutely dissociated 
DRGs produced LPS-induced [Ca2+]i changes in a small percentage of neuronal 
and non-neuronal populations  (Table 4).  Repeated morphine (10 mg/kg) and 
M3G (10 mg/kg) treatment induced a significant increase in LPS calcium 
responsiveness of non-capsaicin sensitive and capsaicin sensitive neurons 
(Table 4).  While the calcium imaging data does not conclusively demonstrate 
that increased TLR4 neuronal expression is causing the increased LPS 
responsiveness, it does demonstrate increased LPS response which is known to 
cause increase intracellular calcium levels through TLR4 (Song et al., 2001).  
This along with the increased TLR-4 positive neurons suggests TLR4 could be 
mediating this response (Fig. 20B).  Further studies would need to be conducted 
to validate TLR4 is responsible for this increased signaling. 
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Figure 20.  TLR4-ir positive neurons are significantly increased following 
repeated morphine (10mg/kg) and M3G (10 mg/kg).  Tissue sections taken from 
naïve, morphine, and M3G treated animals  were collected 5 days following the 
last injection, representative images are presented for TLR4-ir positive neurons 
(red) (A).  Cell counts from tissue section images were conducted and there was 
a significant increase in TLR4-positive neurons in morphine (10mg/kg) and M3G 
(10 mg/kg) animals when compared to naïve (B).  Total neuron cell counts were 
similar among treatment groups (C).  (* p value <0.01, Chi-square with Yates 
Correction). 
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  Naïve Morphine (10 mg/kg) 
Treated 
M3G (5 mg/kg) Treated
                                               Percentage Positive Response 
Non‐capsaicin sensitive neuron  6% (5/85) 23% (26/112)** 31% (23/74)**
Capsaicin Sensitive neuron  8% (6/72) 36% (26/73)** 25% (29/117)*
Glia  7% (3/44) 16% (8/49) 0% (0/25)
 
Table 4.  Repeated morphine and M3G treatment significantly increase the percentage 
of LPS responsive neurons as measured by a change in intracellular calcium.  Daily 
morphine and M3G administration (10 mg/kg for 5 days) were administered to animals.  
Lumbar DRG were acutely dissociated at 4-6 days following the last injection of morphine 
or M3G.  (** p<0.001, * p<0.05, Chi-square with Yates correction). 
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APPENDIX B: 
CCR2 RECEPTOR ANTAGONISM DOES NOT REVERSE MORPHINE-
INDUCED TACTILE HYPERNOCICEPTION 
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Methods 
Animals. Pathogen-free, adult female Sprague-Dawley rats (150–200 g; Harlan 
Laboratories, Madison, WI) were housed in temperature (23 ± 3°C) and light (12-
hlight: 12-h dark cycle; lights on at 07:00 h) controlled rooms with standard 
rodent chow and water available ad libitum.  Experiments were performed during 
the light cycle. These experiments were approved by the Institutional Animal 
Care and Use Committee of Loyola University, Chicago.  All procedures were 
conducted in accordance with the Guide for Care and Use of Laboratory Animals 
published by the National Institutes of Health and the ethical guidelines of the 
International Association for the Study of Pain. All animals were randomly 
assigned to either treatment or control groups. 
Drugs and method of administration The drugs, morphine sulfate salt and the 
CCR2 antagonist (R)-4-Acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-3-
hydroxy-1,5-dihydro-2H-pyrrol-2-one (CCR2 RA), were employed in this study. 
Morphine sulfate salt and CCR2 RA were supplied by the NIDA Drug Supply 
Program (Rockville, MD) and Eli Lilly (Indianapolis, IN), respectively.   All drugs 
were freshly prepared in saline on the day of the experiment. Morphine sulfate- 
and vehicle-treated groups were given intraperitoneal (i.p.) injections once daily 
for 5 days of 10 mg/kg or saline (vehicle). After tactile hypernociception was 
established, animals were given an i.p. injection of CCR2 RA (10 mg/kg) 5 days 
following the last morphine injection (PID5).  
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Tactile Behavioral assessment von Frey filaments were used to test 
mechanical sensitivity before, during and after cessation of morphine sulfate 
administration. Prior to initial von Frey tactile testing, all rodents were habituated 
to testing chambers for at least two days. Animals were tested for baseline 
responses (BL) at least two times before undergoing the repeated morphine 
sulfate treatment (10 mg/kg, i.p. daily). Mechanical testing with von Frey 
filaments during the morphine sulfate dosing paradigm was limited to injection 
day (ID) 3. Behavioral assessment on ID3 occurred 18-20 hours after the ID2 
morphine administration and before ID3 morphine or vehicle treatment.   
Additional behavioral assessment following drug or vehicle administration 
occurred on post-injection day (PID) 3, 5, 7, and 14.  All behavioral testing was 
performed by laboratory assistants who were blinded to the experimental 
conditions and unfamiliar with the experimental aims. 
The incidence of foot withdrawal in response to mechanical indentation of 
the plantar surface of each hindpaw was measured with a von Frey filament 
capable of exerting forces of 10, 20, 40, 60, 80 and 120 mN. These probes 
exhibit a uniform tip diameter (0.2 mm) and were applied to 6 designated loci 
distributed over the plantar surface of the foot (Ma et al., 2003). These 6 spots 
are representative of the distal nerve distributions of saphenous, tibial and sural 
nerves (medial to lateral) in the glabrous hindpaw.  During each test, the rodent 
was placed in a transparent plastic cage with a floor of wire with ~1×1 cm 
openings. The cage is elevated so that stimulation can be applied to each hind 
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foot from beneath the rodent.  The filaments were applied in order of ascending 
force. Each filament was applied alternately to each foot and to each locus. The 
duration of each stimulus was approximately 1 s and the inter-stimulus interval 
was approximately 10–15 s. The incidence of foot withdrawal is expressed as a 
percentage of the 6 applications of each stimulus and the percentage of 
withdrawals was then plotted as a function of force (Bhangoo et al., 2007a; Ma et 
al., 2003).  The von Frey withdrawal threshold was defined as the force that 
evoked a minimum detectable withdrawal observed on 50% of the tests given at 
the same force level. For cases in which none of the specific filaments used 
evoked withdrawals on exactly 50% of the tests, linear interpolation was used to 
define the threshold.   
Statistics. Prism 5 (GraphPad, LaJolla, CA) was used to determine the statistical 
significance of differences in the mean threshold forces for foot withdrawal to 
punctate indentation as a function of time and between experimental groups by 
means of one way analyses of variance (one-way ANOVA) followed by post hoc 
pairwise comparisons (Tukey method).  
Results 
Morphine-induced tactile hypernociception is not reversed with CCR2 
receptor antagonist.   
Animals were administered morphine (10 mg/kg, one a day for five days) and 
tactile behavior was assessed with von Frey filaments.  Behavioral assessment 
of tactile hypernociception was performed prior to the start of the injection 
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paradigm (BL), during the 5 day dosing regimen (ID), and following the repeated 
morphine treatment paradigm (PID) (Fig.21).  The mean paw withdrawal 
threshold (PWT) of the tested hind paws exhibited a significant decrease at ID4, 
PID3, and PID5 as compared to BL (Fig. 21).   Administration of the CCR2 
receptor antagonist (10 mg/kg, i.p.) at PID5 did not induce a significant change in 
PWT as compared to PID5 prior to injection (Fig. 21).   
 
 
Figure 21.  CCR2 receptor antagonism does not reverse morphine 
induced tactile hypernociception.  Repeated morphine treatment (10 mg/kg 
for 5 days) results in the development of tactile hypernociception as 
measured by von Frey filaments.  Five days following the last morphine 
injection (PID5) rats received an i.p. injection of CCR2 antagonist (10 
mg/kg) and tactile behavior was measured by von Frey filaments 1 hour 
post injection.  BL, baseline, ID, injection day, PID, post injection day, 
CCR2 RA, CCR2 receptor antagonist (One-way ANOVA; *p<0.05, 
significant difference from baseline) (n=6) 
 
 
115 
 
REFERENCES 
Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, 
DeMartino JA, MacIntyre DE and Forrest MJ (2003) Impaired neuropathic 
pain responses in mice lacking the chemokine receptor CCR2. Proc Natl 
Acad Sci U S A 100:7947-7952. 
 
Adler MW, Geller EB, Chen X and Rogers TJ (2005) Viewing chemokines as a 
third major system of communication in the brain. AAPS J 7:E865-870. 
 
Ahn SH, Cho, Y.W., Ahn, M.W., Jang, S.H., Sohn, Y.K., Kim, H.S. (2002) mRNA 
expression of cytokines and chemokines in herniated lumbar intervertebral 
discs. Spine 27:911-917. 
 
Aibara K and Akaike N (1991) Acetylcholine-activated ionic currents in isolated 
paratracheal ganglion cells of the rat. Brain Res 558:20-26. 
 
Alexander GM, Perreault MJ, Reichenberger ER and Schwartzman RJ (2007) 
Changes in immune and glial markers in the CSF of patients with Complex 
Regional Pain Syndrome. Brain Behav Immun 21:668-676. 
 
Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ and Schwartzman RJ 
(2005) Changes in cerebrospinal fluid levels of pro-inflammatory cytokines 
in CRPS. Pain 116:213-219. 
 
Aley KO, Green PG and Levine JD (1995) Opioid and adenosine peripheral 
antinociception are subject to tolerance and withdrawal. J Neurosci 
15:8031-8038. 
 
Aley KO and Levine JD (1997) Dissociation of tolerance and dependence for 
opioid peripheral antinociception in rats. J Neurosci 17:3907-3912. 
 
Alicea C, Belkowski S, Eisenstein TK, Adler MW and Rogers TJ (1996) Inhibition 
of primary murine macrophage cytokine production in vitro following 
treatment with the kappa-opioid agonist U50,488H. J Neuroimmunol 
64:83-90. 
 
Amir R and Devor M (1996) Chemically mediated cross-excitation in rat dorsal 
root ganglia. J Neurosci 16:4733-4741. 
 
116 
 
 
Angst MS, Koppert W, Pahl I, Clark DJ and Schmelz M (2003) Short-term 
infusion of the mu-opioid agonist remifentanil in humans causes 
hyperalgesia during withdrawal. Pain 106:49-57. 
 
Arner S, Rawal N and Gustafsson LL (1988) Clinical experience of long-term 
treatment with epidural and intrathecal opioids--a nationwide survey. Acta 
Anaesthesiol Scand 32:253-259. 
 
Atweh SF and Kuhar MJ (1977) Autoradiographic localization of opiate receptors 
in rat brain. I. Spinal cord and lower medulla. Brain Res 124:53-67. 
 
Avdoshina V, Biggio F, Palchik G, Campbell LA and Mocchetti I (2010) Morphine 
induces the release of CCL5 from astrocytes: potential neuroprotective 
mechanism against the HIV protein gp120. Glia 58:1630-1639. 
 
Baker L and Ratka A (2002) Sex-specific differences in levels of morphine, 
morphine-3-glucuronide, and morphine antinociception in rats. Pain 95:65-
74. 
 
Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, 
Arenzana-Seisdedos F, Thelen M and Bachelerie F (2005) The 
chemokine SDF-1/CXCL12 binds to and signals through the orphan 
receptor RDC1 in T lymphocytes. J Biol Chem 280:35760-35766. 
 
Barber A, Bartoszyk GD, Bender HM, Gottschlich R, Greiner HE, Harting J, 
Mauler F, Minck KO, Murray RD, Simon M and et al. (1994) A 
pharmacological profile of the novel, peripherally-selective kappa-opioid 
receptor agonist, EMD 61753. Br J Pharmacol 113:1317-1327. 
 
Barjavel MJ, Scherrmann JM and Bhargava HN (1995) Relationship between 
morphine analgesia and cortical extracellular fluid levels of morphine and 
its metabolites in the rat: a microdialysis study. Br J Pharmacol 116:3205-
3210. 
 
Bartlett SE, Cramond T and Smith MT (1994) The excitatory effects of morphine-
3-glucuronide are attenuated by LY274614, a competitive NMDA receptor 
antagonist, and by midazolam, an agonist at the benzodiazepine site on 
the GABAA receptor complex. Life Sci 54:687-694. 
 
Bean BP, Williams CA and Ceelen PW (1990) ATP-activated channels in rat and 
bullfrog sensory neurons: current-voltage relation and single-channel 
behavior. J Neurosci 10:11-19. 
 
117 
 
 
Belanger S, Ma W, Chabot JG and Quirion R (2002) Expression of calcitonin 
gene-related peptide, substance P and protein kinase C in cultured dorsal 
root ganglion neurons following chronic exposure to mu, delta and kappa 
opiates. Neuroscience 115:441-453. 
 
Belkowski SM, Alicea C, Eisenstein TK, Adler MW and Rogers TJ (1995) 
Inhibition of interleukin-1 and tumor necrosis factor-alpha synthesis 
following treatment of macrophages with the kappa opioid agonist U50, 
488H. J Pharmacol Exp Ther 273:1491-1496. 
 
Belmadani A, Tran PB, Ren D, Assimacopoulos S, Grove EA and Miller RJ 
(2005) The chemokine stromal cell-derived factor-1 regulates the 
migration of sensory neuron progenitors. J Neurosci 25:3995-4003. 
 
Benamar K, Geller EB and Adler MW (2008a) Elevated level of the 
proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey 
causes hyperalgesia in rats. Eur J Pharmacol 592:93-95. 
 
Benamar K, Geller EB and Adler MW (2008b) First in vivo evidence for a 
functional interaction between chemokine and cannabinoid systems in the 
brain. J Pharmacol Exp Ther 325:641-645. 
 
Bhangoo S, Ren D, Miller RJ, Henry KJ, Lineswala J, Hamdouchi C, Li B, 
Monahan PE, Chan DM, Ripsch MS and White FA (2007a) Delayed 
functional expression of neuronal chemokine receptors following focal 
nerve demyelination in the rat: a mechanism for the development of 
chronic sensitization of peripheral nociceptors. Mol Pain 3:38. 
 
Bhangoo SK, Ren D, Miller RJ, Chan DM, Ripsch MS, Weiss C, McGinnis C and 
White FA (2007b) CXCR4 chemokine receptor signaling mediates pain 
hypersensitivity in association with antiretroviral toxic neuropathy. Brain 
Behav Immun 21:581-591. 
 
Bhattacharyya BJ, Banisadr G, Jung H, Ren D, Cronshaw DG, Zou Y and Miller 
RJ (2008) The chemokine stromal cell-derived factor-1 regulates 
GABAergic inputs to neural progenitors in the postnatal dentate gyrus. J 
Neurosci 28:6720-6730. 
 
Bilecki W, Wawrzczak-Bargiela A and Przewlocki R (2004) Activation of AP-1 
and CRE-dependent gene expression via mu-opioid receptor. J 
Neurochem 90:874-882. 
 
118 
 
 
Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J and Springer 
TA (1996) The lymphocyte chemoattractant SDF-1 is a ligand for 
LESTR/fusin and blocks HIV-1 entry. Nature 382:829-833. 
 
Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, 
Minina S, Wilson D, Xu Q and Raz E (2008) Control of chemokine-guided 
cell migration by ligand sequestration. Cell 132:463-473. 
 
Borgland SL, Connor M and Christie MJ (2001) Nociceptin inhibits calcium 
channel currents in a subpopulation of small nociceptive trigeminal 
ganglion neurons in mouse. J Physiol 536:35-47. 
 
Boutet A, Salim H, Leclerc P and Tardieu M (2001) Cellular expression of 
functional chemokine receptor CCR5 and CXCR4 in human embryonic 
neurons. Neuroscience Letters 311:105-108. 
 
Bouvier MM, Evans ML and Benham CD (1991) Calcium Influx Induced by 
Stimulation of ATP Receptors on Neurons Cultured from Rat Dorsal Root 
Ganglia. Eur J Neurosci 3:285-291. 
 
Brown N and Panksepp J (2009) Low-dose naltrexone for disease prevention 
and quality of life. Med Hypotheses 72:333-337. 
 
Burger JA and Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between 
tumor cells and their microenvironment. Blood 107:1761-1767. 
 
Burgess PR and Perl ER (1967) Myelinated afferent fibres responding 
specifically to noxious stimulation of the skin. J Physiol 190:541-562. 
 
Buzas B and Cox BM (1997) Quantitative analysis of mu and delta opioid 
receptor gene expression in rat brain and peripheral ganglia using 
competitive polymerase chain reaction. Neuroscience 76:479-489. 
 
Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P and Simonnet G 
(2000) Long-lasting hyperalgesia induced by fentanyl in rats: preventive 
effect of ketamine. Anesthesiology 92:465-472. 
 
Chakrabarti S and Gintzler AR (2007) Phosphorylation of Galphas influences its 
association with the micro-opioid receptor and is modulated by long-term 
morphine exposure. Mol Pharmacol 72:753-760. 
 
Chakrabarti S, Regec A and Gintzler AR (2005) Biochemical demonstration of 
mu-opioid receptor association with Gsalpha: enhancement following 
morphine exposure. Brain Res Mol Brain Res 135:217-224. 
119 
 
 
 
Chakrabarti S, Rivera M, Yan SZ, Tang WJ and Gintzler AR (1998) Chronic 
morphine augments G(beta)(gamma)/Gs(alpha) stimulation of adenylyl 
cyclase: relevance to opioid tolerance. Mol Pharmacol 54:655-662. 
 
Chao CC, Hu S, Molitor TW, Zhou Y, Murtaugh MP, Tsang M and Peterson PK 
(1992) Morphine potentiates transforming growth factor-beta release from 
human peripheral blood mononuclear cell cultures. J Pharmacol Exp Ther 
262:19-24. 
 
Chen C, Li J, Bot G, Szabo I, Rogers TJ and Liu-Chen LY (2004) 
Heterodimerization and cross-desensitization between the mu-opioid 
receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483:175-
186. 
 
Chen JJ, Dymshitz J and Vasko MR (1997) Regulation of opioid receptors in rat 
sensory neurons in culture. Mol Pharmacol 51:666-673. 
 
Chen X, Geller EB, Rogers TJ and Adler MW (2007a) The chemokine 
CX3CL1/fractalkine interferes with the antinociceptive effect induced by 
opioid agonists in the periaqueductal grey of rats. Brain Res. 
 
Chen X, Geller EB, Rogers TJ and Adler MW (2007b) Rapid heterologous 
desensitization of antinociceptive activity between mu or delta opioid 
receptors and chemokine receptors in rats. Drug Alcohol Depend 88:36-
41. 
 
Chen Y, Mestek A, Liu J, Hurley JA and Yu L (1993) Molecular cloning and 
functional expression of a mu-opioid receptor from rat brain. Mol 
Pharmacol 44:8-12. 
 
Chen Y, Yang C and Wang ZJ (2010) Ca2+/calmodulin-dependent protein kinase 
IIalpha is required for the initiation and maintenance of opioid-induced 
hyperalgesia. J Neurosci 30:38-46. 
 
Chizhmakov I, Yudin Y, Mamenko N, Prudnikov I, Tamarova Z and Krishtal O 
(2005) Opioids inhibit purinergic nociceptors in the sensory neurons and 
fibres of rat via a G protein-dependent mechanism. Neuropharmacology 
48:639-647. 
 
Choi Y, Chuang LF, Lam KM, Kung HF, Wang JM, Osburn BI and Chuang RY 
(1999) Inhibition of chemokine-induced chemotaxis of monkey leukocytes 
by mu-opioid receptor agonists. In Vivo 13:389-396. 
 
120 
 
 
Chuang LF, Chuang TK, Killam KF, Jr., Chuang AJ, Kung HF, Yu L and Chuang 
RY (1994) Delta opioid receptor gene expression in lymphocytes. 
Biochem Biophys Res Commun 202:1291-1299. 
 
Chuang LF, Chuang TK, Killam KF, Jr., Qiu Q, Wang XR, Lin JJ, Kung HF, 
Sheng W, Chao C, Yu L and et al. (1995) Expression of kappa opioid 
receptors in human and monkey lymphocytes. Biochem Biophys Res 
Commun 209:1003-1010. 
 
Chuang LF, Killam KF, Jr. and Chuang RY (1993) Increased replication of simian 
immunodeficiency virus in CEM x174 cells by morphine sulfate. Biochem 
Biophys Res Commun 195:1165-1173. 
 
Coggeshall RE, Zhou S and Carlton SM (1997) Opioid receptors on peripheral 
sensory axons. Brain Res 764:126-132. 
 
Coller JK, Christrup LL and Somogyi AA (2009) Role of active metabolites in the 
use of opioids. Eur J Clin Pharmacol 65:121-139. 
 
Colpaert FC (2002) Mechanisms of opioid-induced pain and antinociceptive 
tolerance: signal transduction. Pain 95:287-288. 
 
Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A and Meucci O (2010) 
Interactions between chemokines: regulation of fractalkine/CX3CL1 
homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem 285:10563-
10571. 
 
Craft RM, Henley SR, Haaseth RC, Hruby VJ and Porreca F (1995) Opioid 
antinociception in a rat model of visceral pain: systemic versus local drug 
administration. J Pharmacol Exp Ther 275:1535-1542. 
 
Cryz SJ, Jr., Pitt TL, Furer E and Germanier R (1984) Role of lipopolysaccharide 
in virulence of Pseudomonas aeruginosa. Infect Immun 44:508-513. 
 
Cunha FQ, Lorenzetti BB, Poole S and Ferreira SH (1991) Interleukin-8 as a 
mediator of sympathetic pain. Br J Pharmacol 104:765-767. 
 
Dado RJ, Law PY, Loh HH and Elde R (1993) Immunofluorescent identification of 
a delta (delta)-opioid receptor on primary afferent nerve terminals. 
Neuroreport 5:341-344. 
 
 
 
121 
 
 
Dambly-Chaudiere C, Cubedo N and Ghysen A (2007) Control of cell migration 
in the development of the posterior lateral line: antagonistic interactions 
between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev 
Biol 7:23. 
 
Desireddi NV, Campbell PL, Stern JA, Sobkoviak R, Chuai S, Shahrara S, 
Thumbikat P, Pope RM, Landis JR, Koch AE and Schaeffer AJ (2008) 
Monocyte chemoattractant protein-1 and macrophage inflammatory 
protein-1alpha as possible biomarkers for the chronic pelvic pain 
syndrome. J Urol 179:1857-1861; discussion 1861-1852. 
 
Dionne RA, Lepinski AM, Gordon SM, Jaber L, Brahim JS and Hargreaves KM 
(2001) Analgesic effects of peripherally administered opioids in clinical 
models of acute and chronic inflammation. Clinical Pharmacology & 
Therapeutics 70:66-73. 
 
Donahoe RM and Vlahov D (1998) Opiates as potential cofactors in progression 
of HIV-1 infections to AIDS. J Neuroimmunol 83:77-87. 
 
Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway 
GP, Sakmar TP, Henson G, De Clercq E and Moore JP (1998) AMD3100, 
a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat 
Med 4:72-77. 
 
Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J and Wang TC (2009) 
Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and 
lymphocytic cancer cell lines. J Biol Chem 284:3650-3662. 
 
Dubovy P, Klusakova I, Svizenska I and Brazda V (2010) Spatio-temporal 
changes of SDF1 and its CXCR4 receptor in the dorsal root ganglia 
following unilateral sciatic nerve injury as a model of neuropathic pain. 
Histochem Cell Biol 133:323-337. 
 
Ekblom M, Gardmark M and Hammarlund-Udenaes M (1993) Pharmacokinetics 
and pharmacodynamics of morphine-3-glucuronide in rats and its 
influence on the antinociceptive effect of morphine. Biopharm Drug Dispos 
14:1-11. 
 
El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed JL, Bruce-Keller AJ and 
Hauser KF (2006) HIV-1 Tat and opiate-induced changes in astrocytes 
promote chemotaxis of microglia through the expression of MCP-1 and 
alternative chemokines. Glia 53:132-146. 
 
122 
 
 
Endres-Becker J, Heppenstall PA, Mousa SA, Labuz D, Oksche A, Schafer M, 
Stein C and Zollner C (2007) Mu-opioid receptor activation modulates 
transient receptor potential vanilloid 1 (TRPV1) currents in sensory 
neurons in a model of inflammatory pain. Mol Pharmacol 71:12-18. 
 
England S, Heblich F, James IF, Robbins J and Docherty RJ (2001) Bradykinin 
evokes a Ca2+-activated chloride current in non-neuronal cells isolated 
from neonatal rat dorsal root ganglia. J Physiol 530:395-403. 
 
Evans CJ, Keith DE, Jr., Morrison H, Magendzo K and Edwards RH (1992) 
Cloning of a delta opioid receptor by functional expression. Science 
258:1952-1955. 
 
Feng Y, Broder CC, Kennedy PE and Berger EA (1996) HIV-1 entry cofactor: 
functional cDNA cloning of a seven-transmembrane, G protein-coupled 
receptor. Science 272:872-877. 
 
Fields HL, Emson PC, Leigh BK, Gilbert RF and Iversen LL (1980) Multiple 
opiate receptor sites on primary afferent fibres. Nature 284:351-353. 
 
Forster R, Kremmer E, Schubel A, Breitfeld D, Kleinschmidt A, Nerl C, Bernhardt 
G and Lipp M (1998) Intracellular and surface expression of the HIV-1 
coreceptor CXCR4/fusin on various leukocyte subsets: rapid 
internalization and recycling upon activation. J Immunol 160:1522-1531. 
 
Furst S, Riba P, Friedmann T, Timar J, Al-Khrasani M, Obara I, Makuch W, 
Spetea M, Schutz J, Przewlocki R, Przewlocka B and Schmidhammer H 
(2005) Peripheral versus central antinociceptive actions of 6-amino acid-
substituted derivatives of 14-O-methyloxymorphone in acute and 
inflammatory pain in the rat. J Pharmacol Exp Ther 312:609-618. 
 
Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP, Jr., Lai 
J and Porreca F (2002) Sustained morphine exposure induces a spinal 
dynorphin-dependent enhancement of excitatory transmitter release from 
primary afferent fibers. J Neurosci 22:6747-6755. 
 
Gendron L, Lucido AL, Mennicken F, O'Donnell D, Vincent JP, Stroh T and 
Beaudet A (2006) Morphine and pain-related stimuli enhance cell surface 
availability of somatic delta-opioid receptors in rat dorsal root ganglia. J 
Neurosci 26:953-962. 
 
Gillard SE, Lu M, Mastracci RM and Miller RJ (2002) Expression of functional 
chemokine receptors by rat cerebellar neurons. Journal of 
Neuroimmunology 124:16-28. 
123 
 
 
 
Glajchen M (2001) Chronic pain: treatment barriers and strategies for clinical 
practice. J Am Board Fam Pract 14:211-218. 
 
Gold MS, Reichling DB, Shuster MJ and Levine JD (1996) Hyperalgesic agents 
increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc Natl 
Acad Sci U S A 93:1108-1112. 
 
Goldman S (2003) Glia as neural progenitor cells. Trends Neurosci 26:590-596. 
 
Gould HJ, 3rd, England JD, Liu ZP and Levinson SR (1998) Rapid sodium 
channel augmentation in response to inflammation induced by complete 
Freund's adjuvant. Brain Res 802:69-74. 
bin/cas/tree/store/bres/cas_sub/browse/browse.cgi?year=1998&volume=1
802&i ssue=1991-1992&aid=14748. 
 
Grimm MC, Ben-Baruch A, Taub DD, Howard OM, Wang JM and Oppenheim JJ 
(1998) Opiate inhibition of chemokine-induced chemotaxis. Ann N Y Acad 
Sci 840:9-20. 
 
Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, Fletcher D 
and Chauvin M (2000) Acute opioid tolerance: intraoperative remifentanil 
increases postoperative pain and morphine requirement. Anesthesiology 
93:409-417. 
 
Gutstein HB (1996) The effects of pain on opioid tolerance: how do we resolve 
the controversy? Pharmacol Rev 48:403-407; discussion 409-411. 
 
Hanani M (2005) Satellite glial cells in sensory ganglia: from form to function. 
Brain Research Reviews 48:457-476. 
 
Hansson E and Ronnback L (2003) Glial neuronal signaling in the central 
nervous system. FASEB J 17:341-348. 
 
Happel C, Kutzler M and Rogers TJ (2010) Opioid-induced chemokine 
expression requires NF-{kappa}B activity: the role of PKC{zeta}. J Leukoc 
Biol 89:301-309. 
 
Happel C, Steele AD, Finley MJ, Kutzler MA and Rogers TJ (2008) DAMGO-
induced expression of chemokines and chemokine receptors: the role of 
TGF-{beta}1. J Leukoc Biol. 
 
124 
 
 
Hasselstrom J and Sawe J (1993) Morphine pharmacokinetics and metabolism in 
humans. Enterohepatic cycling and relative contribution of metabolites to 
active opioid concentrations. Clin Pharmacokinet 24:344-354. 
 
Hatse S, Princen K, Bridger G, De Clercq E and Schols D (2002) Chemokine 
receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 
527:255-262. 
 
Heblich F, England S, Docherty RJ. (2001) Indirect actions of bradykinin on 
neonatal rat dorsal root ganglion neurones: a role for non-neuronal cells 
as nociceptors. J Physiol 2001 Oct 1;536(Pt 1):111-21. 
 
Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath 
E, Bridger G and Henson GW (2000) Pharmacokinetics and safety of 
AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in 
human volunteers. Antimicrob Agents Chemother 44:1667-1673. 
 
Hingtgen CM and Vasko MR (1994) Prostacyclin enhances the evoked-release 
of substance P and calcitonin gene-related peptide from rat sensory 
neurons. Brain Res 655:51-60. 
 
Holz GGt, Dunlap K and Kream RM (1988) Characterization of the electrically 
evoked release of substance P from dorsal root ganglion neurons: 
methods and dihydropyridine sensitivity. J Neurosci 8:463-471. 
 
Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K and 
Akira S (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are 
hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene 
product. J Immunol 162:3749-3752. 
 
Hou YN, Vlaskovska M, Cebers G, Kasakov L, Liljequist S and Terenius L (1996) 
A mu-receptor opioid agonist induces AP-1 and NF-kappa B transcription 
factor activity in primary cultures of rat cortical neurons. Neurosci Lett 
212:159-162. 
 
Huang LY and Neher E (1996) Ca(2+)-dependent exocytosis in the somata of 
dorsal root ganglion neurons. Neuron 17:135-145. 
 
Huettner JE (1990) Glutamate receptor channels in rat DRG neurons: Activation 
by kainate and quisqualate and blockade of desensitization by con A. 
Neuron 5:255 - 266. 
 
125 
 
 
Huskens D, Princen K, Schreiber M and Schols D (2007) The role of N-
glycosylation sites on the CXCR4 receptor for CXCL-12 binding and 
signaling and X4 HIV-1 viral infectivity. Virology 363:280-287. 
 
Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, Baker 
EM, Jekich BM, Wieseler JL, Somogyi AA, Martin D, Poole S, Judd CM, 
Maier SF and Watkins LR (2008) Proinflammatory cytokines oppose 
opioid-induced acute and chronic analgesia. Brain Behav Immun 22:1178-
1189. 
 
Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, 
Somogyi AA, Yin H, Maier SF, Rice KC and Watkins LR (2010) Possible 
involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of 
opioid inactive isomers causes spinal proinflammation and related 
behavioral consequences. Neuroscience 167:880-893. 
 
Hutchinson MR, Ramos KM, Loram LC, Wieseler J, Sholar PW, Kearney JJ, 
Lewis MT, Crysdale NY, Zhang Y, Harrison JA, Maier SF, Rice KC and 
Watkins LR (2009) Evidence for a role of heat shock protein-90 in toll like 
receptor 4 mediated pain enhancement in rats. Neuroscience 164:1821-
1832. 
 
Ibuki T, Marsala M, Masuyama T and Yaksh TL (2003) Spinal amino acid release 
and repeated withdrawal in spinal morphine tolerant rats. Br J Pharmacol 
138:689-697. 
 
Ingram SL and Williams JT (1994) Opioid inhibition of Ih via adenylyl cyclase. 
Neuron 13:179-186. 
 
Jeftinija S and Jeftinija K (1990) Calcitonin gene-related peptide immunoreactivity 
in neuronal perikarya in dorsal root. Brain Res 519:324-328. 
 
Jeon SM, Lee KM, Park ES, Jeon YH and Cho HJ (2008) Monocyte 
chemoattractant protein-1 immunoreactivity in sensory ganglia and 
hindpaw after adjuvant injection. Neuroreport 19:183-186. 
 
Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, 
Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF and 
Watkins LR (2004) A role for proinflammatory cytokines and fractalkine in 
analgesia, tolerance, and subsequent pain facilitation induced by chronic 
intrathecal morphine. J Neurosci 24:7353-7365. 
 
 
 
126 
 
 
Jung H, Bhangoo S, Banisadr G, Freitag C, Ren D, White FA and Miller RJ 
(2009) Visualization of chemokine receptor activation in transgenic mice 
reveals peripheral activation of CCR2 receptors in states of neuropathic 
pain. J Neurosci 29:8051-8062. 
 
Jung H and Miller RJ (2008) Activation of the nuclear factor of activated T-cells 
(NFAT) mediates upregulation of CCR2 chemokine receptors in dorsal 
root ganglion (DRG) neurons: A possible mechanism for activity-
dependent transcription in DRG neurons in association with neuropathic 
pain. Mol Cell Neurosci 37:170-177. 
 
Jung H, Toth PT, White FA and Miller RJ (2008) Monocyte chemoattractant 
protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J 
Neurochem 104:254-263. 
 
Jung J, Bhangoo SK, Fitzgerald MP, Miller RJ and White FA (2007) Expression 
of functional chemokine receptors in bladder-associated sensory neurons 
following focal demyelination of sciatic nerve., in Society for Neuroscience 
Annual Meeting p Program No. 185.188, Society for Neuroscience, San 
Diego, CA  
 
Junger H, Moore AC and Sorkin LS (2002) Effects of full-thickness burns on 
nociceptor sensitization in anesthetized rats. Burns 28:772-777. 
 
Juni A, Klein G, Pintar JE and Kest B (2007) Nociception increases during opioid 
infusion in opioid receptor triple knock-out mice. Neuroscience 147:439-
444. 
 
Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS and Heveker 
N (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. 
Mol Pharmacol 75:1240-1247. 
 
 
Katoh M and Katoh M (2010) Integrative genomic analyses of CXCR4: 
Transcriptional regulation of CXCR4 based on TGF beta, Nodal, Activin 
signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 
transcription factors. International Journal of Oncology 36:415-420. 
 
Kim C, Cheng R and Corrigall WA (1988) Measurement of Naltrexone in Rat-
Brain Regions and Serum by High-Performance Liquid-Chromatography 
with Electrochemical Detection. Chromatographia 25:91-94. 
 
127 
 
 
Kleinschnitz C, Brinkhoff J, Sommer C and Stoll G (2005) Contralateral cytokine 
gene induction after peripheral nerve lesions: Dependence on the mode of 
injury and NMDA receptor signaling. Brain Res Mol Brain Res 136:23-28. 
 
Knerlich-Lukoschus F, Juraschek M, Blomer U, Lucius R, Mehdorn HM and Held-
Feindt J (2008) Force-Dependent Development of Neuropathic Central 
Pain and Time-Related CCL2/CCR2 Expression after Graded Spinal Cord 
Contusion Injuries of the Rat. J Neurotrauma. 
 
Kolodziej A, Schulz S, Guyon A, Wu DF, Pfeiffer M, Odemis V, Hollt V and 
Stumm R (2008) Tonic activation of CXC chemokine receptor 4 in 
immature granule cells supports neurogenesis in the adult dentate gyrus. 
J Neurosci 28:4488-4500. 
 
Koppert W, Likar R, Geisslinger G, Zeck S, Schmelz M and Sittl R (1999) 
Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, 
stimulation in healthy volunteers after ultraviolet-B irradiation. Anesth 
Analg 88:117-122. 
 
Kuhar MJ, Pert CB and Snyder SH (1973) Regional distribution of opiate receptor 
binding in monkey and human brain. Nature 245:447-450. 
 
Kumamoto T, Fukuhara N, Miyatake T, Araki K, Takahashi Y and Araki S (1986) 
Experimental neuropathy induced by methyl mercury compounds: 
autoradiographic study of GABA uptake by dorsal root ganglia. Eur Neurol 
25:269-277. 
 
Labella FS, Pinsky C and Havlicek V (1979) Morphine derivatives with 
diminished opiate receptor potency show enhanced central excitatory 
activity. Brain Res 174:263-271. 
 
Labuz D, Mousa SA, Schafer M, Stein C and Machelska H (2007) Relative 
contribution of peripheral versus central opioid receptors to 
antinociception. Brain Res 1160:30-38. 
 
Lamotte C, Pert CB and Snyder SH (1976) Opiate receptor binding in primate 
spinal cord: distribution and changes after dorsal root section. Brain Res 
112:407-412. 
 
Laulin JP, Celerier E, Larcher A, Le Moal M and Simonnet G (1999) Opiate 
tolerance to daily heroin administration: an apparent phenomenon 
associated with enhanced pain sensitivity. Neuroscience 89:631-636. 
128 
 
 
Laulin JP, Larcher A, Celerier E, Le Moal M and Simonnet G (1998) Long-lasting 
increased pain sensitivity in rat following exposure to heroin for the first 
time. Eur J Neurosci 10:782-785. 
 
Levoye A, Balabanian K, Baleux F, Bachelerie F and Lagane B (2009) CXCR7 
heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein 
signaling. Blood 113:6085-6093. 
 
Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, Rice KC 
and Watkins LR (2010) Evidence that intrathecal morphine-3-glucuronide 
may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-
1beta. Neuroscience 165:569-583. 
 
Li M and Ransohoff RM (2008) Multiple roles of chemokine CXCL12 in the 
central nervous system: A migration from immunology to neurobiology. 
Prog Neurobiol 84:116-131. 
 
Liang DY, Shi X, Qiao Y, Angst MS, Yeomans DC and Clark JD (2008) Chronic 
morphine administration enhances nociceptive sensitivity and local 
cytokine production after incision. Mol Pain 4:7. 
 
Likar R, Kapral S, Steinkellner H, Stein C and Schafer M (1999) Dose-
dependency of intra-articular morphine analgesia. Br J Anaesth 83:241-
244. 
 
Lim G, Wang S, Zeng Q, Sung B, Yang L and Mao J (2005) Expression of spinal 
NMDA receptor and PKCgamma after chronic morphine is regulated by 
spinal glucocorticoid receptor. J Neurosci 25:11145-11154. 
 
Lindia JA, McGowan E, Jochnowitz N and Abbadie C (2005) Induction of 
CX3CL1 Expression in Astrocytes and CX3CR1 in Microglia in the Spinal 
Cord of a Rat Model of Neuropathic Pain. J Pain 6:434-438. 
 
Liu X, Chung K and Chung JM (1999) Ectopic discharges and adrenergic 
sensitivity of sensory neurons after spinal nerve injury. Brain Res 849:244-
247. 
 
Lovinger DM and Weight FF (1988) Glutamate induces a depolarization of adult 
rat dorsal root ganglion neurons that is mediated predominantly by NMDA 
receptors. Neurosci Lett 94:314-320. 
 
Lu M, Grove EA and Miller RJ (2002) Abnormal development of the hippocampal 
dentate gyrus in mice lacking the CXCR4 chemokine receptor. PNAS 
99:7090-7095. 
129 
 
 
 
Luginbuhl M, Gerber A, Schnider TW, Petersen-Felix S, Arendt-Nielsen L and 
Curatolo M (2003) Modulation of remifentanil-induced analgesia, 
hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth 
Analg 96:726-732, table of contents. 
 
Ma C and LaMotte RH (2005) Enhanced excitability of dissociated primary 
sensory neurons after chronic compression of the dorsal root ganglion in 
the rat. Pain 113:106-112. 
 
Ma C, Shu Y, Zheng Z, Chen Y, Yao H, Greenquist KW, White FA and LaMotte 
RH (2003) Similar Electrophysiological Changes in Axotomized and 
Neighboring Intact Dorsal Root Ganglion Neurons. J Neurophysiol 
89:1588-1602. 
 
Machelska H, Pfluger M, Weber W, Piranvisseh-Volk M, Daubert JD, Dehaven R 
and Stein C (1999) Peripheral effects of the kappa-opioid agonist EMD 
61753 on pain and inflammation in rats and humans. J Pharmacol Exp 
Ther 290:354-361. 
 
Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE and Nair MP 
(2005) Morphine modulates chemokine gene regulation in normal human 
astrocytes. Clin Immunol 115:323-332. 
 
Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H and Watson SJ 
(1994) Mu, delta, and kappa opioid receptor mRNA expression in the rat 
CNS: an in situ hybridization study. J Comp Neurol 350:412-438. 
 
Mao J, Price DD and Mayer DJ (1994) Thermal hyperalgesia in association with 
the development of morphine tolerance in rats: roles of excitatory amino 
acid receptors and protein kinase C. J Neurosci 14:2301-2312. 
 
Mao J, Price DD and Mayer DJ (1995) Mechanisms of hyperalgesia and 
morphine tolerance: a current view of their possible interactions. Pain 
62:259-274. 
 
Mao J, Sung B, Ji RR and Lim G (2002) Chronic morphine induces 
downregulation of spinal glutamate transporters: implications in morphine 
tolerance and abnormal pain sensitivity. J Neurosci 22:8312-8323. 
 
Mason RT, Peterfreund RA, Sawchenko PE, Corrigan AZ, Rivier JE and Vale 
WW (1984) Release of the predicted calcitonin gene-related peptide from 
cultured rat trigeminal ganglion cells. Nature 308:653-655. 
 
130 
 
 
Menetski J, Mistry S, Lu M, Mudgett JS, Ransohoff RM, Demartino JA, Macintyre 
DE and Abbadie C (2007) Mice overexpressing chemokine ligand 2 
(CCL2) in astrocytes display enhanced nociceptive responses. 
Neuroscience 149:706-714. 
 
Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ and Akil H 
(1993) Cloning and pharmacological characterization of a rat kappa opioid 
receptor. Proc Natl Acad Sci U S A 90:9954-9958. 
 
Messmer D, Hatsukari I, Hitosugi N, Schmidt-Wolf IG and Singhal PC (2006) 
Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-
derived human dendritic cells and enhances T cell activation. Mol Med 
12:284-290. 
 
Miller RJ, Banisadr G and Bhattacharyya BJ (2008) CXCR4 signaling in the 
regulation of stem cell migration and development. J Neuroimmunol. 
 
Milligan E, Zapata V, Schoeniger D, Chacur M, Green P, Poole S, Martin D, 
Maier SF and Watkins LR (2005) An initial investigation of spinal 
mechanisms underlying pain enhancement induced by fractalkine, a 
neuronally released chemokine. Eur J Neurosci 22:2775-2782. 
 
Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, O'Connor KA, 
Verge GM, Chapman G, Green P, Foster AC, Naeve GS, Maier SF and 
Watkins LR (2004) Evidence that exogenous and endogenous fractalkine 
can induce spinal nociceptive facilitation in rats. Eur J Neurosci 20:2294-
2302. 
 
Minami M, Maekawa K, Yabuuchi K and Satoh M (1995) Double in situ 
hybridization study on coexistence of mu-, delta- and kappa-opioid 
receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root 
ganglia. Brain Res Mol Brain Res 30:203-210. 
 
Minami M and Satoh M (1995) Molecular biology of the opioid receptors: 
structures, functions and distributions. Neurosci Res 23:121-145. 
 
Miyagi T, Chuang LF, Doi RH, Carlos MP, Torres JV and Chuang RY (2000) 
Morphine induces gene expression of CCR5 in human CEMx174 
lymphocytes. J Biol Chem 275:31305-31310. 
 
Mousa SA, Straub RH, Schafer M and Stein C (2007) Beta-endorphin, Met-
enkephalin and corresponding opioid receptors within synovium of 
patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann 
Rheum Dis 66:871-879. 
131 
 
 
 
Neudeck BL, Loeb J and Buck J (2003) Activation of the kappa-opioid receptor in 
Caco-2 cells decreases interleukin-8 secretion. Eur J Pharmacol 467:81-
84. 
 
Ninkovic M, Hunt SP and Gleave JR (1982) Localization of opiate and histamine 
H1-receptors in the primate sensory ganglia and spinal cord. Brain Res 
241:197-206. 
 
Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos 
F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, 
Baggiolini M and Moser B (1996) The CXC chemokine SDF-1 is the ligand 
for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. 
Nature 382:833-835. 
 
Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL and Miller RJ (2001) 
Chemokines and Glycoprotein120 Produce Pain Hypersensitivity by 
Directly Exciting Primary Nociceptive Neurons. J Neurosci 21:5027-5035. 
 
Osborne R, Joel S, Trew D and Slevin M (1990) Morphine and metabolite 
behavior after different routes of morphine administration: demonstration 
of the importance of the active metabolite morphine-6-glucuronide. Clin 
Pharmacol Ther 47:12-19. 
 
Ossipov MH, Lai J, King T, Vanderah TW, Malan TP, Jr., Hruby VJ and Porreca 
F (2004) Antinociceptive and nociceptive actions of opioids. J Neurobiol 
61:126-148. 
 
Pannese E (1981) The satellite cells of the sensory ganglia. Adv Anat Embryol 
Cell Biol 65:1-111. 
 
Pare M, Elde R, Mazurkiewicz JE, Smith AM and Rice FL (2001) The Meissner 
Corpuscle Revised: A Multiafferented Mechanoreceptor with Nociceptor 
Immunochemical Properties. J Neurosci 21:7236-7246. 
 
Pasternak GW, Bodnar RJ, Clark JA and Inturrisi CE (1987) Morphine-6-
glucuronide, a potent mu agonist. Life Sci 41:2845-2849. 
 
Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM and Slevin ML (2000) 
Randomized placebo-controlled trial of the activity of the morphine 
glucuronides. Clin Pharmacol Ther 68:667-676. 
 
Pert CB, Kuhar MJ and Snyder SH (1976) Opiate receptor: autoradiographic 
localization in rat brain. Proc Natl Acad Sci U S A 73:3729-3733. 
132 
 
 
 
Pert CB and Snyder SH (1973) Opiate receptor: demonstration in nervous tissue. 
Science 179:1011-1014. 
 
Pertovaara A and Wei H (2001) Peripheral effects of morphine in neuropathic 
rats: role of sympathetic postganglionic nerve fibers. Eur J Pharmacol 
429:139-145. 
 
Peterson PK, Gekker G, Hu S, Anderson WR, Kravitz F, Portoghese PS, Balfour 
HH, Jr. and Chao CC (1994) Morphine amplifies HIV-1 expression in 
chronically infected promonocytes cocultured with human brain cells. J 
Neuroimmunol 50:167-175. 
 
Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K and Balfour HH, 
Jr. (1990) Morphine promotes the growth of HIV-1 in human peripheral 
blood mononuclear cell cocultures. AIDS 4:869-873. 
 
Platika D, Boulos MH, Baizer L and Fishman MC (1985) Neuronal traits of clonal 
cell lines derived by fusion of dorsal root ganglia neurons with 
neuroblastoma cells. Proc Natl Acad Sci U S A 82:3499-3503. 
 
Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ and Tobias PS 
(1993) Lipopolysaccharide activation of human endothelial and epithelial 
cells is mediated by lipopolysaccharide-binding protein and soluble CD14. 
Proc Natl Acad Sci U S A 90:2744-2748. 
 
Raghavendra V, Tanga FY and DeLeo JA (2004) Attenuation of morphine 
tolerance, withdrawal-induced hyperalgesia, and associated spinal 
inflammatory immune responses by propentofylline in rats. 
Neuropsychopharmacology 29:327-334. 
 
Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C and 
Lefkowitz RJ (2010) Beta-arrestin- but not G protein-mediated signaling by 
the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A 107:628-632. 
 
Rau KK, Caudle RM, Cooper BY and Johnson RD (2005) Diverse 
immunocytochemical expression of opioid receptors in 
electrophysiologically defined cells of rat dorsal root ganglia. J Chem 
Neuroanat 29:255-264. 
 
Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI and Reisine T (1994) 
Pharmacological characterization of the cloned kappa-, delta-, and mu-
opioid receptors. Mol Pharmacol 45:330-334. 
 
133 
 
 
Reichenbach A (1991) Glial K+ permeability and CNS K+ clearance by diffusion 
and spatial buffering. Ann N Y Acad Sci 633:272-286. 
 
Reichert JA, Daughters RS, Rivard R and Simone DA (2001) Peripheral and 
preemptive opioid antinociception in a mouse visceral pain model. Pain 
89:221-227. 
 
Rittner HL, Labuz D, Schaefer M, Mousa SA, Schulz S, Schafer M, Stein C and 
Brack A (2006) Pain control by CXCR2 ligands through Ca2+-regulated 
release of opioid peptides from polymorphonuclear cells. Faseb J. 
 
Robertson B (1989) Characteristics of GABA-activated chloride channels in 
mammalian dorsal root ganglion neurones. J Physiol 411:285-300. 
 
Rock RB, Hu S, Sheng WS and Peterson PK (2006) Morphine stimulates CCL2 
production by human neurons. J Neuroinflammation 3:32. 
 
Rogers TJ, Steele AD, Howard OM and Oppenheim JJ (2000) Bidirectional 
heterologous desensitization of opioid and chemokine receptors. Ann N Y 
Acad Sci 917:19-28. 
 
Roy S, Cain KJ, Chapin RB, Charboneau RG and Barke RA (1998) Morphine 
modulates NF kappa B activation in macrophages. Biochem Biophys Res 
Commun 245:392-396. 
 
Russell NJ, Schaible HG and Schmidt RF (1987) Opiates inhibit the discharges 
of fine afferent units from inflamed knee joint of the cat. Neurosci Lett 
76:107-112. 
 
Sato K, Kiyama H, Park HT and Tohyama M (1993) AMPA, KA and NMDA 
receptors are expressed in the rat DRG neurones. Neuroreport 4:1263-
1265. 
 
Schabath R, Muller G, Schubel A, Kremmer E, Lipp M and Forster R (1999) The 
murine chemokine receptor CXCR4 is tightly regulated during T cell 
development and activation. J Leukoc Biol 66:996-1004. 
 
Schiller PW, Nguyen TM, Chung NN, Dionne G and Martel R (1990) Peripheral 
antinociceptive effect of an extremely mu-selective polar dermorphin 
analog (DALDA). Prog Clin Biol Res 328:53-56. 
 
 
 
134 
 
 
Schiller PW, Nguyen TM, Chung NN and Lemieux C (1989) Dermorphin 
analogues carrying an increased positive net charge in their "message" 
domain display extremely high mu opioid receptor selectivity. J Med Chem 
32:698-703. 
 
Schlaepfer WW (1969) Experimental lead neuropathy: a disease of the 
supporting cells in the peripheral nervous system. J Neuropathol Exp 
Neurol 28:401-418. 
 
Schols D, Struyf S, Van Damme J, Este JA, Henson G and De Clercq E (1997) 
Inhibition of T-tropic HIV strains by selective antagonization of the 
chemokine receptor CXCR4. J Exp Med 186:1383-1388. 
 
Shannon HE and Lutz EA (2002) Comparison of the peripheral and central 
effects of the opioid agonists loperamide and morphine in the formalin test 
in rats. Neuropharmacology 42:253-261. 
 
Sheng WS, Hu S, Lokensgard JR and Peterson PK (2003) U50,488 inhibits HIV-
1 Tat-induced monocyte chemoattractant protein-1 (CCL2) production by 
human astrocytes. Biochem Pharmacol 65:9-14. 
 
Sherrington CS (1906) The Integrative Action of the Nervous System., Yale 
University Press., New Haven, CT. 
 
Shinder V and Devor M (1994) Structural basis of neuron-to-neuron cross-
excitation in dorsal root ganglia. J Neurocytol 23:515-531. 
 
Silbert SC, Beacham DW and McCleskey EW (2003) Quantitative single-cell 
differences in mu-opioid receptor mRNA distinguish myelinated and 
unmyelinated nociceptors. J Neurosci 23:34-42. 
 
Singla A, Stojanovic MP, Chen L and Mao J (2007) A differential diagnosis of 
hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. 
Anesth Analg 105:1816-1819, table of contents. 
 
Skarke C, Geisslinger G and Lotsch J (2005) Is morphine-3-glucuronide of 
therapeutic relevance? Pain 116:177-180. 
 
Slezak M and Pfrieger FW (2003) New roles for astrocytes: regulation of CNS 
synaptogenesis. Trends Neurosci 26:531-535. 
 
Smith MT, Watt JA and Cramond T (1990) Morphine-3-glucuronide--a potent 
antagonist of morphine analgesia. Life Sci 47:579-585. 
 
135 
 
 
Song PI, Abraham TA, Park Y, Zivony AS, Harten B, Edelhauser HF, Ward SL, 
Armstrong CA and Ansel JC (2001) The expression of functional LPS 
receptor proteins CD14 and toll-like receptor 4 in human corneal cells. 
Invest Ophthalmol Vis Sci 42:2867-2877. 
 
Spigelman I and Puil E (1991) Substance P actions on sensory neurons. Ann N 
Y Acad Sci 632:220-228. 
 
Steele AD, Henderson EE and Rogers TJ (2003) Mu-opioid modulation of HIV-1 
coreceptor expression and HIV-1 replication. Virology 309:99-107. 
 
Stein C, Comisel K, Haimerl E, Yassouridis A, Lehrberger K, Herz A and Peter K 
(1991) Analgesic effect of intraarticular morphine after arthroscopic knee 
surgery. N Engl J Med 325:1123-1126. 
 
Stein C, Gramsch C and Herz A (1990) Intrinsic mechanisms of antinociception 
in inflammation: local opioid receptors and beta-endorphin. J Neurosci 
10:1292-1298. 
 
Sun JH, Yang B, Donnelly DF, Ma C and LaMotte RH (2006) MCP-1 enhances 
excitability of nociceptive neurons in chronically compressed dorsal root 
ganglia. J Neurophysiol 96:2189-2199. 
 
Sun S, Cao H, Han M, Li TT, Pan HL, Zhao ZQ and Zhang YQ (2007) New 
evidence for the involvement of spinal fractalkine receptor in pain 
facilitation and spinal glial activation in rat model of monoarthritis. Pain 
129:64-75. 
 
Szabo I, Chen XH, Xin L, Adler MW, Howard OM, Oppenheim JJ and Rogers TJ 
(2002) Heterologous desensitization of opioid receptors by chemokines 
inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad 
Sci U S A 99:10276-10281. 
 
Szeto HH, Lovelace JL, Fridland G, Soong Y, Fasolo J, Wu D, Desiderio DM and 
Schiller PW (2001) In vivo pharmacokinetics of selective mu-opioid 
peptide agonists. J Pharmacol Exp Ther 298:57-61. 
 
Tai YH, Wang YH, Wang JJ, Tao PL, Tung CS and Wong CS (2006) 
Amitriptyline suppresses neuroinflammation and up-regulates glutamate 
transporters in morphine-tolerant rats. Pain 124:77-86. 
 
 
 
136 
 
 
Takeda M, Takahashi M and Matsumoto S (2008) Contribution of activated 
interleukin receptors in trigeminal ganglion neurons to hyperalgesia via 
satellite glial interleukin-1beta paracrine mechanism. Brain Behav Immun 
22:1016-1023. 
 
Takeda M, Tanimoto T, Kadoi J, Nasu M, Takahashi M, Kitagawa J and 
Matsumoto S (2007) Enhanced excitability of nociceptive trigeminal 
ganglion neurons by satellite glial cytokine following peripheral 
inflammation. Pain 129:155-166. 
 
Tanaka M, Cummins TR, Ishikawa K, Dib-Hajj SD, Black JA and Waxman SG 
(1998) SNS Na+ channel expression increases in dorsal root ganglion 
neurons in the carrageenan inflammatory pain model. Neuroreport 9:967-
972. 
Tanaka T, Minami M, Nakagawa T and Satoh M (2004) Enhanced production of 
monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat 
model of neuropathic pain: possible involvement in the development of 
neuropathic pain. Neurosci Res 48:463-469. 
 
Tang CH, Chuang JY, Fong YC, Maa MC, Way TD and Hung CH (2008) Bone-
derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB 
pathways and promotes osteoclastogenesis in human oral cancer cells. 
Carcinogenesis 29:1483-1492. 
 
Tarasova NI, Stauber RH and Michejda CJ (1998) Spontaneous and ligand-
induced trafficking of CXC-chemokine receptor 4. J Biol Chem 273:15883-
15886. 
 
Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T and Honjo T (1993) Signal 
sequence trap: a cloning strategy for secreted proteins and type I 
membrane proteins. Science 261:600-603. 
 
Thayer SA, Perney TM and Miller RJ (1988) Regulation of calcium homeostasis 
in sensory neurons by bradykinin. J Neurosci 8:4089-4097. 
 
Todorovic SM and Anderson EG (1990) Pharmacological characterization of 5-
hydroxytryptamine2 and 5-hydroxytryptamine3 receptors in rat dorsal root 
ganglion cells. J Pharmacol Exp Ther 254:109-115. 
 
Triantafilou M, Lepper PM, Briault CD, Ahmed MA, Dmochowski JM, Schumann 
C and Triantafilou K (2008) Chemokine receptor 4 (CXCR4) is part of the 
lipopolysaccharide "sensing apparatus". Eur J Immunol 38:192-203. 
 
137 
 
 
Uceyler N, Eberle T, Rolke R, Birklein F and Sommer C (2007) Differential 
expression patterns of cytokines in complex regional pain syndrome. Pain 
132:195-205. 
 
Utzschneider D, Kocsis J and Devor M (1992) Mutual excitation among dorsal 
root ganglion neurons in the rat. Neurosci Lett 146:53-56. 
 
Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, Zhang 
ET, Malan TP, Jr., Ossipov MH, Lai J and Porreca F (2000) Dynorphin 
promotes abnormal pain and spinal opioid antinociceptive tolerance. J 
Neurosci 20:7074-7079. 
 
Vanderah TW, Suenaga NM, Ossipov MH, Malan TP, Jr., Lai J and Porreca F 
(2001) Tonic descending facilitation from the rostral ventromedial medulla 
mediates opioid-induced abnormal pain and antinociceptive tolerance. J 
Neurosci 21:279-286. 
 
Vedder H and Otten U (1991) Biosynthesis and release of tachykinins from rat 
sensory neurons in culture. J Neurosci Res 30:288-299. 
 
Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC, 3rd, Basnet 
H, Sakmar TP and Volkman BF (2008) Structural basis of CXCR4 
sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal 
1:ra4. 
 
Verebey K, Volavka J, Mule SJ and Resnick RB (1976) Naltrexone: disposition, 
metabolism, and effects after acute and chronic dosing. Clin Pharmacol 
Ther 20:315-328. 
 
Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS and Foster AC (2004) 
Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in 
spinal cord and dorsal root ganglia under basal and neuropathic pain 
conditions. Eur J Neurosci 20:1150-1160. 
 
Vit JP, Ohara PT, Tien DA, Fike JR, Eikmeier L, Beitz A, Wilcox GL and Jasmin L 
(2006) The analgesic effect of low dose focal irradiation in a mouse model 
of bone cancer is associated with spinal changes in neuro-mediators of 
nociception. Pain 120:188-201. 
 
Volk T, Schenk M, Voigt K, Tohtz S, Putzier M and Kox WJ (2004) Postoperative 
epidural anesthesia preserves lymphocyte, but not monocyte, immune 
function after major spine surgery. Anesth Analg 98:1086-1092, table of 
contents. 
 
138 
 
 
Wall PD and Devor M (1983) Sensory afferent impulses originate from dorsal 
root ganglia as well as from the periphery in normal and nerve injured rats. 
Pain 17:321-339. 
 
Wang H and Wessendorf MW (2001) Equal proportions of small and large DRG 
neurons express opioid receptor mRNAs. J Comp Neurol 429:590-600. 
 
Wang J, Barke RA and Roy S (2007) Transcriptional and epigenetic regulation of 
interleukin-2 gene in activated T cells by morphine. J Biol Chem 282:7164-
7171. 
 
Wang JG, Strong JA, Xie W, Yang RH, Coyle DE, Wick DM, Dorsey ED and 
Zhang JM (2008) The chemokine CXCL1/growth related oncogene 
increases sodium currents and neuronal excitability in small diameter 
sensory neurons. Mol Pain 4:38. 
 
Wenk HN and Honda CN (1999) Immunohistochemical localization of delta 
opioid receptors in peripheral tissues. J Comp Neurol 408:567-579. 
 
Werz MA and Macdonald RL (1982) Opioid peptides decrease calcium-
dependent action potential duration of mouse dorsal root ganglion neurons 
in cell culture. Brain Res 239:315-321. 
 
White FA, Feldman P and Miller RJ (2009) Chemokine signaling and the 
management of neuropathic pain. Mol Interv 9:188-195. 
 
White FA, Jung H and Miller RJ (2007) Chemokines and the pathophysiology of 
neuropathic pain. Proc Natl Acad Sci U S A 104:20151-20158. 
 
White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, Steflik J, Cortright DN, 
Lamotte RH and Miller RJ (2005) Excitatory monocyte chemoattractant 
protein-1 signaling is up-regulated in sensory neurons after chronic 
compression of the dorsal root ganglion. Proc Natl Acad Sci U S A 
102:14092-14097. 
 
Wick MJ, Minnerath SR, Roy S, Ramakrishnan S and Loh HH (1996) Differential 
expression of opioid receptor genes in human lymphoid cell lines and 
peripheral blood lymphocytes. J Neuroimmunol 64:29-36. 
 
Wilson NM, Jung H, Ripsch MS, Miller RJ and White FA (2011) CXCR4 signaling 
mediates morphine-induced tactile hyperalgesia. Brain Behav Immun 
25:565-573. 
 
139 
 
 
Woolf CJ (1981) Intrathecal high dose morphine produces hyperalgesia in the 
rat. Brain Res 209:491-495. 
 
Woolf CJ and Fitzgerald M (1981) Lamina-specific alteration of C-fibre evoked 
activity by morphine in the dorsal horn of the rat spinal cord. Neurosci Lett 
25:37-41. 
 
Wybran J, Appelboom T, Famaey JP and Govaerts A (1979) Suggestive 
evidence for receptors for morphine and methionine-enkephalin on normal 
human blood T lymphocytes. J Immunol 123:1068-1070. 
 
Xie WR, Deng H, Li H, Bowen TL, Strong JA and Zhang JM (2006) Robust 
increase of cutaneous sensitivity, cytokine production and sympathetic 
sprouting in rats with localized inflammatory irritation of the spinal ganglia. 
Neuroscience 142(3):809-822:809-822. 
 
Yaksh TL, Harty GJ and Onofrio BM (1986) High dose of spinal morphine 
produce a nonopiate receptor-mediated hyperesthesia: clinical and 
theoretic implications. Anesthesiology 64:590-597. 
 
Zabel BA, Wang Y, Lewen S, Berahovich RD, Penfold ME, Zhang P, Powers J, 
Summers BC, Miao Z, Zhao B, Jalili A, Janowska-Wieczorek A, Jaen JC 
and Schall TJ (2009) Elucidation of CXCR7-mediated signaling events 
and inhibition of CXCR4-mediated tumor cell transendothelial migration by 
CXCR7 ligands. J Immunol 183:3204-3211. 
 
Zhang H, Mei X, Zhang P, Ma C, White FA, Donnelly DF and Lamotte RH (2009) 
Altered functional properties of satellite glial cells in compressed spinal 
ganglia. Glia 57:1588-1599. 
 
Zhang J and De Koninck Y (2006) Spatial and temporal relationship between 
monocyte chemoattractant protein-1 expression and spinal glial activation 
following peripheral nerve injury. J Neurochem 97:772-783. 
 
Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y and Rivest S (2007) 
Expression of CCR2 in both resident and bone marrow-derived microglia 
plays a critical role in neuropathic pain. J Neurosci 27:12396-12406. 
 
Zhang L and Rogers TJ (2000) Kappa-opioid regulation of thymocyte IL-7 
receptor and C-C chemokine receptor 2 expression. J Immunol 164:5088-
5093. 
 
 
140 
 
 
Zhang N, Rogers TJ, Caterina M and Oppenheim JJ (2004a) Proinflammatory 
Chemokines, Such as C-C Chemokine Ligand 3, Desensitize {micro}-
Opioid Receptors on Dorsal Root Ganglia Neurons. J Immunol 173:594-
599. 
 
Zhang X, Bao L, Arvidsson U, Elde R and Hokfelt T (1998) Localization and 
regulation of the delta-opioid receptor in dorsal root ganglia and spinal 
cord of the rat and monkey: evidence for association with the membrane 
of large dense-core vesicles. Neuroscience 82:1225-1242. 
 
Zhang Y, Foudi A, Geay JF, Berthebaud M, Buet D, Jarrier P, Jalil A, 
Vainchenker W and Louache F (2004b) Intracellular localization and 
constitutive endocytosis of CXCR4 in human CD34+ hematopoietic 
progenitor cells. Stem Cells 22:1015-1029. 
 
Zhou L, Zhang Q, Stein C and Schafer M (1998) Contribution of opioid receptors 
on primary afferent versus sympathetic neurons to peripheral opioid 
analgesia. J Pharmacol Exp Ther 286:1000-1006. 
 
Zlotnik A and Yoshie O (2000) Chemokines: a new classification system and 
their role in immunity. Immunity 12:121-127. 
 
 
 
141 
 
VITA 
 
Natalie Wilson was born in Bedford, IA on April 7, 1983 to Robert and 
Sandra Wilson.  Before attending Loyola University of Chicago, she attended 
Buena Vista University in Storm Lake, IA.  At Buena Vista University she earned 
a Bachelor of Science in Biology and Chemistry in May 2005.  In the summer of 
2005, Natalie began her graduate work in the Department of Molecular 
Pharmacology & Therapeutics at Loyola University of Chicago.  In the summer of 
2007, she joined the lab of Dr. Fletcher White where she studied the chemokine 
signaling component of morphine-induced hypernociception. 
While at Loyola, Natalie served on several committees, including the 
Pharmacology Department Student Representative to Faculty, Graduate Student 
Advisory Committee, and Graduate Student Committee.  Natalie also received an 
NSF GK-12 Fellowship from June 2010 through May 2011.  
Natalie has accepted a post-doctoral position in the lab of Dr. Doug Wright 
in the Department of Anatomy and Cell Biology at Kansas University Medical 
Center, Kansas City, KS.
 
 
142 
 
DISSERTATION APPROVAL SHEET 
The dissertation submitted by Natalie M. Wilson has been read and approved by 
the following committee:  
Fletcher A. White, Ph.D., Director 
Professor of Anesthesiology 
Indiana University School of Medicine 
Lecturer 
Loyola University of Chicago 
 
Richard J. Miller, Ph.D. 
Professor of Molecular Pharmacology and Biological Chemistry 
Northwestern University 
 
Adriano Marchese, Ph.D. 
Associate Professor of Pharmacology 
Loyola University Chicago 
 
Neil A. Clipstone, Ph.D. 
Associate Professor of Pharmacology 
Loyola University Chicago 
 
Ajay Rana, Ph.D. 
Professor of Pharmacology 
Loyola University Chicago 
The final copies have been examined by the director of the dissertation and the 
signature which appears below verifies the fact that any necessary changes have 
been incorporated and that the dissertation is now given final approval by the 
committee with reference to content and form.  
The dissertation is therefore accepted in partial fulfillment of the requirements for 
the degree of Doctor of Philosophy.  
 
__________________      ____________________________________ 
Date            Director’s Signature 
